Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of July 2024

 

Commission File Number: 001-41661

 

JIN MEDICAL INTERNATIONAL LTD.

(Exact name of registrant as specified in its charter)

 

No. 33 Lingxiang Road, Wujin District

Changzhou City, Jiangsu Province

People’s Republic of China

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

 

 

 

 

 

 

EXPLANATORY NOTE

 

Jin Medical International Ltd., a Cayman Islands exempted company (the “Company”), is furnishing this current report on Form 6-K to provide its unaudited condensed consolidated financial statements for the six months ended March 31, 2024.

 

Financial Statements and Exhibits.

 

Exhibits:

 

Exhibit No.		Description
99.1		Unaudited Condensed Consolidated Financial Statements as of March 31, 2024 and for the Six Months Ended March 31, 2024 and 2023.
99.2		Operating and Financial Review and Prospects in Connection with the Unaudited Condensed Consolidated Financial Statements for the Six Months March 31, 2024 and 2023.
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Jin Medical International Ltd.
Date: July 26, 2024	By:	/s/ Erqi Wang
		Erqi Wang
		Chief Executive Officer

 

	By:	/s/ Ziqiang Wang
		Ziqiang Wang
		Chief Financial Officer

 

 

2

 

 

Exhibit 99.1

 

JIN MEDICAL INTERNATIONAL LTD. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

 

		March 31,				September 30,
		2024				2023
		(Unaudited)
ASSETS
CURRENT ASSETS:
Cash		$	8,874,902			$	6,929,508
Short-term investments			17,113,103				9,768,835
Accounts receivable, net			3,856,529				3,283,266
Accounts receivable - related parties			1,524,570				947,949
Inventories			4,540,852				5,053,136
Due from related parties			65,037				4,240,524
Prepaid expenses and other current assets			2,202,847				892,597
TOTAL CURRENT ASSETS			38,177,840				31,115,815
Operating lease right-of-use assets			263,331				-
Property, plant and equipment, net			1,464,107				1,480,796
Land use right, net			1,124,404				154,364
Deferred tax assets, net			130,441				152,475
TOTAL ASSETS		$	41,160,123			$	32,903,450
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Short-term bank loans		$	9,681,150			$	4,113,000
Accounts payable			3,146,451				3,391,079
Accrued liabilities and other payables			527,822				318,500
Deferred revenue			546,988				710,099
Deferred revenue - related parties			131,521				119,120
Taxes payable			564,626				271,423
Due to related parties			138,664				1,124
Operating lease liabilities, current			88,297				-
TOTAL CURRENT LIABILITIES			14,825,519				8,924,345
NON-CURRENT LIABILITIES:
Operating lease liabilities, non-current			179,691				-
			179,691				-
TOTAL LIABILITIES			15,005,210				8,924,345
COMMITMENTS AND CONTINGENCIES							’
SHAREHOLDERS’ EQUITY
Ordinary shares, $0.00005 par value, 1,000,000,000 shares authorized, 156,547,100 shares155,947,100  shares were issued and outstanding as of March 31, 2024 and September 30, 2023, respectively*			7,827				7,797
Additional paid-in capital			6,749,144				6,437,179
Statutory reserves			2,277,430				2,010,890
Retained earnings			18,455,159				16,927,605
Accumulated other comprehensive loss			(1,245,394	)			(1,404,366	)
TOTAL SHAREHOLDERS’ EQUITY			26,244,166				23,979,105
Non-controlling interest			(89,253	)			-
TOTAL EQUITY			26,154,913				23,979,105
TOTAL LIABILITIES AND EQUITY		$	41,160,123			$	32,903,450

 

*

Retrospectively restated for effect of a 20-for-1 forward split on February 8, 2024.

 

 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-1

 

 

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

 

		For the Six months ended March 31,
		2024				2023
REVENUE
Revenue - third party		$	9,380,513			$	9,890,292
Revenue - related party			1,176,378				362,871
Total revenue			10,556,891				10,253,163
COST OF REVENUE AND RELATED TAX
Cost of revenue			6,759,586				6,620,447
Business and sales related tax			60,975				101,843
Total cost of revenue and related tax			6,820,561				6,722,290
GROSS PROFIT			3,736,330				3,530,873
OPERATING EXPENSES
Selling expenses			358,768				206,194
General and administrative expenses			1,538,680				922,188
Research and development expenses			609,645				631,034
Total operating expenses			2,507,093				1,759,416
INCOME FROM OPERATIONS			1,229,237				1,771,457
OTHER INCOME (EXPENSE)
Interest income, net			681,588				94,571
Foreign exchange gain (loss)			414				(63,253	)
Other income, net			102,164				167,625
Total other income, net			784,166				198,943
INCOME BEFORE INCOME TAX PROVISION			2,013,403				1,970,400
PROVISION FOR INCOME TAXES			309,013				204,053
NET INCOME			1,704,390				1,766,347
Less: net loss attributable to non-controlling interest			(89,704	)			-
NET INCOME ATTRIBUTABLE TO JIN MEDICAL INTERNATIONAL LTD.		$	1,794,094			$	1,766,347
COMPREHENSIVE INCOME
Net income			1,704,390				1,766,347
Foreign currency translation gain			159,423				570,160
Comprehensive income			1,863,813				2,336,507
Less: comprehensive loss attributable to non-controlling interest			(89,253	)			-
COMPREHENSIVE INCOME ATTRIBUTABLE TO JIN MEDICAL INTERNATIONAL LTD.		$	1,953,066			$	2,336,507
Earnings per common share - basic and diluted		$	0.01			$	0.01
Weighted average shares - basic and diluted*			156,401,198				135,219,780

 

*

Retrospectively restated for effect of a 20-for-1 forward split on February 8, 2024.

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-2

 

 

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN  EQUITY  

FOR THE SIX MONTHS ENDED MARCH 31, 2024 AND 2023

 

		Ordinary Shares*								Additional Paid in				Statutory				Retained				Accumulated Other Comprehensive				Total Shareholders’				Non- controlling				Total
		Shares				Amount				Capital				Reserves				Earnings				Income (Loss)				Equity				Interest				Equity
Balance at September 30, 2022			6,750,000			$	6,750			$	79,810			$	1,651,422			$	14,408,843			$	(911,134	)		$	15,235,691				-				15,235,691
Issuance of ordinary shares  in initial public offerings, gross			1,000,000				1,000				7,999,000				-				-				-				8,000,000				-				8,000,000
Cost directly related to the initial public offering			-				-				(2,025,679	)			-				-				-				(2,025,679	)			-				(2,025,679	)
Net income			-				-				-				-				1,766,347				-				1,766,347				-				1,766,347
Statutory reserve			-				-				-				176,550				(176,550	)			-				-				-				-
Foreign currency translation gain			-				-				-				-				-				570,160				570,160				-				570,160
Balance at March 31, 2023			7,750,000			$	7,750			$	6,053,131			$	1,827,972			$	15,998,640			$	(340,974	)		$	23,546,519				-				23,546,519
Balance at September 30, 2023			155,947,100			$	7,797			$	6,437,179			$	2,010,890			$	16,927,605			$	(1,404,366	)		$	23,979,105				-				23,979,105
Issuance of Ordinary Shares			30,000				30				311,965				-				-				-				311,995				-				311,995
Net income (loss)			-				-				-				-				1,794,094				-				1,794,094				(89,704	)			1,704,390
Statutory reserve			-				-				-				266,540				(266,540	)			-				-				-				-
Foreign currency translation gain			-				-				-				-				-				158,972				158,972				451				159,423
Balance at March 31, 2024			155,977,100			$	7,827			$	6,749,144			$	2,277,430			$	18,455,159			$	(1,245,394	)		$	26,244,166				(89,253	)			26,154,913

 

*

Retrospectively restated for effect of a 20-for-1 forward split on February 8, 2024.

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-3

 

 

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS  

 

		For the Six months ended March 31,
		2024				2023
Cash flows from operating activities:
Net income		$	1,704,390			$	1,766,347
Adjustments to reconcile net income to net cash
provided by operating activities:
Amortization of operating lease right-of-use assets			48,105				-
Depreciation and amortization			120,046				114,465
Gain on disposition of property and equipment			2,590				523
Provision for (net recovery of) credit losses			(87,627	)			171,522
Deferred tax provision			23,711				68,561
Short-term investments income			(11,655	)			-
Changes in operating assets and liabilities:
Accounts receivable			(454,837	)			(75,355	)
Accounts receivable - related parties			(569,807	)			(28,932	)
Inventories			566,734				447,024
Prepaid expenses and other current assets			(1,308,346	)			47,501
Accounts payable			(278,216	)			348,579
Accrued liabilities and other payables			206,416				(29,199	)
Deferred revenue			(171,223	)			(293,968	)
Deferred revenue - related parties			11,241				122,795
Taxes payable			291,899				83,630
Operating lease liabilities			(43,424	)			-
Net cash provided by operating activities			49,997				2,743,493
Cash flows from investing activities:
Additions to property, plant and equipment			(83,680	)			(11,014	)
Additions to land use right			(980,692	)			-
Proceeds from disposal of property and equipment			348				100
Payments for short-term investments			(16,136,000	)			(3,152,600	)
Redemption of short-term investments			8,810,675				850,154
Repayment of (payments of) advances made to related parties			4,240,111				(4,760,469	)
Net cash used in investing activities			(4,149,238	)			(7,073,829	)
Cash flows from financing activities:
Gross proceeds from initial public offerings			-				8,000,000
Direct costs disbursed from initial public offerings proceeds			-				(1,212,779	)
Proceeds from sale of Ordinary Shares, net of issuance costs			311,995				-
Proceeds from short-term bank loans			5,554,080				1,433,000
Proceeds from (repayment of) amount due to related parties			138,223				(120,333	)
Net cash provided by financing activities			6,004,298				8,099,888
Effect of exchange rate changes on cash			40,337				122,004
Net increase in cash			1,945,394				3,891,556
Cash, beginning of period			6,929,508				4,792,632
Cash, end of period		$	8,874,902			$	8,684,188
Supplemental disclosure information:
Cash paid for income tax		$	2,234			$	28,415
Cash paid for interest		$	93,256			$	-
Non-cash operating, investing and financing activities
Deferred IPO cost offset with additional paid-in capital		$	-			$	812,900
Right of use assets obtained in exchange for operating lease liabilities		$	312,767			$	-

 

  The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

F-4

 

 

JIN MEDICAL INTERNATIONAL LTD. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 1 — ORGANIZATION AND BUSINESS DESCRIPTION

 

JIN MEDICAL INTERNATIONAL LTD. (“Jin Med” or the “Company”) was established under the laws of the Cayman Islands on January 14, 2020 as a holding company.

 

Jin Med owns 100% equity interest of Zhongjin International Limited (“Zhongjin HK”), an entity incorporated on February 25, 2020 in accordance with the laws and regulations in Hong Kong.

 

Erhua Medical Technology (Changzhou) Co., Ltd. (“Erhua Med”) was formed on September 24, 2020, as a Wholly Foreign-Owned Enterprise (“WFOE”) in the People’s Republic of China (“PRC”). Zhongjin HK owns 100% equity interest of Erhua Med.

 

Jin Med, Zhongjin HK and Erhua Med are currently not engaging in any active business operations and merely acting as holding companies.

 

Changzhou Zhongjin Medical Equipment Co., Ltd. (“Changzhou Zhongjin”) was incorporated on January 26, 2006 in accordance with PRC laws. Changzhou Zhongjin has two wholly-owned subsidiaries, Zhongjin Medical Equipment Taizhou Co., Ltd. (“Taizhou Zhongjin”), incorporated on June 17, 2013, and Changzhou Zhongjin Jing’ao Trading Co., Ltd (“Zhongjin Jing’ao”), incorporated on December 18, 2014 in accordance with PRC laws.

 

Zhongjin Kangma Information Technology Jiangsu Co., Ltd. (“Zhongjin Kangma”) was incorporated on August 21, 2023 in accordance with PRC laws. Changzhou Zhongjin owns an equity interest of 80% of Zhongjin Kangma, and the remaining 20% equity interest is owned by one shareholder.

 

Changzhou Zhongjin, Taizhou Zhongjin, Zhongjin Jing’ao and Zhongjin Kangma are collectively referred to as the “Zhongjin Operating Companies” below.

 

Zhongjin Medical Equipment Anhui Co., Ltd. (“Anhui Zhongjin”) was incorporated on October 7, 2023, as a WFOE in the PRC. Zhongjin HK owns 100% equity interest of Anhui Zhongjin. Anhui Zhongjin is currently not engaging in any active business operations.

 

The Company, through its wholly-owned subsidiaries and entities controlled through contractual arrangements, is primarily engaged in the design, development, manufacturing and sales of wheelchair and other living aids products to be used by people with disabilities or impaired mobility. The Company’s products are sold to distributors in both China and in the overseas markets.

 

Reorganization

 

A reorganization of the legal structure of the Company (“Reorganization”) was completed on November 26, 2020. The Reorganization involved the incorporation of Jin Med, Zhongjin HK and Erhua Med, and signing of certain contractual arrangements (collectively, the “VIE Agreements”) between Zhongjin Technology, the shareholders of Changzhou Zhongjin and Changzhou Zhongjin. Consequently, the Company became the ultimate holding company of Zhongjin HK, Erhua Med, and through the contractual arrangements, WFOE, or Erhua Med, became the primary beneficiary of the Variable Interest Entity (“VIE”), Changzhou Zhongjin, and its subsidiaries. Pursuant to the VIE Agreements, Erhua Med has gained effective control over Changzhou Zhongjin. Therefore, Changzhou Zhongjin should be treated as a VIE under the Statements of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810 Consolidation. Since Taizhou Zhongjin and Zhongjin Jing’ao are wholly-owned subsidiaries of Changzhou Zhongjin, they are further referenced as VIE’s subsidiaries.

 

F-5

 

 

NOTE 1 — ORGANIZATION AND BUSINESS DESCRIPTION (continued)

 

Reorganization (continued)

 

The Company, together with its wholly owned subsidiaries, the VIE and the VIE’s subsidiaries, are effectively controlled by the same shareholders before and after the Reorganization and therefore the Reorganization is considered as a recapitalization of entities under common control. The consolidation of the Company, its subsidiaries, the VIE and the VIE’s subsidiaries has been accounted for at historical cost.

 

The unaudited condensed consolidated financial statements of the Company include the following entities:

 

Name of Entity

Date of Incorporation

Place of Incorporation

% of Ownership

Principal Activities

Jin Med

January 14, 2020

Cayman Island

Parent

Investment holding

Zhongjin HK

February 25, 2020

Hong Kong

100%

Investment holding

Erhua Med

September 24, 2020

PRC

100%

WFOE, Investment holding

Changzhou Zhongjin

January 26, 2006

PRC

VIE

Design, development, manufacturing and sales of wheelchair and other mobility products

Taizhou Zhongjin

June 17, 2013

PRC

100% controlled subsidiary of the VIE

Design, development, manufacturing and sales of wheelchair and other mobility products

Zhongjin Jing’ao

December 18, 2014

PRC

100% controlled subsidiary of the VIE

Design, development, manufacturing and sales of wheelchair and other mobility products

Zhongjin Kangma

August 21, 2023

PRC

80% controlled subsidiary of the VIE

Sales of wheelchair and other mobility products

Anhui Zhongjin

October 7, 2023

PRC

100%

Newly incorporated – not in operation yet

 

The VIE contractual arrangements

 

The Company’s main operating entities, Changzhou Zhongjin and its subsidiaries Taizhou Zhongjin, Zhongjin Jing’ao and Zhongjin Kangma (or the “Zhongjin Operating Companies” as referred above), are controlled through contractual arrangements in lieu of direct equity ownership by the Company.

 

A VIE is an entity which has a total equity investment that is insufficient to finance its activities without additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest, such as through voting rights, right to receive the expected residual returns of the entity or obligation to absorb the expected losses of the entity. The variable interest holder, if any, that has a controlling financial interest in a VIE is deemed to be the primary beneficiary of, and must consolidate, the VIE, because it met the condition under the accounting principles generally accepted in the United States of America (“U.S. GAAP”) to consolidate the VIE.

 

F-6

 

 

NOTE 1 — ORGANIZATION AND BUSINESS DESCRIPTION (continued)

 

Erhua Med, is deemed to have a controlling financial interest in and be the primary beneficiary of the Zhongjin Operating Companies because it has both of the following characteristics:

 

●

The power to direct activities of the Zhongjin Operating Companies that most significantly impact such entities’ economic performance, and

 

●

The right to receive benefits from, the Zhongjin Operating Companies that could potentially be significant to such entities.

 

Pursuant to these contractual arrangements, the Zhongjin Operating Companies shall pay service fees equal to all of their net profits after tax payments to Erhua Med. At the same time, Erhua Med has the right to receive substantially all of their economic benefits for accounting purposes. Such contractual arrangements are designed so that the operations of the Zhongjin Operating Companies are solely for the benefit of Erhua Med and ultimately, the Company, and therefore the Company must consolidate the Zhongjin Operating Companies under U.S. GAAP.

 

Risks associated with the VIE structure

 

The Company believes that the contractual arrangements with the VIE and the shareholders of the VIE are in compliance with PRC laws and regulations and are legally enforceable. However, uncertainties in the PRC legal system could limit the Company’s ability to enforce the contractual arrangements. If the legal structure and contractual arrangements were found to be in violation of PRC laws and regulations, the PRC government could:

 

●

revoke the business and operating licenses of the Company’s PRC subsidiaries and VIE;

 

●

discontinue or restrict the operations of any related-party transactions between the Company’s PRC subsidiaries and VIE;

 

●

limit the Company’s business expansion in China by way of entering into contractual arrangements;

 

●

impose fines or other requirements with which the Company’s PRC subsidiaries and VIE may not be able to comply;

 

●

require the Company or the Company’s PRC subsidiaries and VIE to restructure the relevant ownership structure or operations; or

 

●

restrict or prohibit the Company’s use of the proceeds from public offering to finance the Company’s business and operations in China.

 

The Company’s ability to conduct its businesses may be negatively affected if the PRC government were to carry out of any of the aforementioned actions. In such case, the Company may not be able to consolidate the VIE and the VIE’s subsidiaries in its unaudited condensed consolidated financial statements as it may lose the ability to exert effective control over the VIE and its shareholders and it may lose the ability to receive economic benefits from the VIE and the VIE’s subsidiaries for accounting purposes under U.S. GAAP. The Company, however, does not believe such actions would result in the liquidation or dissolution of the Company, its PRC subsidiaries and the VIE and the VIE’s subsidiaries.

 

F-7

 

 

NOTE 1 — ORGANIZATION AND BUSINESS DESCRIPTION (continued)

 

The Company, Zhongjin HK and Erhua Med are essentially holding companies and do not have active operations as of March 31, 2024 and September 30, 2023. As a result, total assets and liabilities presented on the unaudited condensed consolidated balance sheets and revenue, expenses, and net income presented on the unaudited condensed consolidated statement of comprehensive income as well as the cash flows from operating, investing and financing activities presented on the unaudited condensed consolidated statement of cash flows are substantially the financial position, operation results and cash flows of the VIE and the VIE’s subsidiaries. The Company has not provided any financial support to the VIE and the VIE’s subsidiaries during the six months ended March 31, 2024, and 2023. Additionally, pursuant to the VIE Agreements, Erhua Med has the right to receive service fees equal to the VIE’s net profits after tax payments. None of these fees were paid to Erhua Med as of March 31, 2024. Accordingly, as of March 31, 2024 and September 30, 2023, Erhua Med had $10,072,433 and $7,713,617 consulting fee receivables due from the VIE and the VIE’s subsidiaries, respectively. These receivables were fully eliminated upon the consolidation.

 

The following financial statement amounts and balances of the VIE and VIE’s subsidiaries were included in the accompanying unaudited condensed consolidated financial statements after elimination of intercompany transactions and balances:

 

		March 31, 2024				September 30, 2023
Current assets		$	32,548,259			$	24,391,558
Non-current assets			2,011,402				1,787,635
Total assets		$	34,559,661			$	26,179,193
Current liabilities		$	14,687,268			$	8,763,714
Non-current liabilities			179,691				-
Total liabilities		$	14,866,959			$	8,763,714

 

		For the Six Months Ended March 31,
		2024				2023
Net revenue		$	10,556,891			$	10,253,163
Net income		$	2,201,868			$	1,766,347

 

		For the Six Months Ended March 31,
		2024				2023
Net cash provided by operating activities		$	629,983			$	2,743,493
Net cash used in investing activities		$	(3,560,418	)		$	(7,073,829	)
Net cash provided by financing activities		$	5,692,303			$	1,312,667

 

F-8

 

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of consolidation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included in the Company’s unaudited condensed consolidated financial statement. The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and the notes for the years ended September 30, 2023 and 2022. The accompanying unaudited condensed consolidated financial statements include the financial statements of the Company, its wholly owned subsidiaries, and entities it controlled through VIE agreements. All inter-company balances and transactions are eliminated upon consolidation.

 

Uses of estimates

 

In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are based on information as of the date of the unaudited condensed consolidated financial statements. Significant estimates required to be made by management include, but are not limited to, the expected credit losses for receivables, valuation of inventories, useful lives of property, plant and equipment and land use right, the recoverability of long-lived assets, and realization of deferred tax assets. Actual results could differ from those estimates.

 

Cash

 

Cash includes currency on hand and deposits held by banks that can be added or withdrawn without limitation. The Company maintains most of its bank accounts in the PRC. Cash balances in bank accounts in PRC are not insured by the Federal Deposit Insurance Corporation or other programs. As of March 31, 2024 and September 30, 2023, the Company does not have any cash equivalents.

   

Short-term investments

 

The Company’s short-term investments consist of wealth management financial products purchased from PRC banks or financial institution with maturities within one year. The banks or financial institution invest the Company’s funds in certain financial instruments including money market funds, bonds or mutual funds, with rates of return on these investments ranging from 3.4% to 29.6% per annum. The carrying values of the Company’s short-term investments approximate fair value due to their short-term maturities. The interest earned is recognized in the unaudited condensed consolidated statements of comprehensive income over the contractual term of these investments.

 

The Company had short-term investments of $17,113,103 and $9,768,835 as of March 31, 2024 and September 30, 2023, respectively. The Company recorded interest income of $808,363 and $69,840 for the six months ended March 31, 2024 and 2023, respectively.

 

F-9

 

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Accounts receivable, net

 

Accounts receivable are presented net of allowance for credit losses. Delinquent account balances are written-off against the allowance for credit losses after management has determined that the likelihood of collection is not probable. As of March 31, 2024 and September 30, 2023, allowance for credit losses amounted to $39,543 and $125,448, respectively.

 

Credit Losses

 

On October 1, 2023, the Company adopted Accounting Standards Update 2016-13 “Financial Instruments – Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments,” which replaces the incurred loss methodology with an expected loss methodology that is referred to as the current expected credit loss (“CECL”) methodology. The adoption of the credit loss accounting standard has no material impact on the Company’s unaudited condensed consolidated financial statements as of October 1, 2023.

 

The Company’s account receivables and other receivables included in prepaid expenses and other current assets on the unaudited condensed consolidated balance sheets are within the scope of ASC Topic 326. The Company makes estimates of expected credit and collectability trends for the allowance for credit losses based upon assessment of various factors, including historical experience, the age of the accounts receivable and other receivables balances, credit-worthiness of the customers and other debtors, current economic conditions, reasonable and supportable forecasts of future economic conditions, and other factors that may affect its ability to collect from the customers and other debtors. The Company also provides specific provisions for allowance when facts and circumstances indicate that the receivable is unlikely to be collected.

 

Expected credit losses are recorded as allowance for credit losses on the unaudited condensed consolidated statements of operations and comprehensive income. After all attempts to collect a receivable have failed, the receivable is written off against the allowance. In the event the Company recovers amounts previously reserved for, the Company will reduce the specific allowance for credit losses.

 

Inventories

 

Inventories are stated at lower of cost or net realizable value using the weighted average method. Costs include the cost of raw materials, freight, direct labor and related production overhead. Net realizable value is the estimated selling price in the normal course of business less any costs to complete and sell products. Write-down is recorded when future estimated net realizable value is less than cost, which is recorded in cost of revenue in the unaudited condensed consolidated statements of comprehensive income. The Company periodically evaluates inventories against their net realizable value, and reduces the carrying value of those inventories that are obsolete or in excess of the forecasted usage to their estimated net realizable value based on various factors including aging and future demand of each type of inventories. The reversal of inventory written down is prohibited under the U.S. GAAP.

 

F-10

 

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Fair value of financial instruments

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

 

●

Level 1 — inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

●

Level 2 — inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived from or corroborated by observable market data.

 

●

Level 3 — inputs to the valuation methodology are unobservable.

 

Unless otherwise disclosed, the fair value of the Company’s financial instruments, including cash, short-term investments, accounts receivable, due from related parties, short-term bank loan, accounts payable, due to related parties, accrued liabilities and other payable, and taxes payable, approximate the fair value of the respective assets and liabilities as of March 31, 2024 and September 30, 2023 based upon the short-term nature of the assets and liabilities.

  

Property, plant and equipment, net

 

Property, plant and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment is provided using the straight-line method over their expected useful lives, as follows:

 

		Useful life
Property and buildings		20–25 years
Leasehold improvement		Lesser of useful life and lease term
Machinery and equipment		5–10 years
Automobiles		3–5 years
Office and electric equipment		3–5 years

 

Expenditures for maintenance and repairs, which do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures for major renewals and betterments which substantially extend the useful life of assets are capitalized. The cost and related accumulated depreciation of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized in the unaudited condensed consolidated statements of comprehensive income.

 

Leases

 

Effective October 1, 2022, the Company adopted ASC 842, Leases. The adoption of this standard did not have a material impact on the Company’s unaudited condensed consolidated financial statements. Therefore, no adjustments to opening retained earnings were necessary. The Company leases offices spaces and employee dormitories, which is classified as operating leases in accordance with Topic 842. Under Topic 842, lessees are required to recognize the following for all leases (with the exception of short-term leases, usually with an initial term of 12 months or less) on the commencement date: (i) lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and (ii) right-of-use (“ROU”) asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term.

 

F-11

 

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Leases (continued)

 

At the commencement date, the Company recognizes the lease liability at the present value of the lease payments not yet paid, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate for the same term as the underlying lease. The ROU asset is recognized initially at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All ROU assets are reviewed for impairment annually. The Company also established a capitalization threshold of $10,000 for lease to be recognized as ROU and lease liability. There was no impairment for operating lease right-of-use lease assets as of March 31, 2024 and September 30, 2023.

 

Land use rights, net

 

Under the PRC law, all land in the PRC is owned by the government and cannot be sold to an individual or company. The government grants individuals and companies the right to use parcels of land for specified periods of time. Land use rights are stated at cost less accumulated amortization. Land use rights are amortized using the straight-line method with the following estimated useful lives:

 

		Useful life
Land use rights		46 -50 years

 

Impairment of long-lived assets

 

Long-lived assets with finite lives, primarily property, plant and equipment, operating lease right-of-use assets and land use right are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the estimated cash flows from the use of the asset and its eventual disposition are below the asset’s carrying value, then the asset is deemed to be impaired and written down to its fair value. There were no impairments of these assets as of March 31, 2024 and September 30, 2023.

 

Revenue recognition

 

The Company generates its revenues primarily through sales of its products and recognizes revenue in accordance with ASC 606. ASC 606 establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity’s contracts to provide goods or services to customers. The core principle requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to receive in exchange for those goods or services recognized as performance obligations are satisfied.

 

ASC 606 requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation. The application of the five-step model to the revenue streams compared to the prior guidance did not result in significant changes in the way the Company records its revenue.

 

F-12

 

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Revenue recognition (continued)

 

In accordance to ASC 606, the Company recognizes revenue when it transfers goods to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. The Company accounts for the revenue generated from sales of its products on a gross basis as the Company is acting as a principal in these transactions, is subject to inventory risk, has latitude in establishing prices, and is responsible for fulfilling the promise to provide customers the specified goods. All of the Company’s contracts have one single performance obligation as the promise is to transfer the individual goods to customers, and there are no other separately identifiable promises in the contracts. The Company’s revenue streams are recognized at a point in time when the control of goods is transferred to customer, which generally occurs at delivery. The Company’s products are sold with no right of return and the Company does not provide other credits or sales incentive to customers. Revenue is reported net of all value added taxes (“VAT”).

 

The Company generally offers 10 years warranty for the frame of its wheelchairs, and one year warranty for other parts of wheelchairs, except for “wear items”, i.e. those parts that wear out, such as tires or brake pads, which are covered under a warranty for six months. Historically, warranty costs incurred was immaterial, and the warranty costs for the six months ended March 31, 2024 and 2023 were both $nil.

 

Contract Assets and Liabilities

 

Payment terms are established on the Company’s pre-established credit requirements based upon an evaluation of customers’ credit quality. The Company did not have contract assets as of March 31, 2024 and September 30, 2023. Contract liabilities are recognized for contracts where payment has been received in advance of delivery of the products. The contract liability balance can vary significantly depending on the timing when cash is received and when shipment or delivery occurs. As of March 31, 2024 and September 30, 2023, other than deferred revenue, the Company had no other contract liabilities or deferred contract costs recorded on its unaudited condensed consolidated balance sheets, and the Company had no material incremental costs for obtaining a contract. Costs of fulfilling customers’ purchase orders, such as shipping, handling and delivery, which occur prior to the transfer of control, are recognized in selling, general and administrative expense when incurred.

  

Disaggregation of Revenues

 

The Company disaggregates its revenue from contracts by product types and geographic areas, as the Company believes it best depicts how the nature, amount, timing and uncertainty of the revenue and cash flows are affected by economic factors. The Company’s disaggregation of revenues for the six months ended March 31, 2024 and 2023 are as the following:

 

Geographic information

 

The summary of the Company’s total revenues by geographic market for the six months ended March 31, 2024 and 2023 was as follows:

 

		For the Six Months Ended March 31,
		2024				2023
China domestic market		$	2,661,717			$	1,634,219
Overseas market			7,895,174				8,618,944
Total revenue		$	10,556,891			$	10,253,163

 

F-13

 

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Revenue recognition (continued)

 

Revenue by product categories

 

The summary of the Company’s total revenues by product categories for the six months ended March 31, 2024 and 2023 was as follows:

 

		For the Six Months Ended March 31,
		2024				2023
Wheelchair		$	7,694,373			$	8,381,323
Wheelchair components and others			2,862,518				1,871,840
Total revenue		$	10,556,891			$	10,253,163

 

Research and development expenses

 

In connection with the design and development of wheelchair and other living aids products, the Company expense all internal research costs as incurred, which primarily comprise employee costs, internal and external costs related to execution of studies, manufacturing costs, facility costs of the research center, and amortization of land use right, depreciation for property, plant and equipment used in the research and development activities. For the six months ended March 31, 2024 and 2023, research and development expenses were $609,645 and $631,034, respectively.

 

Non-controlling Interest

 

For the Company’s consolidated subsidiaries, the VIE and the VIE’s subsidiaries, non-controlling interests are recognized to reflect the portion of their equity that is not attributable, directly or indirectly, to the Company as the controlling shareholder. Non-controlling interests are classified as a separate line item in the equity section of the Company’s unaudited condensed consolidated balance sheets and have been separately disclosed in the Company’s unaudited condensed consolidated statements of comprehensive income to distinguish the interests from that of the controlling shareholder.

 

Income taxes

 

The Company accounts for current income taxes in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the unaudited condensed consolidated financial statements. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period including the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

 

An uncertain tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the period incurred. No significant penalties or interest relating to income taxes have been incurred during the six months ended March 31, 2024 and 2023. The Company does not believe there was any uncertain tax provision at March 31, 2024 and September 30, 2023.

 

The Company’s subsidiaries, VIE and VIE’s subsidiaries in China are subject to the income tax laws of the PRC. No income was generated outside the PRC for the six months ended March 31, 2024 and 2023. As of March 31, 2024, all of the Company’s tax returns of its PRC Subsidiaries remain open for statutory examination by PRC tax authorities.

 

F-14

 

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Value added tax (“VAT”)

 

Sales revenue is reported net of VAT. The VAT is based on gross sales price and VAT rates range up to 13% in the six months ended March 31, 2024 and 2023, depending on the type of products sold. The VAT may be offset by VAT paid by the Company on purchased raw materials and other materials included in the cost of producing or acquiring its finished products. The Company recorded a VAT payable or receivable net of payments in the accompanying unaudited condensed consolidated financial statements. For domestic sales of wheelchairs, VAT is exempted. Further, when exporting goods, the exporter is entitled to some or all of the refunds of the VAT paid or assessed when the Company completes all the required tax filing procedures. All of the VAT returns filed for the Company have been and remain subject to examination by the tax authorities for five years from the date of filing. VAT tax refunds associated with export sales amounted to $361,431 and $526,779 for the six months ended March 31, 2024 and 2023, respectively.

 

Warrant accounting

 

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480, “Distinguishing Liabilities from Equity” (“ASC 480”) and ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent interim period end date while the warrants are outstanding.

  

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of comprehensive income.

 

As the warrants issued upon the initial public offering meet the criteria for equity classification under ASC 815, therefore, the warrants are classified as equity. 

 

Earnings per share

 

The Company computes earnings per share (“EPS”) in accordance with ASC 260, “Earnings per Share” (“ASC 260”). ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average common shares outstanding for the period. Diluted presents the dilutive effect on a per share basis of potential common shares (e.g., convertible securities, options and warrants), using the treasury stock method, as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted EPS, the treasury stock method assumes that outstanding potential common shares are exercised and the proceeds are used to purchase common share at the average market price during the period. Potential common shares may have a dilutive effect under the treasury stock method only when the average market price of the common share during the period exceeds the exercise price of the potential common shares. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. As of March 31, 2024 and September 30, 2023, there were no dilutive shares.

 

F-15

 

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Risks and uncertainties

 

The main operation of the Company is located in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company’s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results.

 

The Company’s business, financial condition and results of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions, health epidemics and other catastrophic incidents, which could significantly disrupt the Company’s operations.

 

In December 2019, a novel strain of coronavirus (COVID-19) was first reported in Wuhan, China and then spread globally. On March 11, 2020, the World Health Organization categorized COVID-19 as a global pandemic. Due to a resurgence of the COVID-19 pandemic in March 2022 (“2022 Outbreak”) in China, there have been delays in the purchase of raw material supplies and delivery of products to domestic customers in China on a timely basis as a consequence of travel restrictions. Shipments and customer clearance for overseas sales were also delayed due to the stricter border control protocols. Although the situation has eased since mid-May 2022, the number of orders placed by the customers were affected as the business of those customers were negatively impacted by the 2022 Outbreak. Therefore, the 2022 Outbreak negatively affected the Company’s business operations and financial results for the year ended September 30, 2022. In early December 2022, China announced a nationwide loosening of its zero-covid policy, and most of the travel restrictions and quarantine requirements were lifted since December 2022. Although there were significant surges of COVID-19 cases in many cities in China after the lifting of these restrictions, the spread of the COVID-19 was slowed down and it was successfully under control since January 2023, and the Company’s business operations have been recovered to the level prior to the COVID-19 pandemic. Due to the dynamic nature of the circumstances and the uncertainty around the potential resurgence of COVID-19 cases in China, the continual spread of the virus globally especially in Japan, the Company’s major international market, and the instability of local and global government policies and restrictions, the COVID-19 impact over the Company’s business in the future cannot be reasonably estimated at this time. If COVID-19 cases resurge in the area the Company conducted its business and local governments implemented new restrictions in the effort to contain the spread or certain other foreign governments such as Japan imposed new import restrictions, it is expected the Company’s business will be negatively impacted.

 

Additionally, since February, 2022, the global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and Ukraine. The Company’s operation has not been impacted by the ongoing military conflict, however, due to the significant uncertainties around the further development of the conflict, the potential additional sanctions and other volatilities that could be brought to the global market, it is impossible to predict the extent to which the Company’s operation and business may be impacted. 

 

F-16

 

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Foreign currency translation

 

The functional currency for Jin Med is U.S Dollar (“US$”). Zhongjin HK uses Hong Kong dollar as its functional currency. However, Jin Med and Zhongjin HK currently only serve as holding company and do not have active operation as of the date of this report. The Company’s functional currency for its PRC subsidiaries is the Chinese Yuan (“RMB”). The Company’s unaudited condensed consolidated financial statements have been translated into the reporting currency of U.S. Dollars (“US$”). Assets and liabilities of the Company are translated at the exchange rate at each reporting period end date. Equity is translated at historical rates. Income and expense accounts are translated at the average rate of exchange during the reporting period. The resulting translation adjustments are reported under other comprehensive income. Gains and losses resulting from foreign currency transactions are reflected in the results of operations.

 

The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.

 

The following table outlines the currency exchange rates that were used in creating the unaudited condensed consolidated financial statements in this report:

 

		For the Six Months Ended March 31,				For the Year Ended September 30,
		2024		2023		2023
Period-end spot rate		US$1=RMB 7.2221		US$1=RMB 6.8681		US$1=RMB 7.2952
Average rate		US$1=RMB 7.1828		US$1=RMB 6.9784		US$1=RMB 7.0511

 

Comprehensive income

 

Comprehensive income consists of two components, net income and other comprehensive income. The foreign currency translation gain or loss resulting from translation of the financial statements expressed in RMB to US$ is reported in other comprehensive income in the unaudited condensed consolidated statements of comprehensive income.

 

Statement of cash flows

 

In accordance with ASC 230, “Statement of Cash Flows”, cash flows from the Company’s operations are formulated based upon the local currencies. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets.

 

Employee benefit expenses

 

The Company’s subsidiaries, VIE and VIE’s subsidiaries in the PRC participate in a government-mandated employer social insurance plan pursuant to which certain social security benefits, work-related injury benefits, maternity leave insurance, medical insurance, unemployment benefit and housing fund are provided to eligible full-time employees. The relevant labor regulations require the Company’s subsidiaries in the PRC to pay the local labor and social welfare authorities monthly contributions based on the applicable benchmarks and rates stipulated by the local government. The contributions to the plan are expensed as incurred. Employee social security and welfare benefits included as expenses in the unaudited condensed consolidated statements of comprehensive income amounted to $244,722 and $162,598 for the six months ended March 31, 2024 and 2023, respectively.

 

F-17

 

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Recent accounting pronouncements

 

The Company considers the applicability and impact of all accounting standards updates (“ASUs”). Management periodically reviews new accounting standards that are issued.

 

In November 2023, the FASB issued ASU No. 2023-07, “Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures.” This ASU expands required public entities’ segment disclosures, including disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items and interim disclosures of a reportable segment’s profit or loss and assets. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company plans to adopt this guidance effective October 1, 2025 and the adoption of this ASU is not expected to have a material impact on its unaudited condensed consolidated financial statements.

 

In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. This ASU requires additional quantitative and qualitative income tax disclosures to enable financial statements users better assess how an entity’s operations and related tax risks and tax planning and operational opportunities affect its tax rate and prospects for future cash flows. This ASU is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company plans to adopt this guidance effective October 1, 2025 and the adoption of this ASU is not expected to have a material impact on its unaudited condensed consolidated financial statements.

 

NOTE 3 — ACCOUNTS RECEIVABLE, NET

 

Accounts receivable, net consist of the following: 

 

Third Parties		March 31, 2024				September 30, 2023
Accounts receivable		$	3,896,072			$	3,408,714
Less: allowance for credit losses			(39,543	)			(125,448	)
Accounts receivable, net		$	3,856,529			$	3,283,266

 

The Company’s accounts receivable primarily includes balances due from customers when the Company’s wheelchair and living aids products have been sold and delivered to customers, the Company’s contracted performance obligations have been satisfied, amount billed and the Company has an unconditional right to payment, which has not been collected as of the balance sheet dates.

 

For accounts receivable, approximately 82.3%, or $3.2 million of the March 31, 2024 balance have been subsequently collected. The remaining balance of approximately $0.7 million is expected to be collected before March 31, 2025.

 

Allowance for credit losses movement is as follows:

 

		March 31, 2024				September 30, 2023
Beginning balance		$	125,448			$	114,486
Additions (reductions)			(87,627	)			119,021
Less: write-off (1)			-				(104,735	)
Foreign currency translation adjustments			1,722				(3,324	)
Ending balance		$	39,543			$	125,448

 

(1)	The Company wrote off the delinquent account balances against the allowance for credit losses after management has determined that the likelihood of collection is not probable.

 

F-18

 

 

NOTE 4 — INVENTORIES

 

Inventories consisted of the following: 

 

		March 31, 2024				September 30, 2023
Raw materials		$	2,385,295			$	2,618,406
Work-in-progress			1,738,091				1,613,781
Finished goods			417,466				820,949
Inventories		$	4,540,852			$	5,053,136

 

Included in inventory amount is an inventory written down for slow moving items, consisting of raw materials of $848,279 and $901,963, finished goods of $22,411 and $29,885, work-in-progress of $29,740 and $28,861 as of March 31, 2024 and September 30, 2023, respectively.

 

NOTE 5 — PREPAID EXPENSES AND OTHER CURRENT ASSETS

 

Prepaid expenses and other current assets consisted of the following: 

 

		March 31, 2024				September 30, 2023
Other receivable (1)		$	94,958			$	28,852
Advance to suppliers (2)			1,827,237				803,745
Prepaid expenses (3)			280,652				60,000
Prepaid expenses and other current assets		$	2,202,847			$	892,597

 

(1)	Other receivables primarily include advances to employees for business development, rental security deposit for the Company’s office lease and VAT tax refunds receivables and balances to be collected from third-party entities that do not relate to the Company’s normal sales activities.

 

(2)

Advance to suppliers consists of advances to suppliers for purchasing of raw materials that have not been received. As of March 31, 2024, the aging of approximately 80% of our advance to suppliers are within six months. For balance of advance to suppliers aged more than six months, approximately 40% of the balance were subsequently utilized as of the date of the report, and the remaining balance is expected to be utilized by August 2024.

 

(3)	Prepaid expenses primarily include prepaid marketing planning service fees and professional fees.

 

NOTE 6 — LEASES

 

The Company leases offices spaces and employee dormitories under non-cancelable operating leases, with expiration dates between 2024 and 2037. In addition, on April 20, 2014, Taizhou Zhongjin signed a lease agreement with the landlord to lease a factory building for 20 years, with annual rent of approximately $39,000 (RMB 250,000). Taizhou Zhongjin invested a total of approximately $0.79 million (RMB 5 million) in leasehold improvements to the leased factory. Pursuant to the lease agreement, the annual rent expense was waived by the landlord to offset against the leasehold improvements until the end of the lease.

 

The Company considers those renewal or termination options that are reasonably certain to be exercised in the determination of the lease term and initial measurement of ROU assets and lease liabilities. Lease expenses are recognized on a straight-line basis over the lease term. Leases with initial term of 12 months or less are not recorded on the balance sheet.

 

The Company determines whether a contract is or contains a lease at inception of the contract and whether that lease meets the classification criteria of a finance or operating lease. When available, the Company uses the rate implicit in the lease to discount lease payments to present value; however, most of the Company’s leases do not provide a readily determinable implicit rate. Therefore, the Company discounts lease payments based on an estimate of its incremental borrowing rate.

 

F-19

 

 

NOTE 6 — LEASES (continued)

 

The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.

 

The table below presents the operating lease related assets and liabilities recorded on the balance sheets.

 

		March 31, 2024				September 30, 2023
Operating lease right-of-use assets		$	263,331			$	-
Operating lease liabilities – current		$	88,297			$	-
Operating lease liabilities – non-current			179,691				-
Total operating lease liabilities		$	267,988			$	-

 

The weighted average remaining lease terms and discount rates for all of operating leases were as follows as of March 31, 2024 and September 30, 2023:

 

		March 31, 2024				September 30, 2023
Remaining lease term and discount rate:
Weighted average remaining lease term (years)			2.25				-
Weighted average discount rate *			3.0	%			-

 

*	The Company used incremental borrowing rate of 3.0% for its lease contracts.

 

During the six months ended March 31, 2024 and 2023, the Company incurred total operating lease expenses of $88,469 and $24,198, respectively.

 

The following is a schedule, by years, of maturities of lease liabilities as of March 31, 2024:

 

Remainder of 2024		$	68,402
2025			136,806
2026			71,231
Total lease payments			276,439
Less: imputed interest			(8,451	)
Present value of lease liabilities		$	267,988

 

F-20

 

 

NOTE 7 — PROPERTY, PLANT AND EQUIPMENT, NET

 

Property, plant and equipment, net, consist of the following:

 

		March 31, 2024				September 30, 2023
Buildings		$	2,420,992			$	2,396,519
Machinery and equipment			1,792,580				1,778,828
Automobiles			215,829				213,647
Office and electric equipment			588,789				569,261
Leasehold improvements			353,294				280,882
Subtotal			5,371,484				5,239,137
Less: accumulated depreciation			(3,907,377	)			(3,758,341	)
Property, plant and equipment, net		$	1,464,107			$	1,480,796

 

Depreciation expense was $112,713 and $111,964 for the six months ended March 31, 2024 and 2023, respectively. 

 

NOTE 8 — LAND USE RIGHT, NET

 

Land use right, net, consisted of the following:

 

		March 31, 2024				September 30, 2023
Land use rights		$	1,198,186			$	220,178
Less: accumulated amortization			(73,782	)			(65,814	)
Land use right, net		$	1,124,404			$	154,364

 

Amortization expense was $7,333 and $2,501 for the six months ended March 31, 2024 and 2023, respectively.

 

Estimated future amortization expense for land use rights is as follows:

 

Years ending March 31,
2025		$	24,351
2026			24,351
2027			24,351
2028			24,351
2029			24,351
Thereafter			1,002,649
		$	1,124,404

 

F-21

 

 

NOTE 9 — SHORT-TERM BANK LOANS

 

Short-term bank loans consisted of the following:

 

		March 31, 2024				September 30, 2023
Industrial and Commercial Bank of China (1)		$	4,155,000			$	4,113,000
China Merchants Bank (2)			1,385,000				-
Agricultural Bank of China (3)			2,756,150				-
Jiangsu Bank (4)			1,385,000				-
Total short-term bank loans		$	9,681,150			$	4,113,000

 

The terms of the various loan agreements related to short-term bank loans contain certain restrictive covenants which, among other things, require the Company to maintain positive net income and certain financial indicators. The terms also prohibit the Company from entering into transactions that may have a significant adverse impact on the Company’s ability to fulfil its loan obligations, including but not limited to, reorganization of the Company or its subsidiaries, disposing the Company’s business or assets, providing loans or guarantees to third parties, etc. The Company was in compliance with such covenants as of March 31, 2024 and September 30, 2023.

 

(1)

On September 28, 2023, Changzhou Zhongjin signed a loan agreement with Industrial and Commercial Bank of China to borrow $4,155,000 (RMB 30.0 million) as working capital for one year, with a maturity date of September 25, 2024. The loan had a fixed interest rate of 2.90% per annum.

 

(2)

On January 3, 2024, Changzhou Zhongjin entered into a loan agreement with China Merchants Bank to borrow $1,385,000 (RMB 10.0 million) as working capital. The loan has a fixed interest rate of 2.80% per annum and matures in one year. In addition, the Company’s major shareholder Mr. Erqi Wang, signed a maximum guarantee agreement with China Merchants Bank to provide personal credit guarantees for the loan.

 

(3)

On January 3, 2024, Changzhou Zhongjin entered into a loan agreement with Agricultural Bank of China to borrow $2,756,150 (RMB 19.9 million) as working capital. The loan has a fixed interest rate of 2.95% per annum and matures in one year.

 

(4)

On January 10, 2024, Changzhou Zhongjin entered into a loan agreement with Jiangsu Bank to borrow $1,385,000 (RMB 10.0 million) as working capital. The loan has a fixed interest rate of 3% per annum and matures in six months. In addition, the Company’s major shareholder Mr. Erqi Wang, signed a maximum guarantee agreement with Jiangsu Bank to provide personal credit guarantees for the loan. The loan was fully repaid on July 15, 2024.

 

The Company incurred interest expenses of $93,256 and $nil for the six months ended March 31, 2024 and 2023, respectively.

 

F-22

 

 

NOTE 10 — RELATED PARTY TRANSACTIONS

 

a. Accounts receivable - related parties

 

Accounts receivable - related parties consists of the following:

 

Name		Related party relationship		March 31, 2024				September 30, 2023
Shanghai Situma Intelligent Technology Co., Ltd.		Minority shareholder of the Company		$	117,082			$	393,068
Jiangsu Zhongjin Kanglu Information Technology Co., Ltd.		An entity controlled by the CEO			292,387				364,750
Jinmed International Co., Ltd.		An entity controlled by the CEO			-				141,131
Zhongjin Hongkang Medical Technology (Shanghai) Co., Ltd.		An entity controlled by the CEO			656,216				49,000
Zhongjiankanglu Industrial Development (Shanghai) Co., Ltd.		An entity controlled by the CEO			458,885				-
Subtotal					1,524,570				947,949
Less: allowance for credit losses					-				-
Total accounts receivable, net - related parties				$	1,524,570			$	947,949

 

For accounts receivable due from related parties, approximately 56.9%, or $0.9 million of the March 31, 2024 balances have been subsequently collected. The remaining balance is expected to be collected before March 31, 2025. 

 

b. Due from related parties

 

Due from related parties consists of the following:

 

Name		Related party relationship		March 31, 2024				September 30, 2023
Jiangsu Zhongjin Kanglu Information Technology Co., Ltd. (“Zhongjin Kanglu”) (1)		An entity controlled by the CEO		$	-			$	4,189,813
Huaniaoyuan Catering Management (Changzhou) Co. Ltd.		An entity controlled by the CEO			65,037				50,711
Total due from related parties				$	65,037			$	4,240,524

 

(1)

As of September 30, 2023, the balance due from a related party, Zhongjin Kanglu, was $4,189,813. During the year ended September 30, 2023, as a business collaboration, the Company made advances to Zhongjin Kanglu in the amount of $4,113,000 (RMB30.0 million) as for its temporary working capital needs during the normal course of business. The $4,113,000 advance made to Zhongjin Kanglu has been fully collected in October 2023. The Company expects to make no such advances to its related parties in the future.

 

F-23

 

 

NOTE 10 — RELATED PARTY TRANSACTIONS (continued)

 

c. Deferred revenue – related parties

 

Deferred revenue – related parties consist of the following:

 

Name		Related party relationship		March 31, 2024				September 30, 2023
Jin Med Medical (Korea) Co., Ltd.		An entity controlled by the CEO		$	128,860			$	117,424
Zhongjiankanglu Industrial Development (Shanghai) Co., Ltd.		An entity controlled by the CEO			-				1,371
Jinmed International Co., Ltd.		An entity controlled by the CEO			2,332				-
Zhongjin Jingau Rehabilitation Equipment (Beijing) Co. Ltd.		An entity controlled by the CEO			329				325
Total deferred revenue – related parties				$	131,521			$	119,120

 

d. Due to related parties

 

Due to related parties consists of the following:

 

Name		Related party relationship		March 31, 2024				September 30, 2023
Jiangsu Zhongjin Kanglu Information Technology Co., Ltd.		An entity controlled by the CEO		$	116,302			$	-
Shanghai Situma Intelligent Technology Co., Ltd.		Minority shareholder of the Company			21,226				-
Huaniaoyuan Environmental Engineering (Changzhou) Co., Ltd.		An entity controlled by the CEO			637				630
Changzhou Zhongjian Kanglu Information Technology Co., Ltd		An entity controlled by the CEO			499				494
Total due to related parties				$	138,664			$	1,124

 

The balance due to related parties was mainly comprised of advances from entities controlled by the Company’s CEO and used for working capital during the Company’s normal course of business. These advances are non-interest bearing and due on demand.

 

e. Revenue from related parties

 

Revenue from related parties consists of the following:

 

				For the Six Months Ended March 31,
Name		Related party relationship		2024				2023
Jiangsu Zhongjin Kanglu Information Technology Co., Ltd.		An entity controlled by the CEO		$	227,339			$	333,106
Zhongjiankanglu Industrial Development (Shanghai) Co., Ltd.		An entity controlled by the CEO			409,377				17,381
Zhongjin Jingau Rehabilitation Equipment (Beijing) Co. Ltd.		An entity controlled by the CEO			-				12,384
Zhongjin Hongkang Medical Technology (Shanghai) Co., Ltd.		An entity controlled by the CEO			539,662				-
Total revenue from related parties				$	1,176,378			$	362,871

 

F-24

 

 

NOTE 11 — TAXES

 

(a) Corporate Income Taxes (“CIT”)

 

The Company is subject to income taxes on an entity basis on income arising in or derived from the tax jurisdiction in which each entity is domiciled.

 

Cayman Islands

 

Under the current laws of the Cayman Islands, the Company is not subject to tax on income or capital gain. In addition, no Cayman Islands withholding tax will be imposed upon the payment of dividends by the Company to its shareholders.

 

Hong Kong

 

Zhongjin HK is subject to Hong Kong profits tax at a rate of 8.25% on assessable profits up to HK$2,000,000, and 16.5% on any part of assessable profits over HK$2,000,000. However, it did not generate any assessable profits arising in or derived from Hong Kong for the six months ended March 31, 2024 and 2023, and accordingly no provision for Hong Kong profits tax has been made in these periods.

 

PRC

 

Erhua Med, Anhui Zhongjin, Changzhou Zhongjin and its subsidiaries are incorporated in the PRC, and are subject to the PRC Enterprise Income Tax. Under the Enterprise Income Tax (“EIT”) Law of PRC, domestic enterprises and Foreign Investment Enterprises (“FIE”) are subject to a unified 25% enterprise income tax rate while preferential tax rates, tax holidays and even tax exemptions may be granted on case-by-case basis.

 

EIT grants preferential tax treatment to High and New Technology Enterprises (“HNTEs”). Under this preferential tax treatment, HNTEs are entitled to an income tax rate of 15%, subject to a requirement that they re-apply for HNTE status every three years. Changzhou Zhongjin and Taizhou Zhongjin, the VIE and VIE’s main operating subsidiary in the PRC, were approved as HNTEs and are entitled to a reduced income tax rate of 15% beginning November 2018 and November 2019, respectively, which are valid for three years. In November 2021, Changzhou Zhongjin successfully renewed its HNTE certification with local government and continued to enjoy the reduced income tax rate of 15% for another three years through November 2024. In November 2022, Taizhou Zhongjin successfully renewed its HNTE certification with local government and continued to enjoy the reduced income tax rate of 15% for another three years through November 2025.

 

In addition, based on the EIT Law of PRC, and according to the Announcement on Issues Related to the Implementation of Inclusive Income Tax Reduction and Exemption Policy for Small and Low Profit Enterprises issued by the State Administration of Taxation on January 18, 2019 and April 2, 2021, once an enterprise meets certain requirements and is identified as a small-scale minimal profit enterprise, the portion of its taxable income not more than RMB1 million is subject to a reduced rate of 5% (the rate was further reduced to 2.5% for the period from January 1, 2021 to December 31, 2022), and the portion between RMB1 million and RMB3 million is subject to a reduced rate of 10%. The policy is effective for the period from January 1, 2019 to December 31, 2022. According to the Announcement on Implementing the Preferential Income Tax Policies for Small-Scale Minimal Profit Enterprise on March 14, 2022 and March 26, 2023, the taxable income not more than RMB3 million is subject to a reduced rate of 5% during the period from January 1, 2023 to December 31, 2024. Zhongjin Jing’ao is qualified as a small-scale minimal profit enterprise for the six months ended March 31, 2024 and 2023.

 

EIT is typically governed by the local tax authority in the PRC. Each local tax authority at times may grant tax holidays to local enterprises as a way to encourage entrepreneurship and stimulate local economy. The corporate income taxes for the six months ended March 31, 2024 and 2023 were reported at a reduced rate for both Changzhou Zhongjin and Taizhou Zhongjin for being approved as HNTEs and enjoying a reduced income tax rate at 15% instead of 25%, and Zhongjin Jing’ao is qualified as a small-scale minimal profit enterprise for a further reduced income tax rate of 5%. The impact of the tax holidays noted above decreased the Company’s income taxes by $294,310 and $195,135 for the six months ended March 31, 2024 and 2023, respectively. The effect of the tax holidays on net income per share (basic and diluted) was immaterial for the six months ended March 31, 2024 and 2023.

 

F-25

 

 

NOTE 11 — TAXES (continued)

 

(a) Corporate Income Taxes (“CIT”) (continued)

 

The components of the income tax provision are as follows:

 

		For the Six Months Ended March 31
		2024				2023
Current tax provision
BVI		$	-			$	-
Hong Kong			-				-
PRC			285,302				135,492
			285,302				135,492
Deferred tax provision
BVI			-				-
Hong Kong			-				-
PRC			23,711				68,561
			23,711				68,561
Income tax provision		$	309,013			$	204,053

 

Deferred tax assets, net are composed of the following:

 

		March 31, 2024				September 30, 2023
Deferred tax assets:
Net operating loss carry-forwards		$	113,753			$	5,049
Inventory written down			135,064				144,106
Allowance for credit losses			6,124				19,008
Total			254,941				168,163
Valuation allowance			(124,500	)			(15,688	)
Total deferred tax assets, net		$	130,441			$	152,475

 

Movement of the valuation allowance:

 

		March 31, 2024				September 30, 2023
Beginning balance		$	15,688			$	14,248
Current year addition			109,201				1,844
Exchange difference			(389	)			(404	)
Ending balance		$	124,500			$	15,688

 

The Company periodically evaluates the likelihood of the realization of deferred tax assets, and reduces the carrying amount of the deferred tax assets by a valuation allowance to the extent it believes a portion will not be realized. Management considers new evidence, both positive and negative, that could affect the Company’s future realization of deferred tax assets including its recent cumulative earnings experience, expectation of future income, the carry forward periods available for tax reporting purposes and other relevant factors. The Company determined that it is more likely than not its deferred tax assets could not be realized due to uncertainty on future earnings in Zhongjin Jing’ao, Zhongjin Kangma and Anhui Zhongjin. The Company provided a 100% allowance for their deferred tax assets as of March 31, 2024.

 

F-26

 

 

NOTE 11 — TAXES (continued)

 

(a) Corporate Income Taxes (“CIT”) (continued)

 

The following table reconciles the China statutory rates to the Company’s effective tax rate for the six months ended March 31, 2024 and 2023:

 

		For the Six Months Ended March 31,
		2024				2023
China Income tax statutory rate			25.0	%			25.0	%
Effect of PRC tax holiday			(14.6	)%			(9.9	)%
Research and development tax credit			(6.8	)%			(4.8	)%
Non-PRC entity not subject PRC income tax			5.7	%			-	%
Change in valuation allowance			6.5	%			0.1	%
Others			(0.5	)%			-	%
Effective tax rate			15.3	%			10.4	%

 

The Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. As of March 31, 2024, all of the Company’s tax returns of its PRC Subsidiaries remain open for statutory examination by PRC tax authorities.

 

(b) Taxes payable

 

Taxes payable consist of the following:

 

		March 31, 2024				September 30, 2023
Income tax payable		$	547,461			$	263,131
Value added tax payable			12,510				1,627
Other taxes payable			4,655				6,665
Total taxes payable		$	564,626			$	271,423

 

NOTE 12 — CONCENTRATIONS

 

A majority of the Company’s revenue and expense transactions are denominated in RMB and a significant portion of the Company’s assets and liabilities are denominated in RMB. RMB is not freely convertible into foreign currencies. In the PRC, foreign exchange transactions are required by law to be transacted only by authorized financial institutions at exchange rates set by the People’s Bank of China (“PBOC”). Remittances in currencies other than RMB may require certain supporting documentation in order to effect the remittance.

 

As of March 31, 2024 and September 30, 2023, $225,356 and $1,363,617 of the Company’s cash was deposited at financial institutions outside of PRC, $8,637,315 and $5,561,070 of the Company’s cash was on deposit at financial institutions in mainland China, and $1,955 and $108 of the Company’s cash was on deposit at financial institutions in Hong Kong. None of the Company cash deposited at financial institutions maintain insurance to cover bank deposits in the event of bank failure. However, the Company has not experienced any losses in such accounts and believes it is not exposed to any risks on its cash on bank accounts. For the six months ended March 31, 2024 and 2023, the Company’s substantial assets were located in the PRC and all of the Company’s revenues were derived from its subsidiaries located in the PRC.

 

F-27

 

 

NOTE 12 — CONCENTRATIONS (continued)

 

For the six months ended March 31, 2024 and 2023, one customer accounted for approximately 53.7% and 70.3% of the Company’s total revenue. Sales to the subsidiaries of this customer accounted for approximately 5.7% and 7.7% of the Company’s total revenue for the six months ended March 31, 2024 and 2023, respectively. In aggregate, sales to this customer and its subsidiaries represent approximately 59.4% and 78.0% of the Company’s total revenue for the six months ended March 31, 2024 and 2023, respectively.

 

As of March 31, 2024, two customers accounted for 46.5% and 13.6% of the accounts receivable balance. As of September 30, 2023, one customer accounted for 53.1% of the accounts receivable balance.

 

For the six months ended March 31, 2024 and 2023, no supplier accounted for more than 10% of the Company’s total purchases, respectively.

 

As of March 31, 2024 and September 30, 2023, one supplier accounted for 13.2% and 10.5% of the accounts payable balance, respectively.

 

NOTE 13 — SHAREHOLDERS’ EQUITY

 

Ordinary Shares

 

On February 8, 2024, the Company formally executed a forward stock split of its ordinary shares at a ratio of one pre-split ordinary share to 20 post-split ordinary shares. After the stock split, the authorized number of ordinary shares became 1,000,000,000, increased from 50,000,000 pre-split shares. The par value changed from $0.001 to $0.00005 accordingly. The number of shares and per share data are presented herein have been retroactively adjusted to give effect to the stock split.

 

Upon the incorporation of the Company, 400,000,000 ordinary shares were issued. On October 28, 2022, the original shareholders of the Company surrendered 265,000,000 ordinary shares for no consideration. As a result, on a retrospective basis, 135,000,000 ordinary shares were issued and outstanding as of September 30, 2022 and 2021.

 

Initial Public Offering

 

On March 30, 2023, the Company closed its initial public offering (the “Offering”) of 20,000,000 ordinary shares at a public offering price of $0.4 per share for total gross proceeds of $8,000,000 before deducting underwriting discounts and offering expenses. Net proceeds of the Company’s Offering were approximately $6.8 million. In addition, the Company granted the underwriters a 45-day option to purchase up to an additional 3,000,000 ordinary shares at the public offering price, less underwriting discounts, to cover over-allotment, if any. On April 6, 2023, the underwriter partially exercised the over-allotment option to purchase an additional 947,100 ordinary shares for total gross proceeds of $378,840 before deducting underwriting discounts and commissions. As of May 14, 2023, the remaining options were expired. The Company’s ordinary shares began trading on the Nasdaq Capital Market under the symbol “ZJYL” on March 28, 2023.

F-28

 

 

NOTE 13 — SHAREHOLDERS’ EQUITY (continued)

 

Statutory reserve and restricted net assets

 

The Company’s PRC subsidiaries, VIE and VIE’s subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company. The payment of dividends by entities organized in China is subject to limitations, procedures and formalities. Regulations in the PRC currently permit payment of dividends only out of accumulated profits as determined in accordance with accounting standards and regulations in China.

 

The Company is required to make appropriations to certain reserve funds, comprising the statutory surplus reserve and the discretionary surplus reserve, based on after-tax net income determined in accordance with generally accepted accounting principles of the PRC (“PRC GAAP”). Appropriations to the statutory surplus reserve are required to be at least 10% of the after-tax net income determined in accordance with PRC GAAP until the reserve is equal to 50% of the entity’s registered capital. Appropriations to the discretionary surplus reserve are made at the discretion of the Board of Directors. The statutory reserve may be applied against prior year losses, if any, and may be used for general business expansion and production or increase in registered capital, but are not distributable as cash dividends.

 

Relevant PRC laws and regulations restrict the Company’s PRC subsidiaries, VIE and VIE’s subsidiaries from transferring a portion of their net assets, equivalent to their statutory reserves and their share capital, to the Company’s shareholders in the form of loans, advances or cash dividends. Only PRC entities’ accumulated profits may be distributed as dividends to the Company’s shareholders without the consent of a third party. As of March 31, 2024 and September 30, 2023, the restricted amounts as determined pursuant to PRC statutory laws totaled $2,277,430 and $2,010,890, respectively, and total restricted net assets amounted to $2,363,989 and $2,097,449, respectively.

 

NOTE 14 — COMMITMENTS AND CONTINGENCIES

 

Contingencies

 

From time to time, the Company is a party to various legal actions arising in the ordinary course of business. The Company accrues costs associated with these matters when they become probable and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. The Company’s management does not expect any liability from the disposition of such claims and litigation individually or in the aggregate to have a material adverse impact on the Company’s unaudited condensed consolidated financial position, results of operations and cash flows. The Company currently does not have any material legal proceedings.

 

NOTE 15 — SEGMENT REPORTING

 

An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses, and is identified on the basis of the internal financial reports that are provided to and regularly reviewed by the Company’s chief operating decision maker in order to allocate resources and assess performance of the segment.

 

The management of the Company concludes that it has only one reporting segment. The Company designs and manufactures quality wheelchair and other living aids products. The Company’s products have similar economic characteristics with respect to raw materials, vendors, marketing and promotions, customers and methods of distribution. The Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews consolidated results when making decisions about allocating resources and assessing performance of the Company, rather than by product types or geographic area; hence the Company has only one reporting segment.

 

F-29

 

 

NOTE 16 — SUBSEQUENT EVENTS

 

Communications with Nasdaq

 

As previously disclosed, on March 28, 2024, the Company received a hearing decision letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for continued listing on The Nasdaq Stock Market, subject to the condition that the Company files its annual report on Form 20-F for fiscal year 2023 (the “Annual Report”) with the Securities and Exchange Commission (the “SEC”) on or before May 20, 2024. On April 26, 2024, the Company filed its Annual Report with the SEC. On May 9, 2024, the Company received a letter from Nasdaq informing the Company that it has regained compliance with the filing requirement in Listing Rule 5250(c) regarding the filing of the Annual Report, as required by the Panel’s decision dated March 28, 2024. The Company was also notified that the Panel has determined to monitor the Company’s compliance with the filing requirement in Listing Rule 5250(c) (the “Filing Rule”) through May 9, 2025, in accordance with Nasdaq Listing Rule 5815(d)(4)(B) (the “Panel Monitor”). During the period of the Panel Monitor, in the event the Company becomes non-compliant with the Filing Rule, and notwithstanding Nasdaq Listing Rule 5810(c)(2), the Company will not be permitted to provide a compliance plan for the Staff’s review and the Staff will not be permitted to grant additional time to the Company to regain compliance with the Filing Rule. Instead, the Staff will be obligated to issue a delist determination, at which time the Company may request a new hearing before a hearing panel.

 

In accordance with ASC Topic 855, “Subsequent Events”, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before these financial statements are issued, the Company has evaluated all events or transactions that occurred after March 31, 2024, up through July 26, 2024, when the Company issued the unaudited condensed consolidated financial statements.

 

 

 

F-30

 

 

Exhibit 99.2

 

OPERATING AND FINANCIAL REVIEW AND PROSPECTS

 

The following discussion of the financial condition and results of operations is based upon and should be read in conjunction with the unaudited financial results and statements of Jin Medical International Ltd. (the “Company,” “we,” “our,” or “us”) for the six (6) months ended March 31, 2024, furnished as Exhibit 99.1. to this report.

 

Overview

 

Jin Medical International Ltd. through the China-based VIE, Changzhou Zhongjin, and its subsidiaries, design and manufacture wheelchairs and living aids products for people with disabilities, the elderly, and people recovering from injury. Our business focuses primarily on wheelchairs. Currently, our living aids products are only sold to a few selected customers to test the markets for these products. The majority of our products are sold to dealers in Japan and China, while a small number of our products are also sold to dealers located in other regions including the United States, Canada, Australia, Korea, Israel, Singapore, and others.

 

Key Financial Performance Indicators

 

We consider a variety of financial and operating measures in assessing the performance of our business. The key financial performance measures we use are revenue, gross profit and gross margin, operating expenses, and operating income. Our review of these indicators facilitates timely evaluation of the performance of our business and effective communication of results and key decisions, allowing our business to respond promptly to competitive market conditions and different demands and preferences from our customers. The key measures that we use to evaluate the performance of our business are set forth below and are discussed in greater details under “A. Operating Results”.

 

Revenue

 

Our revenue is derived primarily from sales of wheelchairs and wheelchair components and living aids products. We rely to a significant extent on our network of dealers to sell our products to end customers. We distribute approximately 98% of our products through qualified dealers. Our revenue is therefore affected by our ability to establish new relationships and maintain relationships with existing dealers. In addition, revenue is also impacted by competition, current economic conditions, pricing, inflation, and fluctuations in foreign currencies.

 

Gross Profit and Gross Margin

 

Gross profit is the difference between revenue and cost of revenue. Our cost of revenue consists of raw materials, direct labor and other related production overhead. Raw materials account for the largest portion of our cost of revenue. Supplies and prices of our various raw materials can be affected by worldwide supply and demand factors, as well as other factors beyond our control such as financial market trends. We purchase, directly and indirectly through third-party suppliers, significant amounts of aluminum, steel, plastics, titanium alloys, as well as other commodity-sensitive raw materials annually. In particular, in past years, steel and aluminum prices have experienced volatility which has been unforeseen and unexpected. Raw material price fluctuations may adversely affect our operating results and profitability. From time to time, we purchase and store steel, iron, aluminum, and other raw materials up to 3 months in advance to provide economic buffers regarding portions of our pricing and supply. Due to the impact of Covid-19, some of our wheelchair components, such as tires, we had places orders up to 6 months in advance from suppliers in Taiwan and Japan since October 2021. However, the orders from these suppliers have returned to 3 months for delivery since February 2023. For the majority of our raw material purchases we do not typically enter into any fixed-price contracts and may not be able to accurately anticipate future raw material prices for those inputs.

 

 

 

 

Over the past years, we have invested significant time and energy to achieve cost reduction and productivity improvement in our supply chain. We have focused on reducing raw materials costs through increased volume buying, direct purchasing, and price negotiations. In addition, we achieve manufacturing efficiency by standardizing and optimizing certain procedures across our production cycle such as procurement, engineering and product development, manufacturing, dealer management, and pricing. On the other hand, labor is a primary component in the cost of operating our business. Increased labor costs due to competition, increased minimum wage or employee benefits costs, or otherwise, would adversely impact our operating expenses. And our success also depends on our ability to attract, motivate, and retain qualified employees, including senior management and technically competent employees, to keep pace with our growth strategy.

 

Gross margin is gross profit divided by revenue. Gross margin is a measure used by management to indicate whether we are selling our products at an appropriate gross profit. Our gross margin is impacted by our product mix and availability, as some new or high-end products generally provide higher gross margins. Gross margin is also impacted by prices of our products. We consider many factors such as cost of revenue increases and competitive pricing strategies. We have historically been able to launch new products with higher prices, and these new products can reflect market trends and are designed to meet customer new demand. To achieve this, we seek to maintain continued focus on our R&D efforts that we believe will enhance our existing market positions and allow us to compete into new, attractive, wheelchair and other living aids products categories.

 

Operating Expenses

 

Our operating expenses consist of selling expenses, general and administrative expenses and research and development expenses.

 

Our selling expenses primarily include salaries and welfare benefit expenses paid to our sales personnel, advertising expenses to increase our brand awareness, shipping and delivery expenses, expenses incurred for export and custom clearance, our business travel, meals and other sales promotion and marketing activities related expenses. Our selling expenses accounted for 3.4% and 2.0% of our total revenue for the six months ended March 31, 2024 and 2023, respectively. We expect that our overall selling expenses, including but not limited to, advertising expenses and brand promotion expenses, will continue to increase in the foreseeable future if our business further grows.

 

Our general and administrative expenses primarily consist of employee salaries, welfare and insurance expenses, depreciation, bad debt reserve expenses, inspection and maintenance expenses, office supply and utility expenses, business travel and meal expenses and professional service expenses. General and administrative expenses were 14.6% and 9.0% of our revenue for the six months ended March 31, 2024 and 2023, respectively. We expect our general and administrative expenses, including, but not limited to, business consulting expenses, to continue to increase in the foreseeable future, as we expect to incur additional expenses in connection with the expansion of our business operations. We expect our professional fees for legal, audit, and advisory services to increase after we became a public company upon the completion of initial public offering.

 

Our research and development expenses primarily consist of salaries, welfare and insurance expenses paid to our employees involved in the research and development activities, materials and supplies used in the development and testing new wheelchair and living aids products, depreciation and other miscellaneous expenses. Research and development expenses were 5.8%, and 6.2% of our revenue for the six months ended March 31, 2024 and 2023, respectively. Our research and development expenses decreased slightly for the six months ended March 31, 2024, however, we will continue to develop new products and diversify our product offerings to satisfy customer demand, we expect our research and development expenses to increase in the foreseeable future.

 

Operating Income

 

Operating income is the difference between gross profit and operating expenses. Operating income excludes interest income, other income, and income tax expenses. We use operating income as an indicator of the productivity of our business and our ability to manage expenses.

 

2

 

 

A. Operating Results

 

Comparison of Results of Operations for the Six Months Ended March 31, 2024 and 2023

 

The following table summarizes the results of our operations during the six months ended March 31, 2024 and 2023, respectively, and provides information regarding the dollar and percentage increase or (decrease) during such periods.

 

		For the six months ended March 31,								Variance
		2024				2023				Amount				%
Revenue		$	10,556,891			$	10,253,163			$	303,728				3.0	%
Cost of revenue and related tax			6,820,561				6,722,290				98,271				1.5	%
Gross profit			3,736,330				3,530,873				205,457				5.8	%
OPERATING EXPENSES
Selling expenses			358,768				206,194				152,574				74.0	%
General and administrative expenses			1,538,680				922,188				616,492				66.9	%
Research and development expenses			609,645				631,034				(21,389	)			(3.4	)%
Total operating expenses			2,507,093				1,759,416				747,677				42.5	%
INCOME FROM OPERATIONS			1,229,237				1,771,457				(542,220	)			(30.6	)%
OTHER INCOME (EXPENSES)
Interest income, net			681,588				94,571				587,017				620.7	%
Foreign exchange gain (loss)			414				(63,253	)			63,667				(100.7	)%
Other income, net			102,164				167,625				(65,461	)			(39.1	)%
Total other income, net			784,166				198,943				585,223				294.2	%
INCOME BEFORE INCOME TAX PROVISION			2,013,403				1,970,400				43,003				2.2	%
INCOME TAX PROVISION			309,013				204,053				104,960				51.4	%
NET INCOME			1,704,390				1,766,347				(61,957	)			(3.5	)%
Less: net loss attributable to non-controlling interest			(89,704	)			-				(89,704	)			(100.0	)%
NET INCOME ATTRIBUTABLE TO JIN MEDICAL INTERNATIONAL LTD.			1,794,094				1,766,347				27,747				1.6	%

 

Revenues

 

We generate revenue primarily from wheelchair products and wheelchair components and living aids products sold in Japan, China and other countries. Our wheelchair products consist primarily of manual wheelchairs. Our other products consist of wheelchair components and living aids products such as oxygen concentrators, bath aids, rehabilitative devices and shared healthcare products and related infrastructures. Total revenue increased by $303,728, or 3.0%, from $10,253,163 for the six months ended March 31, 2023 to $10,556,891 for the six months ended March 31, 2024.

 

3

 

  

The following table sets forth the breakdown of our revenue for the six months ended March 31, 2024 and 2023, respectively:

 

		For the six months ended March 31,
		2024				2023				Change
		Amount				Amount				Amount				%
Wheelchair		$	7,694,373			$	8,381,323			$	(686,950	)			(8.2	)%
Wheelchair components and other products			2,862,518				1,871,840				990,678				52.9	%
Total revenue		$	10,556,891			$	10,253,163			$	303,728				3.0	%

  

Revenue from wheelchair products accounted for 72.9% and 81.7% of our total revenue for the six months ended March 31, 2024 and 2023, respectively. Revenue from wheelchair products decreased by $686,950, or 8.2%, from $8,381,323 for the six months ended March 31, 2023 to $7,694,373 for the six months ended March 31, 2024. The decrease was mainly due to our sales transactions denominated in Japanese Yen. We sell our wheelchair products to our largest customer in Japanese Yen. However, due to weakening of the Japanese Yen, our revenue decreased after we translate Japanese Yen into our functional currency RMB. The decrease was also due to the depreciation of RMB against U.S. dollars. The average translation rate for the six months ended March 31, 2024 and 2023 was at RMB 1=US$0.1392 and RMB 1=US$0.1433, respectively, resulting in a decrease of 2.9%.

 

Revenue from wheelchair components and other products accounted for 27.1% and 18.3% of our total revenue for the six months ended March 31, 2024 and 2023, respectively. Revenue from wheelchair components and other products increased by $990,678, or 52.9%, from $1,871,840 for the six months ended March 31, 2023 to $2,862,518 for the six months ended March 31, 2024. The increase was mainly due to the increased revenues from newly launched portable nano-thermal therapy bath products and micro hyperbaric oxygen chamber products. The increase was also due to revenue generated by our newly incorporated subsidiary Zhongjin Kangma during the six months ended March 31, 2024.

 

Cost of Revenues and Related Tax

 

Our cost of revenues and related tax primarily consists of inventory costs (raw materials, labor, packaging cost, depreciation and amortization, third-party products purchase price, freight costs and overhead) and business tax. Cost of revenues and related tax generally changes as our production costs change, which are affected by factors including the market price of raw materials, labor productivity, etc. Our overall cost of revenue and related tax increased by $98,271 or 1.5%, from $6,722,290 for the six months ended March 31, 2023 to $6,820,561 for the six months ended March 31, 2024.

 

The following table sets forth the breakdown of our cost of revenue and related tax for the six months ended March 31, 2024 and 2023, respectively:

 

		For the six months ended March 31,
		2024				2023				Change
		Amount				Amount				Amount				%
Wheelchair		$	5,184,260			$	5,628,285			$	(444,025	)			(7.9	)%
Wheelchair components and others			1,636,301				1,094,005				542,296				49.6	%
Total cost of revenue and related tax		$	6,820,561				6,722,290				98,271				1.5	%

 

4

 

 

Cost of revenue and related tax from wheelchair products decreased by $444,025, or 7.9%, from $5,628,285 for the six months ended March 31, 2023 to $5,184,260 for the six months ended March 31, 2024. The decrease in cost of revenue and related tax from wheelchair products was in line with the decrease in revenue from wheelchair products.

 

Cost of revenue and related tax from wheelchair components and other products increased by $542,296, or 49.6%, from $1,094,005 for the six months ended March 31, 2023 to $1,636,301 for the six months ended March 31, 2024. The percentage increase in cost of revenue and related tax from wheelchair components and others products was less than the percentage increase in revenue from wheelchair components and others products, as discussed in greater details below.

 

Gross profit

 

Our gross profit increased by $205,457, or 5.8%, from $3,530,873 for the six months ended March 31, 2023 to $3,736,330 for the six months ended March 31, 2024. The increase was mainly attributable to the increased gross profit from wheelchair components and others, which was partially offset by the decreased gross profit from wheelchair products. Our gross margin remained relatively stable with a slighted increase of 1.0 percentage points from 34.4% for the six months ended March 31, 2023 to 35.4% for the six months ended March 31, 2024.

 

The following table sets forth the breakdown of our gross profit for the six months ended March 31, 2024 and 2023, respectively:

 

		For the six months ended March 31,																Variance
		2024				Margin %				2023				Margin %				Amount				%
Wheelchair		$	2,510,113				32.6	%		$	2,753,038				32.8	%		$	(242,925	)			(8.8	)%
Wheelchair components and others			1,226,217				42.8	%			777,835				41.6	%			448,382				57.6	%
Total Gross Profit and Margin %		$	3,736,330				35.4	%		$	3,530,873				34.4	%		$	205,457				5.8	%

 

The gross profit of wheelchair products decreased by $242,925, or 8.8%, from $2,753,038 for the six months ended March 31, 2023 to $2,510,113 for the six months ended March 31, 2024, which was due to the decrease in revenue from wheelchair products. The gross margin remained relatively stable with a slighted decrease of 0.2% from 32.8% for the six months ended March 31, 2023 to 32.6% for the six months ended March 31, 2024.

 

The gross profit of wheelchair components and other products increased by $448,382, or 57.6%, from $777,835 for the six months ended March 31, 2023 to $1,226,217 for the six months ended March 31, 2024, which was in line with the increase in the revenue of wheelchair components and other products. The gross margin of wheelchair components and other products increased by 1.2% from 41.6% for the six months ended March 31, 2023 to 42.8% for the six months ended March 31, 2024. The increase was mainly due to the increased sales of newly launched portable nano-thermal therapy bath products and micro hyperbaric oxygen chamber products both with higher gross margin during the six months ended March 31, 2024.

 

5

 

 

Operating expenses

 

The following table sets forth the breakdown of our operating expenses for the six months ended March 31, 2024 and 2023, respectively:

 

		For the six months ended March 31,
		2024								2023								Variance
		Amount				% of revenue				Amount				% of revenue				Amount				%
Total revenue		$	10,556,891				100.0	%		$	10,253,163				100.0	%		$	303,728				3.0	%
Operating expenses:
Selling expenses			358,768				3.4	%			206,194				2.0	%			152,574				74.0	%
General and administrative expenses			1,538,680				14.6	%			922,188				9.0	%			616,492				66.9	%
Research and development expenses			609,645				5.8	%			631,034				6.2	%			(21,389	)			(3.4	)%
Total operating expenses		$	2,507,093				23.7	%		$	1,759,416				17.2	%		$	747,677				42.5	%

 

Selling expenses

 

Our selling expenses primarily include salaries and welfare benefit expenses paid to our sales personnel, advertising expenses to increase our brand awareness, shipping and delivery expenses, expenses incurred for export and custom clearance, our business travel, meals and other sales promotion and marketing activities related expenses.

 

Our selling expenses increased by $152,574, or 74.0%, from $206,194 for the six months ended March 31, 2023 to $358,768 for the six months ended March 31, 2024. The increase was mainly due to selling expenses incurred by our newly incorporated subsidiary Zhongjin Kangma. As a percentage of revenues, our selling expenses accounted for 3.4% and 2.0% of our total revenue for the six months ended March 31, 2024 and 2023, respectively.

 

General and administrative expenses

 

Our general and administrative expenses primarily consist of employee salaries, welfare and insurance expenses, depreciation, bad debt reserve expenses, inspection and maintenance expenses, office supply and utility expenses, business travel and meals expenses and professional service expenses.

 

Our general and administrative expenses increased by $616,492 or 66.9%, from $922,188 for the six months ended March 31, 2023 to $1,538,680 for the six months ended March 31, 2024. The increase was due to the increase in audit, legal and accounting related professional service fee after we became a public company upon the completion of the IPO. The increase was also attributable to general and administrative expenses incurred by our newly incorporated subsidiary Zhongjin Kangma. As a percentage of revenues, our general and administrative expenses accounted for 14.6% and 9.0% of our total revenue for the six months ended March 31, 2024 and 2023, respectively.

 

Research and development expenses

 

Our research and development expenses primarily consist of salaries, welfare and insurance expenses paid to our employees involved in the research and development activities, materials and supplies used in the development and testing new wheelchair products, depreciation and other miscellaneous expenses.

 

Our research and development expenses decreased slightly by $21,389, or, 3.4%, from $631,034 for the six months ended March 31, 2023 to $609,645 for the six months ended March 31, 2024. Our research and development expenses (excluding the impact of foreign currency translation) remained relatively stable with a slight decrease by 0.5% for the six months ended March 31, 2024 as compared to the same period last year. The decrease was mainly due to the depreciation of RMB against U.S. dollar as mentioned above. As a percentage of revenues, research and development expenses accounted for 5.8% and 6.2% of our total revenue for the six months ended March 31, 2024 and 2023, respectively.

 

6

 

 

Other income (expenses)

 

Our other income (expenses) primarily includes interest expenses incurred on our short-term bank loans, interest income from our short-term investments, foreign exchange transaction gain (loss), government subsidies and others.

 

Our net interest income increased by $587,017 or 620.7%, from net interest income of $94,571 for the six months ended March 31, 2023 to net interest income of $681,588 for the six months ended March 31, 2024. The increase in interest income was primarily due to more short-term investments we invested during the six months ended March 31, 2024.

  

Our foreign exchange transaction gain was $414 for the six months ended March 31, 2024, as compared to a foreign exchange transaction loss of $63,253 for the six months ended March 31, 2023, primarily due to the significant fluctuation in foreign exchange rate on our cash in bank, accounts receivables and accounts payable that denominated in foreign currencies such as U.S. dollars and Japanese Yen during the six months ended March 31, 2024.

 

Our net other income was $102,164 for the six months ended March 31, 2024 as compared to $167,625 for the six months ended March 31, 2023. The decrease in net other income was mainly due to a donation we made to Shanghai Senior Citizens Foundation amounted to $139,200 which was partially offset by the increased government subsidies we received during the six months ended March 31, 2024.

 

Provision for income taxes

 

Our provision for income taxes was $309,013 for the six months ended March 31, 2024, an increase of $104,960, or 51.4%, from $204,053 for the six months ended March 31, 2023, primarily due to our increased taxable income of generated by the Company’s subsidiaries in China during the six months ended March 31, 2024.

 

Net income

 

As a result of the foregoing, we reported a net income of $1,704,390 for the six months ended March 31, 2024, representing a $61,957, or 3.5% decrease from a net income of $1,766,347 for the six months ended March 31, 2023.

 

Net loss attributable to non-controlling interest

 

Changzhou Zhongjin owns an equity interest of 80% of Zhongjin Kangma which was incorporated on August 21, 2023. Accordingly, we recorded non-controlling interest loss attributed to non-controlling shareholder of Zhongjin Kangma. The net loss attributed to non-controlling interest was $89,704 for the six months ended March 31, 2024.

 

Net income attributable to Jin Medical International Ltd.

 

As a result of the foregoing, we reported a net income attributable to Jin Medical International Ltd. of $1,794,094 for the six months ended March 31, 2024, representing a $27,747, or 1.6% increase from a net income of $1,766,347 for the six months ended March 31, 2023.

 

B. Liquidity and Capital Resources

 

Prior to the 20-for-1 forward stock split as mentioned below, on March 30, 2023, we closed our initial public offering (the “Offering”) of 1,000,000 ordinary shares, par value $0.001 per share (the “Ordinary Shares”), at a public offering price of $8.00 per share for total gross proceeds of $8.0 million before deducting underwriting discounts and offering expenses. Net proceeds of our Offering were approximately $6.8 million. In addition, we granted the representative of the underwriters a 45-day option to purchase up to an additional 150,000 Ordinary Shares at the public offering price. On April 6, 2023, the representative of the underwriters partially exercised the over-allotment option to purchase an additional 47,355 Ordinary Shares at the Offering price of $8.00 per share for total gross proceeds of $378,840 before deducting underwriting discounts and commissions. Our Ordinary Shares commenced trading under the symbol “ZJYL” on the Nasdaq Capital Market on March 28, 2023.

 

7

 

  

On January 30, 2024, the Company’s shareholders approved a 20-for-1 forward split of the Company’s ordinary shares to subdivide each of the issued and unissued ordinary shares with a par value of US$0.001 each in the capital of the Company into twenty (20) ordinary shares with a par value of US$0.00005 each (the “Subdivision”), such that, following the Subdivision, the authorized share capital of the Company is US$50,000 divided into 1,000,000,000 shares with a par value of US$0.00005 each. No fractional shares will be issued in connection with the Subdivision. On February 2, 2024, the board of directors approved a market effective date of February 8, 2024. As a result of the Subdivision, the Company’s shares and per share data as reflected in the unaudited condensed consolidated financial statements were retroactively restated as if the transaction occurred at the beginning of the periods presented.

 

Substantially all of our operations are conducted in China and all of our revenue, expenses, cash are denominated in RMB, which is not freely convertible into foreign currencies. All foreign exchange transactions take place either through the People’s Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the People’s Bank of China. Approval of foreign currency payments by the People’s Bank of China or other regulatory institutions requires submitting a payment application form together with suppliers’ invoices, shipping documents and signed contracts. These currency exchange control procedures imposed by the PRC government authorities may restrict the ability of our PRC operating entities to transfer their net assets to us through loans, advances or cash dividends. See Risk Factors - Government control in currency conversion may adversely affect our financial condition, our ability to remit dividends, and the value of your investment. Furthermore, as an offshore holding company with PRC entities, we may only transfer funds to or finance our PRC operating entities by means of loans or capital contributions. Any capital contributions or loans that we make to our PRC operating entities, including from the proceeds of this offering, are subject to PRC regulations and approvals. See Risk Factors - PRC regulation of loans to, and direct investments in, PRC entities by offshore holding companies may delay or prevent us from using proceeds from this offering and/or future financing activities to make loans or additional capital contributions to our PRC operating entities.

 

As of March 31, 2024, we had $8,874,902 in cash as compared to $6,929,508 as of September 30, 2023, and $17,113,103 in short-term investments as compared to $9,768,835 as of September 30, 2023. We also had $5,381,099 in accounts receivable as compared to $4,231,215 as of September 30, 2023. Collected accounts receivable will be used as working capital in our operations. As of March 31, 2024, we had $9,681,150 in short-term bank loans. The management expects that the Company will be able to renew its existing bank loans upon their maturity based on past experience and its good credit history.

 

As of March 31, 2024, our working capital balance was approximately $23.4 million. In assessing our liquidity, management monitors and analyzes our cash on-hand, our ability to generate sufficient revenue in the future, and our operating and capital expenditure commitments. We believe that our current cash and cash flows provided by operating activities, borrowings from banks, as well as the proceeds we received from the IPO will be sufficient to meet our working capital needs in the foreseeable future. However, if we were to experience an adverse operating environment or incur unanticipated capital expenditures, or if we decided to accelerate our growth, then additional financing may be required. Our capital expenditures, including infrastructure to support ongoing operational initiatives have been and will continue to be significant. We cannot guarantee, however, that additional financing, if required, would be available at all or on favorable terms. Such financing may include the use of additional debt or the sale of additional equity securities. Any financing which involves the sale of equity securities or instruments that are convertible into equity securities could result in immediate and possibly significant dilution to our existing shareholders.

 

In the coming years, we will be looking to financing sources, such as additional bank loans and equity financing, to meet our cash needs. While facing uncertainties in regards to the size and timing of capital raises, we are confident that we can continue to meet operational needs mainly by utilizing cash flows generated from our operating activities and shareholder working capital funding, as necessary.

 

8

 

 

Cash Flows

 

Six Months ended March 31, 2024 and 2023

 

The following table sets forth summary of our cash flows for the periods indicated:

 

		For the six months ended March 31,
		2024				2023
Net cash provided by operating activities		$	49,997			$	2,743,493
Net cash used in investing activities			(4,149,238	)			(7,073,829	)
Net cash provided by financing activities			6,004,298				8,099,888
Effect of exchange rate change on cash			40,337				122,004
Net increase  in cash			1,945,394				3,891,556
Cash, beginning of period			6,929,508				4,792,632
Cash, end of period		$	8,874,902			$	8,684,188

 

Operating Activities

 

Net cash provided by operating activities was $49,997 for the six months ended March 31, 2024, mainly derived from a net income of $1,704,390 for the period, and net changes in our operating assets and liabilities, which mainly included an increase in prepaid expenses and other current assets of $1,308,346 and a decrease in accounts payable of $278,216 during the six months ended March 31, 2024.

 

Net cash provided by operating activities was $2,743,493 for the six months ended March 31, 2023, mainly derived from a net income of $1,766,347 for the period, and net changes in our operating assets and liabilities, which mainly included a decrease in inventories of $447,024 and an increase in accounts payable of $348,579 during the six months ended March 31, 2023.

 

Investing Activities

 

Net cash used in investing activities amounted to $4,149,238 for the six months ended March 31, 2024, and primarily included the payments for short-term investments of $16,136,000 and purchase of land-use right of $980,692, which were partially offset by the redemption of short-term investments of $8,810,675 and repayment of advances made to related parties of $4,240,111.

 

Net cash used in investing activities amounted to $7,073,829 for the six months ended March 31, 2023, and primarily included the payments for short-term investments of $3,152,600 and advances made to related parties of $4,760,469.

 

Financing Activities

 

Net cash provided by financing activities amounted to $6,004,298 for the six months ended March 31, 2024, which included net proceeds from sale of Ordinary Shares of $311,995 and proceeds from short-term bank loans of $5,554,080.

 

Net cash provided by financing activities amounted to $8,099,888 for the six months ended March 31, 2023, which included the proceeds from short-term bank loan of $1,433,000 and gross proceeds from initial public offerings of $8,000,000, which was partially offset by direct costs disbursed from initial public offerings proceeds of $1,212,779.

 

9

 

 

Contractual obligations

 

As of March 31, 2024, our contractual obligations were as follows:

 

Contractual obligations		Total				Less than 1 year				1-2 years				2-3 years				3-4 years				4-5 years				Thereafter
Future lease payments (1)		$	276,439			$	68,402			$	136,806			$	71,231			$	-			$	-			$	-
Short-term bank loans (2)			9,681,150				9,681,150				-				-				-				-				-
Total		$	9,957,589			$	9,749,552			$	136,806			$	71,231			$	-			$	-			$	-

 

(1)	We lease offices spaces and employee dormitories, which are classified as operating leases in accordance with ASC Topic 842. As of March 31, 2024, our future lease payments totaled $276,439.

 

(2)	Represents the outstanding principal balance of short-term loans from banks.

 

Trend Information

 

Other than as disclosed elsewhere in this report, we are not aware of any trends, uncertainties, demands, commitments, or events that are reasonably likely to have a material effect on our net revenues, income from continuing operations, profitability, liquidity or capital resources, or that would cause reported financial information not necessarily to be indicative of future operating results or financial condition.

 

Off-Balance Sheet Arrangements

 

We did not have any off-balance sheet arrangements as of March 31, 2024 and September 30, 2023.

 

Inflation

 

Inflation does not materially affect our business or the results of our operations.

 

Seasonality

 

We have not experienced, and do not expect to experience, any seasonal fluctuations in our results of operations for either our wheelchair business or living aids products business.

 

10

 

 

Key Factors that Affect Our Results of Operations

 

We believe the following key factors may affect our financial condition and results of operations:

 

Our Ability to Attract Additional Dealers and Expand our Dealer Network

 

We sell our products through a network of qualified dealers, many of whom also sell products of our competitors. Our business is therefore affected by our ability to establish new relationships and maintain relationships with existing dealers. The geographic coverage of our dealers and their individual business conditions can affect the ability of our dealers to sell our products to end customers. One major dealer and its subsidiaries represented 59.4% and 78.0% of our revenue for the six months ended March 31, 2024, and 2023, respectively. There may be consolidation and changes in the dealership landscape over time which could affect the performance of our existing dealers. Thus, if we are unable to secure business relationship with our existing dealers or recruit more reputable and qualified dealers, our results of operations may be adversely and materially impacted. If we are unable to renew our contracts with our largest dealer or re-negotiate an agreement under the same or more advantageous terms, our sales and results of operations could be adversely affected. Therefore, the success of our business in the future depends on our efforts to expand our distribution network and attract new dealers in both existing and new markets. The success in expanding our distribution network will depend upon many factors, including our ability to form relationships with, and manage an increasing number of, dealers and optimize our network of dealers. If our marketing efforts fail to convince dealers to accept our products, we may find it difficult to maintain the existing level of sales or to increase such sales. Furthermore, in new markets we may fail to anticipate competitive conditions that are different from those in our existing markets. Should this happen, our net revenues would decline and our growth prospectus would be severely impaired.

 

Our Ability to Increase Awareness of Our Brands and Develop Customer Loyalty

 

Our portfolio of both wheelchairs and living aids products is comprised of quality products. Our brands are integral to our sales and marketing efforts. We believe that maintaining and enhancing our brand name recognition in a cost-effective manner is critical to achieving widespread acceptance of our current and future products and is an important element in our effort to increase our customer base. Successful promotion of our brand names will depend largely on our marketing efforts and ability to provide reliable and quality products at competitive prices. Brand promotion activities may not necessarily yield increased revenue, and even if they do, any increased revenue may not offset the expenses we will incur in marketing activities. If we fail to successfully promote and maintain our brands, or if we incur substantial expenses in an unsuccessful attempt to promote and maintain our brands, we may fail to attract new customers or retain our existing customers, in which case our business, operating results and financial condition, would be materially adversely affected.

 

Our Ability to Control Costs and Expenses and Improve Our Operating Efficiency

 

Our business growth is dependent on our ability to attract and retain qualified and productive employees, identify business opportunities, secure new contracts with customers and our ability to control costs and expenses to improve our operating efficiency. Our inventory costs (including raw materials, direct labor and related production overhead) have a direct impact on our profitability. The raw materials used in the manufacturing of our products are subject to price volatility and inflationary pressures. Our success is dependent, in part, on our ability to reduce our exposure to increase in those costs through a variety of ways, while maintaining and improving margins and market share. Raw materials price increases may offset our productivity gains and price increases and may adversely impact our financial results. In addition, our staffing costs (including payroll and employee benefit expenses) and operating expenses also have a direct impact on our profitability. Our ability to drive the productivity of our staff and enhance our operating efficiency affects our profitability. To the extent that the costs we are required to pay to our suppliers and our staff exceed our estimates, our profits may be impaired. If we fail to implement initiatives to control costs and improve our operating efficiency over time, our profitability will be negatively impacted.

 

11

 

 

Our Ability to Compete Successfully

 

The wheelchair and living aids markets are developing rapidly, and related technology trends are constantly evolving. This results in the frequent introduction of new products and services, relatively short product design cycles and significant price competition. We have competitors in China and Japan that manufacture products similar to ours. Some of our current or potential competitors may have significantly greater financial resources and expertise in research and development, manufacturing, product testing, obtaining regulatory approvals and marketing approved products than we do, which could result in our competitors establishing a strong market position before our new products are able to enter the market. Additionally, technologies developed by our competitors may render our product uneconomical or obsolete. If we do not compete effectively, our operating results could be harmed.

 

A Severe or Prolonged Slowdown in the Global or Chinese Economy Could Materially and Adversely Affect Our Business and Our Financial Condition

 

The growth of the Chinese economy has been slowing down since 2012 and this slowdown may continue in the future. There is considerable uncertainty over trade conflicts between the United States and China and the long-term effects of the expansionary monetary and fiscal policies adopted by the central banks and financial authorities of some of the world’s leading economies, including the United States and China. The withdrawal of these expansionary monetary and fiscal policies could lead to a contraction. There continue to be concerns over unrest and terrorist threats in the Middle East, Europe, and Africa, which have resulted in volatility in oil and other markets. There are also concerns about the relationships between China and other Asian countries, which may result in or intensify potential conflicts in relation to territorial disputes. The eruption of armed conflict could adversely affect global or Chinese discretionary spending, either of which could have a material and adverse effect on our business, results of operation in financial condition. Economic conditions in China are sensitive to global economic conditions, as well as changes in domestic economic and political policies and the expected or perceived overall economic growth rate in China. Any severe or prolonged slowdown in the global or Chinese economy would likely materially and adversely affect our business, results of operations and financial condition. In addition, continued turbulence in the international markets may adversely affect our ability to access capital markets to meet liquidity needs.

 

COVID-19 Impact

 

Our business has been adversely affected by the COVID-19 pandemic. The World Health Organization declared the COVID-19 a pandemic on March 11, 2020, after the virus speeded from China to other countries around the world.

 

Due to a resurgence of the COVID-19 pandemic in March 2022 (“2022 Outbreak”) in China, there have been delays in the purchase of raw material supplies and delivery of products to domestic customers in China on a timely basis as a consequence of travel restrictions. Shipments and customer clearance for overseas sales were also delayed due to the stricter border control protocols. Although the situation has eased since mid-May 2022, the number of orders placed by the customers were affected as the business of those customers were negatively impacted by the 2022 Outbreak. In early December 2022, China announced a nationwide loosening of its zero-covid policy, and most of the travel restrictions and quarantine requirements were lifted since December 2022. Although there were significant surges of COVID-19 cases in many cities in China after the lifting of these restrictions, the spread of the COVID-19 was slowed down and it was successfully under control since January 2023, and the Company’s business operations have been recovered from COVID-19 pandemic. Although, the spread of the COVID-19 appears to be under control as of the date of this report, the extent of the future impact of COVID-19 is still highly uncertain and cannot be predicted, and we may have to scale back again in the future. If this pandemic persists, commercial activities throughout the world could be further curtailed with decreased consumer spending, business operation disruptions, interrupted supply chains, difficulties in travel, and reduced workforces. As such, the extent to which the COVID-19 pandemic may impact our operations and financial results in the long-run will depend on its further developments in China and worldwide, which we cannot predict with a reasonable degree of certainty.

 

12

 

 

C. Critical Accounting Estimates

 

We prepare our unaudited condensed consolidated financial statements in accordance with U.S. GAAP, which requires us to make judgments, estimates and assumptions that affect (i) the reported amounts of our assets and liabilities; (ii) the disclosure of our contingent assets and liabilities at the end of each reporting period; and (iii) the reported amounts of revenues and expenses during each reporting period. We continually evaluate these judgments, estimates and assumptions based on our own historical experience, knowledge and assessment of current business and other conditions and our expectations regarding the future based on available information, which together form our basis for making judgments about matters that are not readily apparent from other sources. Since the use of estimates is an integral component of the financial reporting process, our actual results could differ from those estimates. Some of our accounting policies require a higher degree of judgment than others in their application.

 

When reading our unaudited condensed consolidated financial statements, you should consider our selection of critical accounting policies, the judgment and other uncertainties affecting the application of such policies and the sensitivity of reported results to changes in conditions and assumptions. Our critical accounting policies and practices include the following: (i) revenue recognition; (ii) income taxes and (iii) fair value measurements. See “Note 2—Summary of Significant Accounting Policies” to our unaudited condensed consolidated financial statements for the disclosure of these accounting policies. We believe the following accounting estimates involve the most significant judgments used in the preparation of our financial statements.

 

Impairment of long-lived assets

 

We evaluate our long-lived assets, including property, plant and equipment, operating lease right-of-use assets and land use right for impairment whenever events or changes in circumstances, such as a significant adverse change to market conditions that will impact the future use of the assets, indicate that the carrying amount of an asset may not be fully recoverable. When these events occur, we evaluate the recoverability of long-lived assets by comparing the carrying amount of the assets to the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the assets, we recognize an impairment loss based on the excess of the carrying amount of the assets over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the assets, when the market prices are not readily available. The adjusted carrying amount of the assets become new cost basis and are depreciated over the assets’ remaining useful lives. Long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. Given no events or changes in circumstances indicating the carrying amount of long-lived assets may not be recovered through the related future net cash flows, we did not recognize any impairment loss on long-lived assets for the six months ended March 31, 2024 and 2023.

 

Credit Losses

 

On October 1, 2023, we adopted Accounting Standards Update 2016-13 “Financial Instruments – Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments,” which replaces the incurred loss methodology with an expected loss methodology that is referred to as the current expected credit loss (“CECL”) methodology. The adoption of the credit loss accounting standard has no material impact on our unaudited condensed consolidated financial statements as of October 1, 2023.

 

Our account receivables and other receivables included in prepaid expenses and other current assets on the unaudited condensed consolidated balance sheets are within the scope of ASC Topic 326. We make estimates of expected credit and collectability trends for the allowance for credit losses based upon assessment of various factors, including historical experience, the age of the accounts receivable and other receivables balances, credit-worthiness of the customers and other debtors, current economic conditions, reasonable and supportable forecasts of future economic conditions, and other factors that may affect its ability to collect from the customers and other debtors. We also provide specific provisions for allowance when facts and circumstances indicate that the receivable is unlikely to be collected.

 

13

 

 

Expected credit losses are recorded as allowance for credit losses on the unaudited condensed consolidated statements of operations and comprehensive income. After all attempts to collect a receivable have failed, the receivable is written off against the allowance. In the event we recover amounts previously reserved for, we will reduce the specific allowance for credit losses.

 

Income taxes

 

We are required to make estimates and apply our judgements in determining the provision for income tax expenses for financial reporting purpose based on tax laws in various jurisdictions in which we operate. In calculating the effective income tax rate, we make estimates and judgements, including the calculation of tax credits and the timing differences of recognition of income and expenses between financial reporting and tax reporting. These estimates and judgements may result in adjustments of pre-tax income amount filed with local tax authorities in accordance with relevant local tax rules and regulations in various tax jurisdictions. Although we believe that our estimates and judgments are reasonable, actual results may be materially different from the estimated amounts. Changes in these estimates and judgements may result in material increase or decrease in our provision for income tax expenses.

 

Deferred tax assets and liabilities are recognized for expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and tax credit carry forwards. A valuation allowance is recorded when it is more likely than not that some of the deferred tax assets will not be realized. When we determine and quantify the valuation allowances, we consider such factors as projected future taxable income, the availability of tax planning strategies, the historical taxable income/losses in prior years, and future reversals of existing taxable temporary differences. The assumptions used in determining projected future taxable income require significant judgment. Actual operating results in future years could differ from our current assumptions, judgments and estimates. Changes in these estimates and assumptions may materially affect the tax position measurement and financial statement recognition. If, in the future, we determine that we would not be able to realize our recorded deferred tax assets, an increase in the valuation allowance would decrease our earnings in the period in which such a determination is made. As of March 31, 2024 and September 30, 2023, we recorded deferred tax assets of $254,941 and $168,163, net of valuation allowance of $124,500 and $15,688, respectively.

 

 

14 

 

 

Document And Entity Information	6 Months Ended
	Mar. 31, 2024
Document Information Line Items
Entity Registrant Name	JIN MEDICAL INTERNATIONAL LTD.
Document Type	6-K
Current Fiscal Year End Date	--09-30
Amendment Flag	false
Entity Central Index Key	0001837821
Document Period End Date	Mar. 31, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity File Number	001-41661

Unaudited Condensed Consolidated Balance Sheets - USD ($)		Mar. 31, 2024	Sep. 30, 2023
CURRENT ASSETS:
Cash		$ 8,874,902	$ 6,929,508
Short-term investments		17,113,103	9,768,835
Accounts receivable, net		3,856,529	3,283,266
Inventories		4,540,852	5,053,136
Prepaid expenses and other current assets		2,202,847	892,597
TOTAL CURRENT ASSETS		38,177,840	31,115,815
Operating lease right-of-use assets		263,331
Property, plant and equipment, net		1,464,107	1,480,796
Land use right, net		1,124,404	154,364
Deferred tax assets, net		130,441	152,475
TOTAL ASSETS		41,160,123	32,903,450
CURRENT LIABILITIES:
Short-term bank loans		9,681,150	4,113,000
Accounts payable		3,146,451	3,391,079
Accrued liabilities and other payables		527,822	318,500
Deferred revenue		546,988	710,099
Deferred revenue - related parties		131,521	119,120
Taxes payable		564,626	271,423
Operating lease liabilities, current		88,297
TOTAL CURRENT LIABILITIES		14,825,519	8,924,345
NON-CURRENT LIABILITIES:
Operating lease liabilities, non-current		179,691
Total non current liabilities		179,691
TOTAL LIABILITIES		15,005,210	8,924,345
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY
Ordinary shares, $0.00005 par value, 1,000,000,000 shares authorized, 156,547,100 shares155,947,100 shares were issued and outstanding as of March 31, 2024 and September 30, 2023, respectively	[1]	7,827	7,797
Additional paid-in capital		6,749,144	6,437,179
Statutory reserves		2,277,430	2,010,890
Retained earnings		18,455,159	16,927,605
Accumulated other comprehensive loss		(1,245,394)	(1,404,366)
TOTAL SHAREHOLDERS’ EQUITY		26,244,166	23,979,105
Non-controlling interest		(89,253)
TOTAL EQUITY		26,154,913	23,979,105
TOTAL LIABILITIES AND EQUITY		41,160,123	32,903,450
Related Party
CURRENT ASSETS:
Accounts receivable - related parties		1,524,570	947,949
Due from related parties		65,037	4,240,524
CURRENT LIABILITIES:
Due to related parties		$ 138,664	$ 1,124
[1] Retrospectively restated for effect of a 20-for-1 forward split on February 8, 2024.

Unaudited Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares		Mar. 31, 2024	Sep. 30, 2023
Statement of Financial Position [Abstract]
Ordinary shares, par value (in Dollars per share)	[1]	$ 0.00005	$ 0.00005
Ordinary shares, shares authorized	[1]	1,000,000,000	1,000,000,000
Ordinary shares, shares issued	[1]	156,547,100	155,947,100
Ordinary shares, shares outstanding	[1]	156,547,100	155,947,100
[1] Retrospectively restated for effect of a 20-for-1 forward split on February 8, 2024.

Unaudited Condensed Consolidated Statements of Comprehensive Income - USD ($)		6 Months Ended
		Mar. 31, 2024	Mar. 31, 2023
REVENUE
Total revenue		$ 10,556,891	$ 10,253,163
COST OF REVENUE AND RELATED TAX
Cost of revenue		6,759,586	6,620,447
Business and sales related tax		60,975	101,843
Total cost of revenue and related tax		6,820,561	6,722,290
GROSS PROFIT		3,736,330	3,530,873
OPERATING EXPENSES
Selling expenses		358,768	206,194
General and administrative expenses		1,538,680	922,188
Research and development expenses		609,645	631,034
Total operating expenses		2,507,093	1,759,416
INCOME FROM OPERATIONS		1,229,237	1,771,457
OTHER INCOME (EXPENSE)
Interest income, net		681,588	94,571
Foreign exchange gain (loss)		414	(63,253)
Other income, net		102,164	167,625
Total other income, net		784,166	198,943
INCOME BEFORE INCOME TAX PROVISION		2,013,403	1,970,400
PROVISION FOR INCOME TAXES		309,013	204,053
NET INCOME		1,704,390	1,766,347
Less: net loss attributable to non-controlling interest		(89,704)
NET INCOME ATTRIBUTABLE TO JIN MEDICAL INTERNATIONAL LTD.		1,794,094	1,766,347
COMPREHENSIVE INCOME
Net income		1,704,390	1,766,347
Foreign currency translation gain		159,423	570,160
Comprehensive income		1,863,813	2,336,507
Less: comprehensive loss attributable to non-controlling interest		(89,253)
COMPREHENSIVE INCOME ATTRIBUTABLE TO JIN MEDICAL INTERNATIONAL LTD.		$ 1,953,066	$ 2,336,507
Earnings per common share - basic (in Dollars per share)		$ 0.01	$ 0.01
Weighted average shares - basic (in Shares)	[1]	156,401,198	135,219,780
Revenue - third party
REVENUE
Revenue		$ 9,380,513	$ 9,890,292
Revenue - related party
REVENUE
Revenue		$ 1,176,378	$ 362,871
[1] Retrospectively restated for effect of a 20-for-1 forward split on February 8, 2024.

Unaudited Condensed Consolidated Statements of Comprehensive Income (Parentheticals) - $ / shares		6 Months Ended
		Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Earnings per common share - diluted		$ 0.01	$ 0.01
Weighted average shares - diluted	[1]	156,401,198	135,219,780
[1] Retrospectively restated for effect of a 20-for-1 forward split on February 8, 2024.

Unaudited Condensed Consolidated Statements of Changes in Equity - USD ($)		Ordinary Shares		Additional Paid in Capital	Statutory Reserves	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Total Shareholders' Equity	Non- controlling Interest	Total
Balance at Sep. 30, 2022		$ 6,750	[1]	$ 79,810	$ 1,651,422	$ 14,408,843	$ (911,134)	$ 15,235,691		$ 15,235,691
Balance (in Shares) at Sep. 30, 2022	[1]	6,750,000
Issuance of Ordinary Shares		$ 1,000	[1]	7,999,000				8,000,000		8,000,000
Issuance of Ordinary Shares (in Shares)	[1]	1,000,000
Cost directly related to the initial public offering			[1]	(2,025,679)				(2,025,679)		(2,025,679)
Net income (loss)			[1]			1,766,347		1,766,347		1,766,347
Statutory reserve			[1]		176,550	(176,550)
Foreign currency translation gain			[1]				570,160	570,160		570,160
Balance at Mar. 31, 2023		$ 7,750	[1]	6,053,131	1,827,972	15,998,640	(340,974)	23,546,519		23,546,519
Balance (in Shares) at Mar. 31, 2023	[1]	7,750,000
Balance at Sep. 30, 2023		$ 7,797	[1]	6,437,179	2,010,890	16,927,605	(1,404,366)	23,979,105		$ 23,979,105
Balance (in Shares) at Sep. 30, 2023		155,947,100	[1]							155,947,100	[2]
Issuance of Ordinary Shares		$ 30	[1]	311,965				311,995		$ 311,995
Issuance of Ordinary Shares (in Shares)	[1]	30,000
Net income (loss)			[1]			1,794,094		1,794,094	(89,704)	1,704,390
Statutory reserve			[1]		266,540	(266,540)
Foreign currency translation gain			[1]				158,972	158,972	451	159,423
Balance at Mar. 31, 2024		$ 7,827	[1]	$ 6,749,144	$ 2,277,430	$ 18,455,159	$ (1,245,394)	$ 26,244,166	$ (89,253)	$ 26,154,913
Balance (in Shares) at Mar. 31, 2024		155,977,100	[1]							156,547,100	[2]
[1] Retrospectively restated for effect of a 20-for-1 forward split on February 8, 2024. [2] Retrospectively restated for effect of a 20-for-1 forward split on February 8, 2024.

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net income	$ 1,704,390	$ 1,766,347
Adjustments to reconcile net income to net cash
Amortization of operating lease right-of-use assets	48,105
Depreciation and amortization	120,046	114,465
Gain on disposition of property and equipment	2,590	523
Provision for (net recovery of) credit losses	(87,627)	171,522
Deferred tax provision	23,711	68,561
Short-term investments income	(11,655)
Changes in operating assets and liabilities:
Accounts receivable	(454,837)	(75,355)
Accounts receivable - related parties	(569,807)	(28,932)
Inventories	566,734	447,024
Prepaid expenses and other current assets	(1,308,346)	47,501
Accounts payable	(278,216)	348,579
Accrued liabilities and other payables	206,416	(29,199)
Deferred revenue	(171,223)	(293,968)
Deferred revenue - related parties	11,241	122,795
Taxes payable	291,899	83,630
Operating lease liabilities	(43,424)
Net cash provided by operating activities	49,997	2,743,493
Cash flows from investing activities:
Additions to property, plant and equipment	(83,680)	(11,014)
Additions to land use right	(980,692)
Proceeds from disposal of property and equipment	348	100
Payments for short-term investments	(16,136,000)	(3,152,600)
Redemption of short-term investments	8,810,675	850,154
Repayment of (payments of) advances made to related parties	4,240,111	(4,760,469)
Net cash used in investing activities	(4,149,238)	(7,073,829)
Cash flows from financing activities:
Gross proceeds from initial public offerings		8,000,000
Direct costs disbursed from initial public offerings proceeds		(1,212,779)
Proceeds from sale of Ordinary Shares, net of issuance costs	311,995
Proceeds from short-term bank loans	5,554,080	1,433,000
Proceeds from (repayment of) amount due to related parties	138,223	(120,333)
Net cash provided by financing activities	6,004,298	8,099,888
Effect of exchange rate changes on cash	40,337	122,004
Net increase in cash	1,945,394	3,891,556
Cash, beginning of period	6,929,508	4,792,632
Cash, end of period	8,874,902	8,684,188
Supplemental disclosure information:
Cash paid for income tax	2,234	28,415
Cash paid for interest	93,256
Non-cash operating, investing and financing activities
Deferred IPO cost offset with additional paid-in capital		812,900
Right of use assets obtained in exchange for operating lease liabilities	$ 312,767

Organization and Business Description	6 Months Ended
	Mar. 31, 2024
Organization and Business Description [Abstract]
ORGANIZATION AND BUSINESS DESCRIPTION	NOTE 1 — ORGANIZATION AND BUSINESS DESCRIPTION   JIN MEDICAL INTERNATIONAL LTD. (“Jin Med” or the “Company”) was established under the laws of the Cayman Islands on January 14, 2020 as a holding company.   Jin Med owns 100% equity interest of Zhongjin International Limited (“Zhongjin HK”), an entity incorporated on February 25, 2020 in accordance with the laws and regulations in Hong Kong.   Erhua Medical Technology (Changzhou) Co., Ltd. (“Erhua Med”) was formed on September 24, 2020, as a Wholly Foreign-Owned Enterprise (“WFOE”) in the People’s Republic of China (“PRC”). Zhongjin HK owns 100% equity interest of Erhua Med.   Jin Med, Zhongjin HK and Erhua Med are currently not engaging in any active business operations and merely acting as holding companies.   Changzhou Zhongjin Medical Equipment Co., Ltd. (“Changzhou Zhongjin”) was incorporated on January 26, 2006 in accordance with PRC laws. Changzhou Zhongjin has two wholly-owned subsidiaries, Zhongjin Medical Equipment Taizhou Co., Ltd. (“Taizhou Zhongjin”), incorporated on June 17, 2013, and Changzhou Zhongjin Jing’ao Trading Co., Ltd (“Zhongjin Jing’ao”), incorporated on December 18, 2014 in accordance with PRC laws.   Zhongjin Kangma Information Technology Jiangsu Co., Ltd. (“Zhongjin Kangma”) was incorporated on August 21, 2023 in accordance with PRC laws. Changzhou Zhongjin owns an equity interest of 80% of Zhongjin Kangma, and the remaining 20% equity interest is owned by one shareholder.   Changzhou Zhongjin, Taizhou Zhongjin, Zhongjin Jing’ao and Zhongjin Kangma are collectively referred to as the “Zhongjin Operating Companies” below.   Zhongjin Medical Equipment Anhui Co., Ltd. (“Anhui Zhongjin”) was incorporated on October 7, 2023, as a WFOE in the PRC. Zhongjin HK owns 100% equity interest of Anhui Zhongjin. Anhui Zhongjin is currently not engaging in any active business operations.   The Company, through its wholly-owned subsidiaries and entities controlled through contractual arrangements, is primarily engaged in the design, development, manufacturing and sales of wheelchair and other living aids products to be used by people with disabilities or impaired mobility. The Company’s products are sold to distributors in both China and in the overseas markets.   Reorganization   A reorganization of the legal structure of the Company (“Reorganization”) was completed on November 26, 2020. The Reorganization involved the incorporation of Jin Med, Zhongjin HK and Erhua Med, and signing of certain contractual arrangements (collectively, the “VIE Agreements”) between Zhongjin Technology, the shareholders of Changzhou Zhongjin and Changzhou Zhongjin. Consequently, the Company became the ultimate holding company of Zhongjin HK, Erhua Med, and through the contractual arrangements, WFOE, or Erhua Med, became the primary beneficiary of the Variable Interest Entity (“VIE”), Changzhou Zhongjin, and its subsidiaries. Pursuant to the VIE Agreements, Erhua Med has gained effective control over Changzhou Zhongjin. Therefore, Changzhou Zhongjin should be treated as a VIE under the Statements of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810 Consolidation. Since Taizhou Zhongjin and Zhongjin Jing’ao are wholly-owned subsidiaries of Changzhou Zhongjin, they are further referenced as VIE’s subsidiaries.   The Company, together with its wholly owned subsidiaries, the VIE and the VIE’s subsidiaries, are effectively controlled by the same shareholders before and after the Reorganization and therefore the Reorganization is considered as a recapitalization of entities under common control. The consolidation of the Company, its subsidiaries, the VIE and the VIE’s subsidiaries has been accounted for at historical cost.   The unaudited condensed consolidated financial statements of the Company include the following entities:   Name of Entity   Date of Incorporation     Place of Incorporation   % of Ownership     Principal Activities Jin Med     January 14, 2020      Cayman Island     Parent      Investment holding                           Zhongjin HK     February 25, 2020      Hong Kong     100%     Investment holding                           Erhua Med     September 24, 2020      PRC     100%     WFOE, Investment holding                           Changzhou Zhongjin     January 26, 2006      PRC     VIE      Design, development, manufacturing and sales of wheelchair and other mobility products                           Taizhou Zhongjin     June 17, 2013      PRC     100% controlled subsidiary of the VIE      Design, development, manufacturing and sales of wheelchair and other mobility products                           Zhongjin Jing’ao     December 18, 2014      PRC     100% controlled subsidiary of the VIE      Design, development, manufacturing and sales of wheelchair and other mobility products                           Zhongjin Kangma     August 21, 2023     PRC     80% controlled subsidiary of the VIE     Sales of wheelchair and other mobility products                           Anhui Zhongjin     October 7, 2023     PRC     100%     Newly incorporated – not in operation yet   The VIE contractual arrangements   The Company’s main operating entities, Changzhou Zhongjin and its subsidiaries Taizhou Zhongjin, Zhongjin Jing’ao and Zhongjin Kangma (or the “Zhongjin Operating Companies” as referred above), are controlled through contractual arrangements in lieu of direct equity ownership by the Company.   A VIE is an entity which has a total equity investment that is insufficient to finance its activities without additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest, such as through voting rights, right to receive the expected residual returns of the entity or obligation to absorb the expected losses of the entity. The variable interest holder, if any, that has a controlling financial interest in a VIE is deemed to be the primary beneficiary of, and must consolidate, the VIE, because it met the condition under the accounting principles generally accepted in the United States of America (“U.S. GAAP”) to consolidate the VIE.   Erhua Med, is deemed to have a controlling financial interest in and be the primary beneficiary of the Zhongjin Operating Companies because it has both of the following characteristics:     ● The power to direct activities of the Zhongjin Operating Companies that most significantly impact such entities’ economic performance, and     ● The right to receive benefits from, the Zhongjin Operating Companies that could potentially be significant to such entities.   Pursuant to these contractual arrangements, the Zhongjin Operating Companies shall pay service fees equal to all of their net profits after tax payments to Erhua Med. At the same time, Erhua Med has the right to receive substantially all of their economic benefits for accounting purposes. Such contractual arrangements are designed so that the operations of the Zhongjin Operating Companies are solely for the benefit of Erhua Med and ultimately, the Company, and therefore the Company must consolidate the Zhongjin Operating Companies under U.S. GAAP.   Risks associated with the VIE structure   The Company believes that the contractual arrangements with the VIE and the shareholders of the VIE are in compliance with PRC laws and regulations and are legally enforceable. However, uncertainties in the PRC legal system could limit the Company’s ability to enforce the contractual arrangements. If the legal structure and contractual arrangements were found to be in violation of PRC laws and regulations, the PRC government could:     ● revoke the business and operating licenses of the Company’s PRC subsidiaries and VIE;     ● discontinue or restrict the operations of any related-party transactions between the Company’s PRC subsidiaries and VIE;     ● limit the Company’s business expansion in China by way of entering into contractual arrangements;     ● impose fines or other requirements with which the Company’s PRC subsidiaries and VIE may not be able to comply;     ● require the Company or the Company’s PRC subsidiaries and VIE to restructure the relevant ownership structure or operations; or     ● restrict or prohibit the Company’s use of the proceeds from public offering to finance the Company’s business and operations in China.   The Company’s ability to conduct its businesses may be negatively affected if the PRC government were to carry out of any of the aforementioned actions. In such case, the Company may not be able to consolidate the VIE and the VIE’s subsidiaries in its unaudited condensed consolidated financial statements as it may lose the ability to exert effective control over the VIE and its shareholders and it may lose the ability to receive economic benefits from the VIE and the VIE’s subsidiaries for accounting purposes under U.S. GAAP. The Company, however, does not believe such actions would result in the liquidation or dissolution of the Company, its PRC subsidiaries and the VIE and the VIE’s subsidiaries.   The Company, Zhongjin HK and Erhua Med are essentially holding companies and do not have active operations as of March 31, 2024 and September 30, 2023. As a result, total assets and liabilities presented on the unaudited condensed consolidated balance sheets and revenue, expenses, and net income presented on the unaudited condensed consolidated statement of comprehensive income as well as the cash flows from operating, investing and financing activities presented on the unaudited condensed consolidated statement of cash flows are substantially the financial position, operation results and cash flows of the VIE and the VIE’s subsidiaries. The Company has not provided any financial support to the VIE and the VIE’s subsidiaries during the six months ended March 31, 2024, and 2023. Additionally, pursuant to the VIE Agreements, Erhua Med has the right to receive service fees equal to the VIE’s net profits after tax payments. None of these fees were paid to Erhua Med as of March 31, 2024. Accordingly, as of March 31, 2024 and September 30, 2023, Erhua Med had $10,072,433 and $7,713,617 consulting fee receivables due from the VIE and the VIE’s subsidiaries, respectively. These receivables were fully eliminated upon the consolidation.   The following financial statement amounts and balances of the VIE and VIE’s subsidiaries were included in the accompanying unaudited condensed consolidated financial statements after elimination of intercompany transactions and balances:       March 31, 2024     September 30, 2023   Current assets   $ 32,548,259     $ 24,391,558   Non-current assets     2,011,402       1,787,635   Total assets   $ 34,559,661     $ 26,179,193   Current liabilities   $ 14,687,268     $ 8,763,714   Non-current liabilities     179,691       -   Total liabilities   $ 14,866,959     $ 8,763,714         For the Six Months Ended March 31,       2024     2023   Net revenue   $ 10,556,891     $ 10,253,163   Net income   $ 2,201,868     $ 1,766,347         For the Six Months Ended March 31,       2024     2023   Net cash provided by operating activities   $ 629,983     $ 2,743,493   Net cash used in investing activities   $ (3,560,418 )   $ (7,073,829 ) Net cash provided by financing activities   $ 5,692,303     $ 1,312,667

Summary of Significant Accounting Policies	6 Months Ended
	Mar. 31, 2024
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Basis of consolidation   The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included in the Company’s unaudited condensed consolidated financial statement. The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and the notes for the years ended September 30, 2023 and 2022. The accompanying unaudited condensed consolidated financial statements include the financial statements of the Company, its wholly owned subsidiaries, and entities it controlled through VIE agreements. All inter-company balances and transactions are eliminated upon consolidation.   Uses of estimates   In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are based on information as of the date of the unaudited condensed consolidated financial statements. Significant estimates required to be made by management include, but are not limited to, the expected credit losses for receivables, valuation of inventories, useful lives of property, plant and equipment and land use right, the recoverability of long-lived assets, and realization of deferred tax assets. Actual results could differ from those estimates.   Cash   Cash includes currency on hand and deposits held by banks that can be added or withdrawn without limitation. The Company maintains most of its bank accounts in the PRC. Cash balances in bank accounts in PRC are not insured by the Federal Deposit Insurance Corporation or other programs. As of March 31, 2024 and September 30, 2023, the Company does not have any cash equivalents.     Short-term investments   The Company’s short-term investments consist of wealth management financial products purchased from PRC banks or financial institution with maturities within one year. The banks or financial institution invest the Company’s funds in certain financial instruments including money market funds, bonds or mutual funds, with rates of return on these investments ranging from 3.4% to 29.6% per annum. The carrying values of the Company’s short-term investments approximate fair value due to their short-term maturities. The interest earned is recognized in the unaudited condensed consolidated statements of comprehensive income over the contractual term of these investments.   The Company had short-term investments of $17,113,103 and $9,768,835 as of March 31, 2024 and September 30, 2023, respectively. The Company recorded interest income of $808,363 and $69,840 for the six months ended March 31, 2024 and 2023, respectively.   Accounts receivable, net   Accounts receivable are presented net of allowance for credit losses. Delinquent account balances are written-off against the allowance for credit losses after management has determined that the likelihood of collection is not probable. As of March 31, 2024 and September 30, 2023, allowance for credit losses amounted to $39,543 and $125,448, respectively.   Credit Losses   On October 1, 2023, the Company adopted Accounting Standards Update 2016-13 “Financial Instruments – Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments,” which replaces the incurred loss methodology with an expected loss methodology that is referred to as the current expected credit loss (“CECL”) methodology. The adoption of the credit loss accounting standard has no material impact on the Company’s unaudited condensed consolidated financial statements as of October 1, 2023.   The Company’s account receivables and other receivables included in prepaid expenses and other current assets on the unaudited condensed consolidated balance sheets are within the scope of ASC Topic 326. The Company makes estimates of expected credit and collectability trends for the allowance for credit losses based upon assessment of various factors, including historical experience, the age of the accounts receivable and other receivables balances, credit-worthiness of the customers and other debtors, current economic conditions, reasonable and supportable forecasts of future economic conditions, and other factors that may affect its ability to collect from the customers and other debtors. The Company also provides specific provisions for allowance when facts and circumstances indicate that the receivable is unlikely to be collected.   Expected credit losses are recorded as allowance for credit losses on the unaudited condensed consolidated statements of operations and comprehensive income. After all attempts to collect a receivable have failed, the receivable is written off against the allowance. In the event the Company recovers amounts previously reserved for, the Company will reduce the specific allowance for credit losses.   Inventories   Inventories are stated at lower of cost or net realizable value using the weighted average method. Costs include the cost of raw materials, freight, direct labor and related production overhead. Net realizable value is the estimated selling price in the normal course of business less any costs to complete and sell products. Write-down is recorded when future estimated net realizable value is less than cost, which is recorded in cost of revenue in the unaudited condensed consolidated statements of comprehensive income. The Company periodically evaluates inventories against their net realizable value, and reduces the carrying value of those inventories that are obsolete or in excess of the forecasted usage to their estimated net realizable value based on various factors including aging and future demand of each type of inventories. The reversal of inventory written down is prohibited under the U.S. GAAP.   Fair value of financial instruments   Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:     ● Level 1 — inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.     ● Level 2 — inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived from or corroborated by observable market data.     ● Level 3 — inputs to the valuation methodology are unobservable.   Unless otherwise disclosed, the fair value of the Company’s financial instruments, including cash, short-term investments, accounts receivable, due from related parties, short-term bank loan, accounts payable, due to related parties, accrued liabilities and other payable, and taxes payable, approximate the fair value of the respective assets and liabilities as of March 31, 2024 and September 30, 2023 based upon the short-term nature of the assets and liabilities.    Property, plant and equipment, net   Property, plant and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment is provided using the straight-line method over their expected useful lives, as follows:       Useful life Property and buildings   20–25 years Leasehold improvement   Lesser of useful life and lease term Machinery and equipment   5–10 years Automobiles   3–5 years Office and electric equipment   3–5 years   Expenditures for maintenance and repairs, which do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures for major renewals and betterments which substantially extend the useful life of assets are capitalized. The cost and related accumulated depreciation of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized in the unaudited condensed consolidated statements of comprehensive income.   Leases   Effective October 1, 2022, the Company adopted ASC 842, Leases. The adoption of this standard did not have a material impact on the Company’s unaudited condensed consolidated financial statements. Therefore, no adjustments to opening retained earnings were necessary. The Company leases offices spaces and employee dormitories, which is classified as operating leases in accordance with Topic 842. Under Topic 842, lessees are required to recognize the following for all leases (with the exception of short-term leases, usually with an initial term of 12 months or less) on the commencement date: (i) lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and (ii) right-of-use (“ROU”) asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term.   At the commencement date, the Company recognizes the lease liability at the present value of the lease payments not yet paid, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate for the same term as the underlying lease. The ROU asset is recognized initially at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All ROU assets are reviewed for impairment annually. The Company also established a capitalization threshold of $10,000 for lease to be recognized as ROU and lease liability. There was no impairment for operating lease right-of-use lease assets as of March 31, 2024 and September 30, 2023.   Land use rights, net   Under the PRC law, all land in the PRC is owned by the government and cannot be sold to an individual or company. The government grants individuals and companies the right to use parcels of land for specified periods of time. Land use rights are stated at cost less accumulated amortization. Land use rights are amortized using the straight-line method with the following estimated useful lives:       Useful life Land use rights   46 -50 years   Impairment of long-lived assets   Long-lived assets with finite lives, primarily property, plant and equipment, operating lease right-of-use assets and land use right are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the estimated cash flows from the use of the asset and its eventual disposition are below the asset’s carrying value, then the asset is deemed to be impaired and written down to its fair value. There were no impairments of these assets as of March 31, 2024 and September 30, 2023.   Revenue recognition   The Company generates its revenues primarily through sales of its products and recognizes revenue in accordance with ASC 606. ASC 606 establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity’s contracts to provide goods or services to customers. The core principle requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to receive in exchange for those goods or services recognized as performance obligations are satisfied.   ASC 606 requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation. The application of the five-step model to the revenue streams compared to the prior guidance did not result in significant changes in the way the Company records its revenue.   In accordance to ASC 606, the Company recognizes revenue when it transfers goods to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. The Company accounts for the revenue generated from sales of its products on a gross basis as the Company is acting as a principal in these transactions, is subject to inventory risk, has latitude in establishing prices, and is responsible for fulfilling the promise to provide customers the specified goods. All of the Company’s contracts have one single performance obligation as the promise is to transfer the individual goods to customers, and there are no other separately identifiable promises in the contracts. The Company’s revenue streams are recognized at a point in time when the control of goods is transferred to customer, which generally occurs at delivery. The Company’s products are sold with no right of return and the Company does not provide other credits or sales incentive to customers. Revenue is reported net of all value added taxes (“VAT”).   The Company generally offers 10 years warranty for the frame of its wheelchairs, and one year warranty for other parts of wheelchairs, except for “wear items”, i.e. those parts that wear out, such as tires or brake pads, which are covered under a warranty for six months. Historically, warranty costs incurred was immaterial, and the warranty costs for the six months ended March 31, 2024 and 2023 were both $nil.   Contract Assets and Liabilities   Payment terms are established on the Company’s pre-established credit requirements based upon an evaluation of customers’ credit quality. The Company did not have contract assets as of March 31, 2024 and September 30, 2023. Contract liabilities are recognized for contracts where payment has been received in advance of delivery of the products. The contract liability balance can vary significantly depending on the timing when cash is received and when shipment or delivery occurs. As of March 31, 2024 and September 30, 2023, other than deferred revenue, the Company had no other contract liabilities or deferred contract costs recorded on its unaudited condensed consolidated balance sheets, and the Company had no material incremental costs for obtaining a contract. Costs of fulfilling customers’ purchase orders, such as shipping, handling and delivery, which occur prior to the transfer of control, are recognized in selling, general and administrative expense when incurred.    Disaggregation of Revenues   The Company disaggregates its revenue from contracts by product types and geographic areas, as the Company believes it best depicts how the nature, amount, timing and uncertainty of the revenue and cash flows are affected by economic factors. The Company’s disaggregation of revenues for the six months ended March 31, 2024 and 2023 are as the following:   Geographic information   The summary of the Company’s total revenues by geographic market for the six months ended March 31, 2024 and 2023 was as follows:       For the Six Months Ended March 31,       2024     2023   China domestic market   $ 2,661,717     $ 1,634,219   Overseas market     7,895,174       8,618,944   Total revenue   $ 10,556,891     $ 10,253,163     Revenue by product categories   The summary of the Company’s total revenues by product categories for the six months ended March 31, 2024 and 2023 was as follows:       For the Six Months Ended March 31,       2024     2023   Wheelchair   $ 7,694,373     $ 8,381,323   Wheelchair components and others     2,862,518       1,871,840   Total revenue   $ 10,556,891     $ 10,253,163     Research and development expenses   In connection with the design and development of wheelchair and other living aids products, the Company expense all internal research costs as incurred, which primarily comprise employee costs, internal and external costs related to execution of studies, manufacturing costs, facility costs of the research center, and amortization of land use right, depreciation for property, plant and equipment used in the research and development activities. For the six months ended March 31, 2024 and 2023, research and development expenses were $609,645 and $631,034, respectively.   Non-controlling Interest   For the Company’s consolidated subsidiaries, the VIE and the VIE’s subsidiaries, non-controlling interests are recognized to reflect the portion of their equity that is not attributable, directly or indirectly, to the Company as the controlling shareholder. Non-controlling interests are classified as a separate line item in the equity section of the Company’s unaudited condensed consolidated balance sheets and have been separately disclosed in the Company’s unaudited condensed consolidated statements of comprehensive income to distinguish the interests from that of the controlling shareholder.   Income taxes   The Company accounts for current income taxes in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the unaudited condensed consolidated financial statements. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period including the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.   An uncertain tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the period incurred. No significant penalties or interest relating to income taxes have been incurred during the six months ended March 31, 2024 and 2023. The Company does not believe there was any uncertain tax provision at March 31, 2024 and September 30, 2023.   The Company’s subsidiaries, VIE and VIE’s subsidiaries in China are subject to the income tax laws of the PRC. No income was generated outside the PRC for the six months ended March 31, 2024 and 2023. As of March 31, 2024, all of the Company’s tax returns of its PRC Subsidiaries remain open for statutory examination by PRC tax authorities.   Value added tax (“VAT”)   Sales revenue is reported net of VAT. The VAT is based on gross sales price and VAT rates range up to 13% in the six months ended March 31, 2024 and 2023, depending on the type of products sold. The VAT may be offset by VAT paid by the Company on purchased raw materials and other materials included in the cost of producing or acquiring its finished products. The Company recorded a VAT payable or receivable net of payments in the accompanying unaudited condensed consolidated financial statements. For domestic sales of wheelchairs, VAT is exempted. Further, when exporting goods, the exporter is entitled to some or all of the refunds of the VAT paid or assessed when the Company completes all the required tax filing procedures. All of the VAT returns filed for the Company have been and remain subject to examination by the tax authorities for five years from the date of filing. VAT tax refunds associated with export sales amounted to $361,431 and $526,779 for the six months ended March 31, 2024 and 2023, respectively.   Warrant accounting   The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480, “Distinguishing Liabilities from Equity” (“ASC 480”) and ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent interim period end date while the warrants are outstanding.    For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of comprehensive income.   As the warrants issued upon the initial public offering meet the criteria for equity classification under ASC 815, therefore, the warrants are classified as equity.    Earnings per share   The Company computes earnings per share (“EPS”) in accordance with ASC 260, “Earnings per Share” (“ASC 260”). ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average common shares outstanding for the period. Diluted presents the dilutive effect on a per share basis of potential common shares (e.g., convertible securities, options and warrants), using the treasury stock method, as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted EPS, the treasury stock method assumes that outstanding potential common shares are exercised and the proceeds are used to purchase common share at the average market price during the period. Potential common shares may have a dilutive effect under the treasury stock method only when the average market price of the common share during the period exceeds the exercise price of the potential common shares. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. As of March 31, 2024 and September 30, 2023, there were no dilutive shares.   Risks and uncertainties   The main operation of the Company is located in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company’s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results.   The Company’s business, financial condition and results of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions, health epidemics and other catastrophic incidents, which could significantly disrupt the Company’s operations.   In December 2019, a novel strain of coronavirus (COVID-19) was first reported in Wuhan, China and then spread globally. On March 11, 2020, the World Health Organization categorized COVID-19 as a global pandemic. Due to a resurgence of the COVID-19 pandemic in March 2022 (“2022 Outbreak”) in China, there have been delays in the purchase of raw material supplies and delivery of products to domestic customers in China on a timely basis as a consequence of travel restrictions. Shipments and customer clearance for overseas sales were also delayed due to the stricter border control protocols. Although the situation has eased since mid-May 2022, the number of orders placed by the customers were affected as the business of those customers were negatively impacted by the 2022 Outbreak. Therefore, the 2022 Outbreak negatively affected the Company’s business operations and financial results for the year ended September 30, 2022. In early December 2022, China announced a nationwide loosening of its zero-covid policy, and most of the travel restrictions and quarantine requirements were lifted since December 2022. Although there were significant surges of COVID-19 cases in many cities in China after the lifting of these restrictions, the spread of the COVID-19 was slowed down and it was successfully under control since January 2023, and the Company’s business operations have been recovered to the level prior to the COVID-19 pandemic. Due to the dynamic nature of the circumstances and the uncertainty around the potential resurgence of COVID-19 cases in China, the continual spread of the virus globally especially in Japan, the Company’s major international market, and the instability of local and global government policies and restrictions, the COVID-19 impact over the Company’s business in the future cannot be reasonably estimated at this time. If COVID-19 cases resurge in the area the Company conducted its business and local governments implemented new restrictions in the effort to contain the spread or certain other foreign governments such as Japan imposed new import restrictions, it is expected the Company’s business will be negatively impacted.   Additionally, since February, 2022, the global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and Ukraine. The Company’s operation has not been impacted by the ongoing military conflict, however, due to the significant uncertainties around the further development of the conflict, the potential additional sanctions and other volatilities that could be brought to the global market, it is impossible to predict the extent to which the Company’s operation and business may be impacted.    Foreign currency translation   The functional currency for Jin Med is U.S Dollar (“US$”). Zhongjin HK uses Hong Kong dollar as its functional currency. However, Jin Med and Zhongjin HK currently only serve as holding company and do not have active operation as of the date of this report. The Company’s functional currency for its PRC subsidiaries is the Chinese Yuan (“RMB”). The Company’s unaudited condensed consolidated financial statements have been translated into the reporting currency of U.S. Dollars (“US$”). Assets and liabilities of the Company are translated at the exchange rate at each reporting period end date. Equity is translated at historical rates. Income and expense accounts are translated at the average rate of exchange during the reporting period. The resulting translation adjustments are reported under other comprehensive income. Gains and losses resulting from foreign currency transactions are reflected in the results of operations.   The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.   The following table outlines the currency exchange rates that were used in creating the unaudited condensed consolidated financial statements in this report:       For the Six Months Ended March 31,   For the Year Ended September 30,     2024   2023   2023 Period-end spot rate   US$1=RMB 7.2221   US$1=RMB 6.8681   US$1=RMB 7.2952 Average rate   US$1=RMB 7.1828   US$1=RMB 6.9784   US$1=RMB 7.0511   Comprehensive income   Comprehensive income consists of two components, net income and other comprehensive income. The foreign currency translation gain or loss resulting from translation of the financial statements expressed in RMB to US$ is reported in other comprehensive income in the unaudited condensed consolidated statements of comprehensive income.   Statement of cash flows   In accordance with ASC 230, “Statement of Cash Flows”, cash flows from the Company’s operations are formulated based upon the local currencies. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets.   Employee benefit expenses   The Company’s subsidiaries, VIE and VIE’s subsidiaries in the PRC participate in a government-mandated employer social insurance plan pursuant to which certain social security benefits, work-related injury benefits, maternity leave insurance, medical insurance, unemployment benefit and housing fund are provided to eligible full-time employees. The relevant labor regulations require the Company’s subsidiaries in the PRC to pay the local labor and social welfare authorities monthly contributions based on the applicable benchmarks and rates stipulated by the local government. The contributions to the plan are expensed as incurred. Employee social security and welfare benefits included as expenses in the unaudited condensed consolidated statements of comprehensive income amounted to $244,722 and $162,598 for the six months ended March 31, 2024 and 2023, respectively.   Recent accounting pronouncements   The Company considers the applicability and impact of all accounting standards updates (“ASUs”). Management periodically reviews new accounting standards that are issued.   In November 2023, the FASB issued ASU No. 2023-07, “Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures.” This ASU expands required public entities’ segment disclosures, including disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items and interim disclosures of a reportable segment’s profit or loss and assets. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company plans to adopt this guidance effective October 1, 2025 and the adoption of this ASU is not expected to have a material impact on its unaudited condensed consolidated financial statements.   In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. This ASU requires additional quantitative and qualitative income tax disclosures to enable financial statements users better assess how an entity’s operations and related tax risks and tax planning and operational opportunities affect its tax rate and prospects for future cash flows. This ASU is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company plans to adopt this guidance effective October 1, 2025 and the adoption of this ASU is not expected to have a material impact on its unaudited condensed consolidated financial statements.

Accounts Receivable, Net	6 Months Ended
	Mar. 31, 2024
Accounts Receivable, Net [Abstract]
ACCOUNTS RECEIVABLE, NET	NOTE 3 — ACCOUNTS RECEIVABLE, NET   Accounts receivable, net consist of the following:    Third Parties   March 31, 2024     September 30, 2023   Accounts receivable   $ 3,896,072     $ 3,408,714   Less: allowance for credit losses     (39,543 )     (125,448 ) Accounts receivable, net   $ 3,856,529     $ 3,283,266     The Company’s accounts receivable primarily includes balances due from customers when the Company’s wheelchair and living aids products have been sold and delivered to customers, the Company’s contracted performance obligations have been satisfied, amount billed and the Company has an unconditional right to payment, which has not been collected as of the balance sheet dates.   For accounts receivable, approximately 82.3%, or $3.2 million of the March 31, 2024 balance have been subsequently collected. The remaining balance of approximately $0.7 million is expected to be collected before March 31, 2025.   Allowance for credit losses movement is as follows:       March 31, 2024     September 30, 2023   Beginning balance   $ 125,448     $ 114,486   Additions (reductions)     (87,627 )     119,021   Less: write-off (1)     -       (104,735 ) Foreign currency translation adjustments     1,722       (3,324 ) Ending balance   $ 39,543     $ 125,448     (1) The Company wrote off the delinquent account balances against the allowance for credit losses after management has determined that the likelihood of collection is not probable.

Inventories	6 Months Ended
	Mar. 31, 2024
Inventories [Abstract]
INVENTORIES	NOTE 4 — INVENTORIES   Inventories consisted of the following:        March 31, 2024     September 30, 2023   Raw materials   $ 2,385,295     $ 2,618,406   Work-in-progress     1,738,091       1,613,781   Finished goods     417,466       820,949   Inventories   $ 4,540,852     $ 5,053,136     Included in inventory amount is an inventory written down for slow moving items, consisting of raw materials of $848,279 and $901,963, finished goods of $22,411 and $29,885, work-in-progress of $29,740 and $28,861 as of March 31, 2024 and September 30, 2023, respectively.

Prepaid Expenses and Other Current Assets	6 Months Ended
	Mar. 31, 2024
Prepaid Expenses and Other Current Assets [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	NOTE 5 — PREPAID EXPENSES AND OTHER CURRENT ASSETS   Prepaid expenses and other current assets consisted of the following:        March 31, 2024     September 30, 2023   Other receivable (1)   $ 94,958     $ 28,852   Advance to suppliers (2)     1,827,237       803,745   Prepaid expenses (3)     280,652       60,000   Prepaid expenses and other current assets   $ 2,202,847     $ 892,597     (1) Other receivables primarily include advances to employees for business development, rental security deposit for the Company’s office lease and VAT tax refunds receivables and balances to be collected from third-party entities that do not relate to the Company’s normal sales activities.    (2) Advance to suppliers consists of advances to suppliers for purchasing of raw materials that have not been received. As of March 31, 2024, the aging of approximately 80% of our advance to suppliers are within six months. For balance of advance to suppliers aged more than six months, approximately 40% of the balance were subsequently utilized as of the date of the report, and the remaining balance is expected to be utilized by August 2024.     (3) Prepaid expenses primarily include prepaid marketing planning service fees and professional fees.

Leases	6 Months Ended
	Mar. 31, 2024
Leases [Abstract]
LEASES	NOTE 6 — LEASES   The Company leases offices spaces and employee dormitories under non-cancelable operating leases, with expiration dates between 2024 and 2037. In addition, on April 20, 2014, Taizhou Zhongjin signed a lease agreement with the landlord to lease a factory building for 20 years, with annual rent of approximately $39,000 (RMB 250,000). Taizhou Zhongjin invested a total of approximately $0.79 million (RMB 5 million) in leasehold improvements to the leased factory. Pursuant to the lease agreement, the annual rent expense was waived by the landlord to offset against the leasehold improvements until the end of the lease.   The Company considers those renewal or termination options that are reasonably certain to be exercised in the determination of the lease term and initial measurement of ROU assets and lease liabilities. Lease expenses are recognized on a straight-line basis over the lease term. Leases with initial term of 12 months or less are not recorded on the balance sheet.   The Company determines whether a contract is or contains a lease at inception of the contract and whether that lease meets the classification criteria of a finance or operating lease. When available, the Company uses the rate implicit in the lease to discount lease payments to present value; however, most of the Company’s leases do not provide a readily determinable implicit rate. Therefore, the Company discounts lease payments based on an estimate of its incremental borrowing rate.   The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.   The table below presents the operating lease related assets and liabilities recorded on the balance sheets.       March 31, 2024     September 30, 2023   Operating lease right-of-use assets   $ 263,331     $       -                     Operating lease liabilities – current   $ 88,297     $ -   Operating lease liabilities – non-current     179,691       -   Total operating lease liabilities   $ 267,988     $ -     The weighted average remaining lease terms and discount rates for all of operating leases were as follows as of March 31, 2024 and September 30, 2023:       March 31, 2024     September 30, 2023   Remaining lease term and discount rate:             Weighted average remaining lease term (years)     2.25           -   Weighted average discount rate *     3.0 %     -     * The Company used incremental borrowing rate of 3.0% for its lease contracts.   During the six months ended March 31, 2024 and 2023, the Company incurred total operating lease expenses of $88,469 and $24,198, respectively.   The following is a schedule, by years, of maturities of lease liabilities as of March 31, 2024:   Remainder of 2024   $ 68,402   2025     136,806   2026     71,231   Total lease payments     276,439   Less: imputed interest     (8,451 ) Present value of lease liabilities   $ 267,988

Property, Plant and Equipment, Net	6 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment, Net [Abstract]
PROPERTY, PLANT AND EQUIPMENT, NET	NOTE 7 — PROPERTY, PLANT AND EQUIPMENT, NET   Property, plant and equipment, net, consist of the following:       March 31, 2024     September 30, 2023   Buildings   $ 2,420,992     $ 2,396,519   Machinery and equipment     1,792,580       1,778,828   Automobiles     215,829       213,647   Office and electric equipment     588,789       569,261   Leasehold improvements     353,294       280,882   Subtotal     5,371,484       5,239,137   Less: accumulated depreciation     (3,907,377 )     (3,758,341 ) Property, plant and equipment, net   $ 1,464,107     $ 1,480,796     Depreciation expense was $112,713 and $111,964 for the six months ended March 31, 2024 and 2023, respectively.

Land Use Right, Net	6 Months Ended
	Mar. 31, 2024
Land Use Right, Net [Abstract]
LAND USE RIGHT, NET	NOTE 8 — LAND USE RIGHT, NET   Land use right, net, consisted of the following:       March 31, 2024     September 30, 2023   Land use rights   $ 1,198,186     $ 220,178   Less: accumulated amortization     (73,782 )     (65,814 ) Land use right, net   $ 1,124,404     $ 154,364     Amortization expense was $7,333 and $2,501 for the six months ended March 31, 2024 and 2023, respectively.   Estimated future amortization expense for land use rights is as follows:   Years ending March 31,       2025   $ 24,351   2026     24,351   2027     24,351   2028     24,351   2029     24,351   Thereafter     1,002,649       $ 1,124,404

Short-Term Bank Loans	6 Months Ended
	Mar. 31, 2024
Short-Term Bank Loans [Abstract]
SHORT-TERM BANK LOANS	NOTE 9 — SHORT-TERM BANK LOANS   Short-term bank loans consisted of the following:       March 31, 2024     September 30, 2023   Industrial and Commercial Bank of China (1)   $ 4,155,000     $ 4,113,000   China Merchants Bank (2)     1,385,000       -   Agricultural Bank of China (3)     2,756,150       -   Jiangsu Bank (4)     1,385,000       -   Total short-term bank loans   $ 9,681,150     $ 4,113,000     The terms of the various loan agreements related to short-term bank loans contain certain restrictive covenants which, among other things, require the Company to maintain positive net income and certain financial indicators. The terms also prohibit the Company from entering into transactions that may have a significant adverse impact on the Company’s ability to fulfil its loan obligations, including but not limited to, reorganization of the Company or its subsidiaries, disposing the Company’s business or assets, providing loans or guarantees to third parties, etc. The Company was in compliance with such covenants as of March 31, 2024 and September 30, 2023.   (1) On September 28, 2023, Changzhou Zhongjin signed a loan agreement with Industrial and Commercial Bank of China to borrow $4,155,000 (RMB 30.0 million) as working capital for one year, with a maturity date of September 25, 2024. The loan had a fixed interest rate of 2.90% per annum.   (2) On January 3, 2024, Changzhou Zhongjin entered into a loan agreement with China Merchants Bank to borrow $1,385,000 (RMB 10.0 million) as working capital. The loan has a fixed interest rate of 2.80% per annum and matures in one year. In addition, the Company’s major shareholder Mr. Erqi Wang, signed a maximum guarantee agreement with China Merchants Bank to provide personal credit guarantees for the loan.   (3) On January 3, 2024, Changzhou Zhongjin entered into a loan agreement with Agricultural Bank of China to borrow $2,756,150 (RMB 19.9 million) as working capital. The loan has a fixed interest rate of 2.95% per annum and matures in one year.   (4) On January 10, 2024, Changzhou Zhongjin entered into a loan agreement with Jiangsu Bank to borrow $1,385,000 (RMB 10.0 million) as working capital. The loan has a fixed interest rate of 3% per annum and matures in six months. In addition, the Company’s major shareholder Mr. Erqi Wang, signed a maximum guarantee agreement with Jiangsu Bank to provide personal credit guarantees for the loan. The loan was fully repaid on July 15, 2024.   The Company incurred interest expenses of $93,256 and $nil for the six months ended March 31, 2024 and 2023, respectively.

Related Party Transactions	6 Months Ended
	Mar. 31, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 10 — RELATED PARTY TRANSACTIONS   a. Accounts receivable - related parties   Accounts receivable - related parties consists of the following:   Name   Related party relationship   March 31, 2024     September 30, 2023   Shanghai Situma Intelligent Technology Co., Ltd.   Minority shareholder of the Company   $ 117,082     $ 393,068   Jiangsu Zhongjin Kanglu Information Technology Co., Ltd.   An entity controlled by the CEO     292,387       364,750   Jinmed International Co., Ltd.   An entity controlled by the CEO     -       141,131   Zhongjin Hongkang Medical Technology (Shanghai) Co., Ltd.   An entity controlled by the CEO     656,216       49,000   Zhongjiankanglu Industrial Development (Shanghai) Co., Ltd.   An entity controlled by the CEO     458,885       -   Subtotal         1,524,570       947,949   Less: allowance for credit losses         -       -   Total accounts receivable, net - related parties       $ 1,524,570     $ 947,949     For accounts receivable due from related parties, approximately 56.9%, or $0.9 million of the March 31, 2024 balances have been subsequently collected. The remaining balance is expected to be collected before March 31, 2025.    b. Due from related parties   Due from related parties consists of the following:   Name   Related party relationship   March 31, 2024     September 30, 2023   Jiangsu Zhongjin Kanglu Information Technology Co., Ltd. (“Zhongjin Kanglu”) (1)   An entity controlled by the CEO   $ -     $ 4,189,813   Huaniaoyuan Catering Management (Changzhou) Co. Ltd.   An entity controlled by the CEO     65,037       50,711   Total due from related parties       $ 65,037     $ 4,240,524     (1) As of September 30, 2023, the balance due from a related party, Zhongjin Kanglu, was $4,189,813. During the year ended September 30, 2023, as a business collaboration, the Company made advances to Zhongjin Kanglu in the amount of $4,113,000 (RMB30.0 million) as for its temporary working capital needs during the normal course of business. The $4,113,000 advance made to Zhongjin Kanglu has been fully collected in October 2023. The Company expects to make no such advances to its related parties in the future.   c. Deferred revenue – related parties   Deferred revenue – related parties consist of the following:   Name   Related party relationship   March 31, 2024     September 30, 2023   Jin Med Medical (Korea) Co., Ltd.   An entity controlled by the CEO   $ 128,860     $ 117,424   Zhongjiankanglu Industrial Development (Shanghai) Co., Ltd.   An entity controlled by the CEO     -       1,371   Jinmed International Co., Ltd.   An entity controlled by the CEO     2,332       -   Zhongjin Jingau Rehabilitation Equipment (Beijing) Co. Ltd.   An entity controlled by the CEO     329       325   Total deferred revenue – related parties       $ 131,521     $ 119,120     d. Due to related parties   Due to related parties consists of the following:   Name   Related party relationship   March 31, 2024     September 30, 2023   Jiangsu Zhongjin Kanglu Information Technology Co., Ltd.   An entity controlled by the CEO   $ 116,302     $ -   Shanghai Situma Intelligent Technology Co., Ltd.   Minority shareholder of the Company     21,226       -   Huaniaoyuan Environmental Engineering (Changzhou) Co., Ltd.   An entity controlled by the CEO     637       630   Changzhou Zhongjian Kanglu Information Technology Co., Ltd   An entity controlled by the CEO     499       494   Total due to related parties       $ 138,664     $ 1,124     The balance due to related parties was mainly comprised of advances from entities controlled by the Company’s CEO and used for working capital during the Company’s normal course of business. These advances are non-interest bearing and due on demand.   e. Revenue from related parties   Revenue from related parties consists of the following:           For the Six Months Ended March 31,   Name   Related party relationship   2024     2023   Jiangsu Zhongjin Kanglu Information Technology Co., Ltd.   An entity controlled by the CEO   $ 227,339     $ 333,106   Zhongjiankanglu Industrial Development (Shanghai) Co., Ltd.   An entity controlled by the CEO     409,377       17,381   Zhongjin Jingau Rehabilitation Equipment (Beijing) Co. Ltd.   An entity controlled by the CEO     -       12,384   Zhongjin Hongkang Medical Technology (Shanghai) Co., Ltd.   An entity controlled by the CEO     539,662       -   Total revenue from related parties       $ 1,176,378     $ 362,871

Taxes	6 Months Ended
	Mar. 31, 2024
Taxes [Abstract]
TAXES	NOTE 11 — TAXES   (a) Corporate Income Taxes (“CIT”)   The Company is subject to income taxes on an entity basis on income arising in or derived from the tax jurisdiction in which each entity is domiciled.   Cayman Islands   Under the current laws of the Cayman Islands, the Company is not subject to tax on income or capital gain. In addition, no Cayman Islands withholding tax will be imposed upon the payment of dividends by the Company to its shareholders.   Hong Kong   Zhongjin HK is subject to Hong Kong profits tax at a rate of 8.25% on assessable profits up to HK$2,000,000, and 16.5% on any part of assessable profits over HK$2,000,000. However, it did not generate any assessable profits arising in or derived from Hong Kong for the six months ended March 31, 2024 and 2023, and accordingly no provision for Hong Kong profits tax has been made in these periods.   PRC   Erhua Med, Anhui Zhongjin, Changzhou Zhongjin and its subsidiaries are incorporated in the PRC, and are subject to the PRC Enterprise Income Tax. Under the Enterprise Income Tax (“EIT”) Law of PRC, domestic enterprises and Foreign Investment Enterprises (“FIE”) are subject to a unified 25% enterprise income tax rate while preferential tax rates, tax holidays and even tax exemptions may be granted on case-by-case basis.   EIT grants preferential tax treatment to High and New Technology Enterprises (“HNTEs”). Under this preferential tax treatment, HNTEs are entitled to an income tax rate of 15%, subject to a requirement that they re-apply for HNTE status every three years. Changzhou Zhongjin and Taizhou Zhongjin, the VIE and VIE’s main operating subsidiary in the PRC, were approved as HNTEs and are entitled to a reduced income tax rate of 15% beginning November 2018 and November 2019, respectively, which are valid for three years. In November 2021, Changzhou Zhongjin successfully renewed its HNTE certification with local government and continued to enjoy the reduced income tax rate of 15% for another three years through November 2024. In November 2022, Taizhou Zhongjin successfully renewed its HNTE certification with local government and continued to enjoy the reduced income tax rate of 15% for another three years through November 2025.   In addition, based on the EIT Law of PRC, and according to the Announcement on Issues Related to the Implementation of Inclusive Income Tax Reduction and Exemption Policy for Small and Low Profit Enterprises issued by the State Administration of Taxation on January 18, 2019 and April 2, 2021, once an enterprise meets certain requirements and is identified as a small-scale minimal profit enterprise, the portion of its taxable income not more than RMB1 million is subject to a reduced rate of 5% (the rate was further reduced to 2.5% for the period from January 1, 2021 to December 31, 2022), and the portion between RMB1 million and RMB3 million is subject to a reduced rate of 10%. The policy is effective for the period from January 1, 2019 to December 31, 2022. According to the Announcement on Implementing the Preferential Income Tax Policies for Small-Scale Minimal Profit Enterprise on March 14, 2022 and March 26, 2023, the taxable income not more than RMB3 million is subject to a reduced rate of 5% during the period from January 1, 2023 to December 31, 2024. Zhongjin Jing’ao is qualified as a small-scale minimal profit enterprise for the six months ended March 31, 2024 and 2023.   EIT is typically governed by the local tax authority in the PRC. Each local tax authority at times may grant tax holidays to local enterprises as a way to encourage entrepreneurship and stimulate local economy. The corporate income taxes for the six months ended March 31, 2024 and 2023 were reported at a reduced rate for both Changzhou Zhongjin and Taizhou Zhongjin for being approved as HNTEs and enjoying a reduced income tax rate at 15% instead of 25%, and Zhongjin Jing’ao is qualified as a small-scale minimal profit enterprise for a further reduced income tax rate of 5%. The impact of the tax holidays noted above decreased the Company’s income taxes by $294,310 and $195,135 for the six months ended March 31, 2024 and 2023, respectively. The effect of the tax holidays on net income per share (basic and diluted) was immaterial for the six months ended March 31, 2024 and 2023.   The components of the income tax provision are as follows:       For the Six Months Ended March 31       2024     2023   Current tax provision             BVI   $ -     $ -   Hong Kong     -       -   PRC     285,302       135,492         285,302       135,492   Deferred tax provision                 BVI     -       -   Hong Kong     -       -   PRC     23,711       68,561         23,711       68,561   Income tax provision   $ 309,013     $ 204,053     Deferred tax assets, net are composed of the following:       March 31, 2024     September 30, 2023   Deferred tax assets:             Net operating loss carry-forwards   $ 113,753     $ 5,049   Inventory written down     135,064       144,106   Allowance for credit losses     6,124       19,008   Total     254,941       168,163   Valuation allowance     (124,500 )     (15,688 ) Total deferred tax assets, net   $ 130,441     $ 152,475     Movement of the valuation allowance:       March 31, 2024     September 30, 2023   Beginning balance   $ 15,688     $ 14,248   Current year addition     109,201       1,844   Exchange difference     (389 )     (404 ) Ending balance   $ 124,500     $ 15,688     The Company periodically evaluates the likelihood of the realization of deferred tax assets, and reduces the carrying amount of the deferred tax assets by a valuation allowance to the extent it believes a portion will not be realized. Management considers new evidence, both positive and negative, that could affect the Company’s future realization of deferred tax assets including its recent cumulative earnings experience, expectation of future income, the carry forward periods available for tax reporting purposes and other relevant factors. The Company determined that it is more likely than not its deferred tax assets could not be realized due to uncertainty on future earnings in Zhongjin Jing’ao, Zhongjin Kangma and Anhui Zhongjin. The Company provided a 100% allowance for their deferred tax assets as of March 31, 2024.   The following table reconciles the China statutory rates to the Company’s effective tax rate for the six months ended March 31, 2024 and 2023:       For the Six Months Ended March 31,       2024     2023   China Income tax statutory rate     25.0 %     25.0 % Effect of PRC tax holiday     (14.6 )%     (9.9 )% Research and development tax credit     (6.8 )%     (4.8 )% Non-PRC entity not subject PRC income tax     5.7 %     - % Change in valuation allowance     6.5 %     0.1 % Others     (0.5 )%     - % Effective tax rate     15.3 %     10.4 %   The Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. As of March 31, 2024, all of the Company’s tax returns of its PRC Subsidiaries remain open for statutory examination by PRC tax authorities.   (b) Taxes payable   Taxes payable consist of the following:       March 31, 2024     September 30, 2023   Income tax payable   $ 547,461     $ 263,131   Value added tax payable     12,510       1,627   Other taxes payable     4,655       6,665   Total taxes payable   $ 564,626     $ 271,423

Concentrations	6 Months Ended
	Mar. 31, 2024
Concentrations [Abstract]
CONCENTRATIONS	NOTE 12 — CONCENTRATIONS   A majority of the Company’s revenue and expense transactions are denominated in RMB and a significant portion of the Company’s assets and liabilities are denominated in RMB. RMB is not freely convertible into foreign currencies. In the PRC, foreign exchange transactions are required by law to be transacted only by authorized financial institutions at exchange rates set by the People’s Bank of China (“PBOC”). Remittances in currencies other than RMB may require certain supporting documentation in order to effect the remittance.   As of March 31, 2024 and September 30, 2023, $225,356 and $1,363,617 of the Company’s cash was deposited at financial institutions outside of PRC, $8,637,315 and $5,561,070 of the Company’s cash was on deposit at financial institutions in mainland China, and $1,955 and $108 of the Company’s cash was on deposit at financial institutions in Hong Kong. None of the Company cash deposited at financial institutions maintain insurance to cover bank deposits in the event of bank failure. However, the Company has not experienced any losses in such accounts and believes it is not exposed to any risks on its cash on bank accounts. For the six months ended March 31, 2024 and 2023, the Company’s substantial assets were located in the PRC and all of the Company’s revenues were derived from its subsidiaries located in the PRC.   For the six months ended March 31, 2024 and 2023, one customer accounted for approximately 53.7% and 70.3% of the Company’s total revenue. Sales to the subsidiaries of this customer accounted for approximately 5.7% and 7.7% of the Company’s total revenue for the six months ended March 31, 2024 and 2023, respectively. In aggregate, sales to this customer and its subsidiaries represent approximately 59.4% and 78.0% of the Company’s total revenue for the six months ended March 31, 2024 and 2023, respectively.   As of March 31, 2024, two customers accounted for 46.5% and 13.6% of the accounts receivable balance. As of September 30, 2023, one customer accounted for 53.1% of the accounts receivable balance.   For the six months ended March 31, 2024 and 2023, no supplier accounted for more than 10% of the Company’s total purchases, respectively.   As of March 31, 2024 and September 30, 2023, one supplier accounted for 13.2% and 10.5% of the accounts payable balance, respectively.

Shareholders' Equity	6 Months Ended
	Mar. 31, 2024
Shareholders Equity [Abstract]
SHAREHOLDERS' EQUITY	NOTE 13 — SHAREHOLDERS’ EQUITY   Ordinary Shares   On February 8, 2024, the Company formally executed a forward stock split of its ordinary shares at a ratio of one pre-split ordinary share to 20 post-split ordinary shares. After the stock split, the authorized number of ordinary shares became 1,000,000,000, increased from 50,000,000 pre-split shares. The par value changed from $0.001 to $0.00005 accordingly. The number of shares and per share data are presented herein have been retroactively adjusted to give effect to the stock split.   Upon the incorporation of the Company, 400,000,000 ordinary shares were issued. On October 28, 2022, the original shareholders of the Company surrendered 265,000,000 ordinary shares for no consideration. As a result, on a retrospective basis, 135,000,000 ordinary shares were issued and outstanding as of September 30, 2022 and 2021.   Initial Public Offering   On March 30, 2023, the Company closed its initial public offering (the “Offering”) of 20,000,000 ordinary shares at a public offering price of $0.4 per share for total gross proceeds of $8,000,000 before deducting underwriting discounts and offering expenses. Net proceeds of the Company’s Offering were approximately $6.8 million. In addition, the Company granted the underwriters a 45-day option to purchase up to an additional 3,000,000 ordinary shares at the public offering price, less underwriting discounts, to cover over-allotment, if any. On April 6, 2023, the underwriter partially exercised the over-allotment option to purchase an additional 947,100 ordinary shares for total gross proceeds of $378,840 before deducting underwriting discounts and commissions. As of May 14, 2023, the remaining options were expired. The Company’s ordinary shares began trading on the Nasdaq Capital Market under the symbol “ZJYL” on March 28, 2023. Statutory reserve and restricted net assets   The Company’s PRC subsidiaries, VIE and VIE’s subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company. The payment of dividends by entities organized in China is subject to limitations, procedures and formalities. Regulations in the PRC currently permit payment of dividends only out of accumulated profits as determined in accordance with accounting standards and regulations in China.   The Company is required to make appropriations to certain reserve funds, comprising the statutory surplus reserve and the discretionary surplus reserve, based on after-tax net income determined in accordance with generally accepted accounting principles of the PRC (“PRC GAAP”). Appropriations to the statutory surplus reserve are required to be at least 10% of the after-tax net income determined in accordance with PRC GAAP until the reserve is equal to 50% of the entity’s registered capital. Appropriations to the discretionary surplus reserve are made at the discretion of the Board of Directors. The statutory reserve may be applied against prior year losses, if any, and may be used for general business expansion and production or increase in registered capital, but are not distributable as cash dividends.   Relevant PRC laws and regulations restrict the Company’s PRC subsidiaries, VIE and VIE’s subsidiaries from transferring a portion of their net assets, equivalent to their statutory reserves and their share capital, to the Company’s shareholders in the form of loans, advances or cash dividends. Only PRC entities’ accumulated profits may be distributed as dividends to the Company’s shareholders without the consent of a third party. As of March 31, 2024 and September 30, 2023, the restricted amounts as determined pursuant to PRC statutory laws totaled $2,277,430 and $2,010,890, respectively, and total restricted net assets amounted to $2,363,989 and $2,097,449, respectively.

Commitments and Contingencies	6 Months Ended
	Mar. 31, 2024
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 14 — COMMITMENTS AND CONTINGENCIES   Contingencies   From time to time, the Company is a party to various legal actions arising in the ordinary course of business. The Company accrues costs associated with these matters when they become probable and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. The Company’s management does not expect any liability from the disposition of such claims and litigation individually or in the aggregate to have a material adverse impact on the Company’s unaudited condensed consolidated financial position, results of operations and cash flows. The Company currently does not have any material legal proceedings.

Segment Reporting	6 Months Ended
	Mar. 31, 2024
Segment Reporting [Abstract]
SEGMENT REPORTING	NOTE 15 — SEGMENT REPORTING   An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses, and is identified on the basis of the internal financial reports that are provided to and regularly reviewed by the Company’s chief operating decision maker in order to allocate resources and assess performance of the segment.   The management of the Company concludes that it has only one reporting segment. The Company designs and manufactures quality wheelchair and other living aids products. The Company’s products have similar economic characteristics with respect to raw materials, vendors, marketing and promotions, customers and methods of distribution. The Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews consolidated results when making decisions about allocating resources and assessing performance of the Company, rather than by product types or geographic area; hence the Company has only one reporting segment.

Subsequent Events	6 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 16 — SUBSEQUENT EVENTS   Communications with Nasdaq   As previously disclosed, on March 28, 2024, the Company received a hearing decision letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for continued listing on The Nasdaq Stock Market, subject to the condition that the Company files its annual report on Form 20-F for fiscal year 2023 (the “Annual Report”) with the Securities and Exchange Commission (the “SEC”) on or before May 20, 2024. On April 26, 2024, the Company filed its Annual Report with the SEC. On May 9, 2024, the Company received a letter from Nasdaq informing the Company that it has regained compliance with the filing requirement in Listing Rule 5250(c) regarding the filing of the Annual Report, as required by the Panel’s decision dated March 28, 2024. The Company was also notified that the Panel has determined to monitor the Company’s compliance with the filing requirement in Listing Rule 5250(c) (the “Filing Rule”) through May 9, 2025, in accordance with Nasdaq Listing Rule 5815(d)(4)(B) (the “Panel Monitor”). During the period of the Panel Monitor, in the event the Company becomes non-compliant with the Filing Rule, and notwithstanding Nasdaq Listing Rule 5810(c)(2), the Company will not be permitted to provide a compliance plan for the Staff’s review and the Staff will not be permitted to grant additional time to the Company to regain compliance with the Filing Rule. Instead, the Staff will be obligated to issue a delist determination, at which time the Company may request a new hearing before a hearing panel.   In accordance with ASC Topic 855, “Subsequent Events”, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before these financial statements are issued, the Company has evaluated all events or transactions that occurred after March 31, 2024, up through July 26, 2024, when the Company issued the unaudited condensed consolidated financial statements.

Accounting Policies, by Policy (Policies)	6 Months Ended
	Mar. 31, 2024
Summary of Significant Accounting Policies [Abstract]
Basis of consolidation	Basis of consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included in the Company’s unaudited condensed consolidated financial statement. The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and the notes for the years ended September 30, 2023 and 2022. The accompanying unaudited condensed consolidated financial statements include the financial statements of the Company, its wholly owned subsidiaries, and entities it controlled through VIE agreements. All inter-company balances and transactions are eliminated upon consolidation.
Uses of estimates	Uses of estimates In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates are based on information as of the date of the unaudited condensed consolidated financial statements. Significant estimates required to be made by management include, but are not limited to, the expected credit losses for receivables, valuation of inventories, useful lives of property, plant and equipment and land use right, the recoverability of long-lived assets, and realization of deferred tax assets. Actual results could differ from those estimates.
Cash	Cash Cash includes currency on hand and deposits held by banks that can be added or withdrawn without limitation. The Company maintains most of its bank accounts in the PRC. Cash balances in bank accounts in PRC are not insured by the Federal Deposit Insurance Corporation or other programs. As of March 31, 2024 and September 30, 2023, the Company does not have any cash equivalents.
Short-term investments	Short-term investments The Company’s short-term investments consist of wealth management financial products purchased from PRC banks or financial institution with maturities within one year. The banks or financial institution invest the Company’s funds in certain financial instruments including money market funds, bonds or mutual funds, with rates of return on these investments ranging from 3.4% to 29.6% per annum. The carrying values of the Company’s short-term investments approximate fair value due to their short-term maturities. The interest earned is recognized in the unaudited condensed consolidated statements of comprehensive income over the contractual term of these investments. The Company had short-term investments of $17,113,103 and $9,768,835 as of March 31, 2024 and September 30, 2023, respectively. The Company recorded interest income of $808,363 and $69,840 for the six months ended March 31, 2024 and 2023, respectively.
Accounts receivable, net	Accounts receivable, net Accounts receivable are presented net of allowance for credit losses. Delinquent account balances are written-off against the allowance for credit losses after management has determined that the likelihood of collection is not probable. As of March 31, 2024 and September 30, 2023, allowance for credit losses amounted to $39,543 and $125,448, respectively.
Credit Losses	Credit Losses On October 1, 2023, the Company adopted Accounting Standards Update 2016-13 “Financial Instruments – Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments,” which replaces the incurred loss methodology with an expected loss methodology that is referred to as the current expected credit loss (“CECL”) methodology. The adoption of the credit loss accounting standard has no material impact on the Company’s unaudited condensed consolidated financial statements as of October 1, 2023. The Company’s account receivables and other receivables included in prepaid expenses and other current assets on the unaudited condensed consolidated balance sheets are within the scope of ASC Topic 326. The Company makes estimates of expected credit and collectability trends for the allowance for credit losses based upon assessment of various factors, including historical experience, the age of the accounts receivable and other receivables balances, credit-worthiness of the customers and other debtors, current economic conditions, reasonable and supportable forecasts of future economic conditions, and other factors that may affect its ability to collect from the customers and other debtors. The Company also provides specific provisions for allowance when facts and circumstances indicate that the receivable is unlikely to be collected. Expected credit losses are recorded as allowance for credit losses on the unaudited condensed consolidated statements of operations and comprehensive income. After all attempts to collect a receivable have failed, the receivable is written off against the allowance. In the event the Company recovers amounts previously reserved for, the Company will reduce the specific allowance for credit losses.
Inventories	Inventories Inventories are stated at lower of cost or net realizable value using the weighted average method. Costs include the cost of raw materials, freight, direct labor and related production overhead. Net realizable value is the estimated selling price in the normal course of business less any costs to complete and sell products. Write-down is recorded when future estimated net realizable value is less than cost, which is recorded in cost of revenue in the unaudited condensed consolidated statements of comprehensive income. The Company periodically evaluates inventories against their net realizable value, and reduces the carrying value of those inventories that are obsolete or in excess of the forecasted usage to their estimated net realizable value based on various factors including aging and future demand of each type of inventories. The reversal of inventory written down is prohibited under the U.S. GAAP.
Fair value of financial instruments	Fair value of financial instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value. The hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:   ● Level 1 — inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.   ● Level 2 — inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable and inputs derived from or corroborated by observable market data.   ● Level 3 — inputs to the valuation methodology are unobservable. Unless otherwise disclosed, the fair value of the Company’s financial instruments, including cash, short-term investments, accounts receivable, due from related parties, short-term bank loan, accounts payable, due to related parties, accrued liabilities and other payable, and taxes payable, approximate the fair value of the respective assets and liabilities as of March 31, 2024 and September 30, 2023 based upon the short-term nature of the assets and liabilities.
Property, plant and equipment, net	Property, plant and equipment, net Property, plant and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment is provided using the straight-line method over their expected useful lives, as follows:     Useful life Property and buildings   20–25 years Leasehold improvement   Lesser of useful life and lease term Machinery and equipment   5–10 years Automobiles   3–5 years Office and electric equipment   3–5 years Expenditures for maintenance and repairs, which do not materially extend the useful lives of the assets, are charged to expense as incurred. Expenditures for major renewals and betterments which substantially extend the useful life of assets are capitalized. The cost and related accumulated depreciation of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized in the unaudited condensed consolidated statements of comprehensive income.
Leases	Leases Effective October 1, 2022, the Company adopted ASC 842, Leases. The adoption of this standard did not have a material impact on the Company’s unaudited condensed consolidated financial statements. Therefore, no adjustments to opening retained earnings were necessary. The Company leases offices spaces and employee dormitories, which is classified as operating leases in accordance with Topic 842. Under Topic 842, lessees are required to recognize the following for all leases (with the exception of short-term leases, usually with an initial term of 12 months or less) on the commencement date: (i) lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and (ii) right-of-use (“ROU”) asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term.   At the commencement date, the Company recognizes the lease liability at the present value of the lease payments not yet paid, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate for the same term as the underlying lease. The ROU asset is recognized initially at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All ROU assets are reviewed for impairment annually. The Company also established a capitalization threshold of $10,000 for lease to be recognized as ROU and lease liability. There was no impairment for operating lease right-of-use lease assets as of March 31, 2024 and September 30, 2023.
Land use rights, net	Land use rights, net Under the PRC law, all land in the PRC is owned by the government and cannot be sold to an individual or company. The government grants individuals and companies the right to use parcels of land for specified periods of time. Land use rights are stated at cost less accumulated amortization. Land use rights are amortized using the straight-line method with the following estimated useful lives:     Useful life Land use rights   46 -50 years
Impairment of long-lived assets	Impairment of long-lived assets Long-lived assets with finite lives, primarily property, plant and equipment, operating lease right-of-use assets and land use right are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the estimated cash flows from the use of the asset and its eventual disposition are below the asset’s carrying value, then the asset is deemed to be impaired and written down to its fair value. There were no impairments of these assets as of March 31, 2024 and September 30, 2023.
Revenue recognition	Revenue recognition The Company generates its revenues primarily through sales of its products and recognizes revenue in accordance with ASC 606. ASC 606 establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity’s contracts to provide goods or services to customers. The core principle requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to be entitled to receive in exchange for those goods or services recognized as performance obligations are satisfied. ASC 606 requires the use of a new five-step model to recognize revenue from customer contracts. The five-step model requires that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the respective performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies the performance obligation. The application of the five-step model to the revenue streams compared to the prior guidance did not result in significant changes in the way the Company records its revenue.   In accordance to ASC 606, the Company recognizes revenue when it transfers goods to customers in an amount that reflects the consideration to which the Company expects to be entitled in such exchange. The Company accounts for the revenue generated from sales of its products on a gross basis as the Company is acting as a principal in these transactions, is subject to inventory risk, has latitude in establishing prices, and is responsible for fulfilling the promise to provide customers the specified goods. All of the Company’s contracts have one single performance obligation as the promise is to transfer the individual goods to customers, and there are no other separately identifiable promises in the contracts. The Company’s revenue streams are recognized at a point in time when the control of goods is transferred to customer, which generally occurs at delivery. The Company’s products are sold with no right of return and the Company does not provide other credits or sales incentive to customers. Revenue is reported net of all value added taxes (“VAT”). The Company generally offers 10 years warranty for the frame of its wheelchairs, and one year warranty for other parts of wheelchairs, except for “wear items”, i.e. those parts that wear out, such as tires or brake pads, which are covered under a warranty for six months. Historically, warranty costs incurred was immaterial, and the warranty costs for the six months ended March 31, 2024 and 2023 were both $nil. Contract Assets and Liabilities Payment terms are established on the Company’s pre-established credit requirements based upon an evaluation of customers’ credit quality. The Company did not have contract assets as of March 31, 2024 and September 30, 2023. Contract liabilities are recognized for contracts where payment has been received in advance of delivery of the products. The contract liability balance can vary significantly depending on the timing when cash is received and when shipment or delivery occurs. As of March 31, 2024 and September 30, 2023, other than deferred revenue, the Company had no other contract liabilities or deferred contract costs recorded on its unaudited condensed consolidated balance sheets, and the Company had no material incremental costs for obtaining a contract. Costs of fulfilling customers’ purchase orders, such as shipping, handling and delivery, which occur prior to the transfer of control, are recognized in selling, general and administrative expense when incurred. Disaggregation of Revenues The Company disaggregates its revenue from contracts by product types and geographic areas, as the Company believes it best depicts how the nature, amount, timing and uncertainty of the revenue and cash flows are affected by economic factors. The Company’s disaggregation of revenues for the six months ended March 31, 2024 and 2023 are as the following: Geographic information The summary of the Company’s total revenues by geographic market for the six months ended March 31, 2024 and 2023 was as follows:     For the Six Months Ended March 31,       2024     2023   China domestic market   $ 2,661,717     $ 1,634,219   Overseas market     7,895,174       8,618,944   Total revenue   $ 10,556,891     $ 10,253,163     Revenue by product categories The summary of the Company’s total revenues by product categories for the six months ended March 31, 2024 and 2023 was as follows:     For the Six Months Ended March 31,       2024     2023   Wheelchair   $ 7,694,373     $ 8,381,323   Wheelchair components and others     2,862,518       1,871,840   Total revenue   $ 10,556,891     $ 10,253,163
Research and development expenses	Research and development expenses In connection with the design and development of wheelchair and other living aids products, the Company expense all internal research costs as incurred, which primarily comprise employee costs, internal and external costs related to execution of studies, manufacturing costs, facility costs of the research center, and amortization of land use right, depreciation for property, plant and equipment used in the research and development activities. For the six months ended March 31, 2024 and 2023, research and development expenses were $609,645 and $631,034, respectively.
Non-controlling Interest	Non-controlling Interest For the Company’s consolidated subsidiaries, the VIE and the VIE’s subsidiaries, non-controlling interests are recognized to reflect the portion of their equity that is not attributable, directly or indirectly, to the Company as the controlling shareholder. Non-controlling interests are classified as a separate line item in the equity section of the Company’s unaudited condensed consolidated balance sheets and have been separately disclosed in the Company’s unaudited condensed consolidated statements of comprehensive income to distinguish the interests from that of the controlling shareholder.
Income taxes	Income taxes The Company accounts for current income taxes in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the unaudited condensed consolidated financial statements. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period including the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. An uncertain tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the period incurred. No significant penalties or interest relating to income taxes have been incurred during the six months ended March 31, 2024 and 2023. The Company does not believe there was any uncertain tax provision at March 31, 2024 and September 30, 2023. The Company’s subsidiaries, VIE and VIE’s subsidiaries in China are subject to the income tax laws of the PRC. No income was generated outside the PRC for the six months ended March 31, 2024 and 2023. As of March 31, 2024, all of the Company’s tax returns of its PRC Subsidiaries remain open for statutory examination by PRC tax authorities.
Value added tax (“VAT”)	Value added tax (“VAT”) Sales revenue is reported net of VAT. The VAT is based on gross sales price and VAT rates range up to 13% in the six months ended March 31, 2024 and 2023, depending on the type of products sold. The VAT may be offset by VAT paid by the Company on purchased raw materials and other materials included in the cost of producing or acquiring its finished products. The Company recorded a VAT payable or receivable net of payments in the accompanying unaudited condensed consolidated financial statements. For domestic sales of wheelchairs, VAT is exempted. Further, when exporting goods, the exporter is entitled to some or all of the refunds of the VAT paid or assessed when the Company completes all the required tax filing procedures. All of the VAT returns filed for the Company have been and remain subject to examination by the tax authorities for five years from the date of filing. VAT tax refunds associated with export sales amounted to $361,431 and $526,779 for the six months ended March 31, 2024 and 2023, respectively.
Warrant accounting	Warrant accounting The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480, “Distinguishing Liabilities from Equity” (“ASC 480”) and ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent interim period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of comprehensive income. As the warrants issued upon the initial public offering meet the criteria for equity classification under ASC 815, therefore, the warrants are classified as equity.
Earnings per share	Earnings per share The Company computes earnings per share (“EPS”) in accordance with ASC 260, “Earnings per Share” (“ASC 260”). ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net income divided by the weighted average common shares outstanding for the period. Diluted presents the dilutive effect on a per share basis of potential common shares (e.g., convertible securities, options and warrants), using the treasury stock method, as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted EPS, the treasury stock method assumes that outstanding potential common shares are exercised and the proceeds are used to purchase common share at the average market price during the period. Potential common shares may have a dilutive effect under the treasury stock method only when the average market price of the common share during the period exceeds the exercise price of the potential common shares. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. As of March 31, 2024 and September 30, 2023, there were no dilutive shares.
Risks and uncertainties	Risks and uncertainties The main operation of the Company is located in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company’s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results. The Company’s business, financial condition and results of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions, health epidemics and other catastrophic incidents, which could significantly disrupt the Company’s operations. In December 2019, a novel strain of coronavirus (COVID-19) was first reported in Wuhan, China and then spread globally. On March 11, 2020, the World Health Organization categorized COVID-19 as a global pandemic. Due to a resurgence of the COVID-19 pandemic in March 2022 (“2022 Outbreak”) in China, there have been delays in the purchase of raw material supplies and delivery of products to domestic customers in China on a timely basis as a consequence of travel restrictions. Shipments and customer clearance for overseas sales were also delayed due to the stricter border control protocols. Although the situation has eased since mid-May 2022, the number of orders placed by the customers were affected as the business of those customers were negatively impacted by the 2022 Outbreak. Therefore, the 2022 Outbreak negatively affected the Company’s business operations and financial results for the year ended September 30, 2022. In early December 2022, China announced a nationwide loosening of its zero-covid policy, and most of the travel restrictions and quarantine requirements were lifted since December 2022. Although there were significant surges of COVID-19 cases in many cities in China after the lifting of these restrictions, the spread of the COVID-19 was slowed down and it was successfully under control since January 2023, and the Company’s business operations have been recovered to the level prior to the COVID-19 pandemic. Due to the dynamic nature of the circumstances and the uncertainty around the potential resurgence of COVID-19 cases in China, the continual spread of the virus globally especially in Japan, the Company’s major international market, and the instability of local and global government policies and restrictions, the COVID-19 impact over the Company’s business in the future cannot be reasonably estimated at this time. If COVID-19 cases resurge in the area the Company conducted its business and local governments implemented new restrictions in the effort to contain the spread or certain other foreign governments such as Japan imposed new import restrictions, it is expected the Company’s business will be negatively impacted. Additionally, since February, 2022, the global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and Ukraine. The Company’s operation has not been impacted by the ongoing military conflict, however, due to the significant uncertainties around the further development of the conflict, the potential additional sanctions and other volatilities that could be brought to the global market, it is impossible to predict the extent to which the Company’s operation and business may be impacted.
Foreign currency translation	Foreign currency translation The functional currency for Jin Med is U.S Dollar (“US$”). Zhongjin HK uses Hong Kong dollar as its functional currency. However, Jin Med and Zhongjin HK currently only serve as holding company and do not have active operation as of the date of this report. The Company’s functional currency for its PRC subsidiaries is the Chinese Yuan (“RMB”). The Company’s unaudited condensed consolidated financial statements have been translated into the reporting currency of U.S. Dollars (“US$”). Assets and liabilities of the Company are translated at the exchange rate at each reporting period end date. Equity is translated at historical rates. Income and expense accounts are translated at the average rate of exchange during the reporting period. The resulting translation adjustments are reported under other comprehensive income. Gains and losses resulting from foreign currency transactions are reflected in the results of operations. The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation. The following table outlines the currency exchange rates that were used in creating the unaudited condensed consolidated financial statements in this report:     For the Six Months Ended March 31,   For the Year Ended September 30,     2024   2023   2023 Period-end spot rate   US$1=RMB 7.2221   US$1=RMB 6.8681   US$1=RMB 7.2952 Average rate   US$1=RMB 7.1828   US$1=RMB 6.9784   US$1=RMB 7.0511
Comprehensive income	Comprehensive income Comprehensive income consists of two components, net income and other comprehensive income. The foreign currency translation gain or loss resulting from translation of the financial statements expressed in RMB to US$ is reported in other comprehensive income in the unaudited condensed consolidated statements of comprehensive income.
Statement of cash flows	Statement of cash flows In accordance with ASC 230, “Statement of Cash Flows”, cash flows from the Company’s operations are formulated based upon the local currencies. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets.
Employee benefit expenses	Employee benefit expenses The Company’s subsidiaries, VIE and VIE’s subsidiaries in the PRC participate in a government-mandated employer social insurance plan pursuant to which certain social security benefits, work-related injury benefits, maternity leave insurance, medical insurance, unemployment benefit and housing fund are provided to eligible full-time employees. The relevant labor regulations require the Company’s subsidiaries in the PRC to pay the local labor and social welfare authorities monthly contributions based on the applicable benchmarks and rates stipulated by the local government. The contributions to the plan are expensed as incurred. Employee social security and welfare benefits included as expenses in the unaudited condensed consolidated statements of comprehensive income amounted to $244,722 and $162,598 for the six months ended March 31, 2024 and 2023, respectively.
Recent accounting pronouncements	Recent accounting pronouncements The Company considers the applicability and impact of all accounting standards updates (“ASUs”). Management periodically reviews new accounting standards that are issued. In November 2023, the FASB issued ASU No. 2023-07, “Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures.” This ASU expands required public entities’ segment disclosures, including disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items and interim disclosures of a reportable segment’s profit or loss and assets. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company plans to adopt this guidance effective October 1, 2025 and the adoption of this ASU is not expected to have a material impact on its unaudited condensed consolidated financial statements. In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. This ASU requires additional quantitative and qualitative income tax disclosures to enable financial statements users better assess how an entity’s operations and related tax risks and tax planning and operational opportunities affect its tax rate and prospects for future cash flows. This ASU is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company plans to adopt this guidance effective October 1, 2025 and the adoption of this ASU is not expected to have a material impact on its unaudited condensed consolidated financial statements.

Organization and Business Description (Tables)	6 Months Ended
	Mar. 31, 2024
Organization and Business Description [Abstract]
Schedule of Consolidated Financial Statements of the Company	The unaudited condensed consolidated financial statements of the Company include the following entities: Name of Entity   Date of Incorporation     Place of Incorporation   % of Ownership     Principal Activities Jin Med     January 14, 2020      Cayman Island     Parent      Investment holding                           Zhongjin HK     February 25, 2020      Hong Kong     100%     Investment holding                           Erhua Med     September 24, 2020      PRC     100%     WFOE, Investment holding                           Changzhou Zhongjin     January 26, 2006      PRC     VIE      Design, development, manufacturing and sales of wheelchair and other mobility products                           Taizhou Zhongjin     June 17, 2013      PRC     100% controlled subsidiary of the VIE      Design, development, manufacturing and sales of wheelchair and other mobility products                           Zhongjin Jing’ao     December 18, 2014      PRC     100% controlled subsidiary of the VIE      Design, development, manufacturing and sales of wheelchair and other mobility products                           Zhongjin Kangma     August 21, 2023     PRC     80% controlled subsidiary of the VIE     Sales of wheelchair and other mobility products                           Anhui Zhongjin     October 7, 2023     PRC     100%     Newly incorporated – not in operation yet
Schedule of Financial Statement Amounts and Balances of the VIE and VIE’s Subsidiaries	The following financial statement amounts and balances of the VIE and VIE’s subsidiaries were included in the accompanying unaudited condensed consolidated financial statements after elimination of intercompany transactions and balances:     March 31, 2024     September 30, 2023   Current assets   $ 32,548,259     $ 24,391,558   Non-current assets     2,011,402       1,787,635   Total assets   $ 34,559,661     $ 26,179,193   Current liabilities   $ 14,687,268     $ 8,763,714   Non-current liabilities     179,691       -   Total liabilities   $ 14,866,959     $ 8,763,714
Schedule of Revenue	For the Six Months Ended March 31,       2024     2023   Net revenue   $ 10,556,891     $ 10,253,163   Net income   $ 2,201,868     $ 1,766,347
Schedule of Cash Flow Statement	For the Six Months Ended March 31,       2024     2023   Net cash provided by operating activities   $ 629,983     $ 2,743,493   Net cash used in investing activities   $ (3,560,418 )   $ (7,073,829 ) Net cash provided by financing activities   $ 5,692,303     $ 1,312,667

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Mar. 31, 2024
Summary of Significant Accounting Policies (Tables) [Line Items]
Schedule of Land Use Rights	Land use rights are amortized using the straight-line method with the following estimated useful lives:     Useful life Land use rights   46 -50 years
Schedule of Company’s Total Revenues by Geographic Market	The summary of the Company’s total revenues by geographic market for the six months ended March 31, 2024 and 2023 was as follows:     For the Six Months Ended March 31,       2024     2023   China domestic market   $ 2,661,717     $ 1,634,219   Overseas market     7,895,174       8,618,944   Total revenue   $ 10,556,891     $ 10,253,163
Schedule of Company’s Total Revenues by Product Categories	The summary of the Company’s total revenues by product categories for the six months ended March 31, 2024 and 2023 was as follows:     For the Six Months Ended March 31,       2024     2023   Wheelchair   $ 7,694,373     $ 8,381,323   Wheelchair components and others     2,862,518       1,871,840   Total revenue   $ 10,556,891     $ 10,253,163
Schedule of Currency Exchange Rates	The following table outlines the currency exchange rates that were used in creating the unaudited condensed consolidated financial statements in this report:     For the Six Months Ended March 31,   For the Year Ended September 30,     2024   2023   2023 Period-end spot rate   US$1=RMB 7.2221   US$1=RMB 6.8681   US$1=RMB 7.2952 Average rate   US$1=RMB 7.1828   US$1=RMB 6.9784   US$1=RMB 7.0511
Straight Line Method [Member]
Summary of Significant Accounting Policies (Tables) [Line Items]
Schedule of Depreciation and Amortization of Property and Equipment	Depreciation and amortization of property and equipment is provided using the straight-line method over their expected useful lives, as follows:     Useful life Property and buildings   20–25 years Leasehold improvement   Lesser of useful life and lease term Machinery and equipment   5–10 years Automobiles   3–5 years Office and electric equipment   3–5 years

Accounts Receivable, Net (Tables)	6 Months Ended
	Mar. 31, 2024
Accounts Receivable, Net [Abstract]
Schedule of Accounts Receivable, Net	Accounts receivable, net consist of the following: Third Parties   March 31, 2024     September 30, 2023   Accounts receivable   $ 3,896,072     $ 3,408,714   Less: allowance for credit losses     (39,543 )     (125,448 ) Accounts receivable, net   $ 3,856,529     $ 3,283,266
Schedule of Allowance for Credit Losses	Allowance for credit losses movement is as follows:     March 31, 2024     September 30, 2023   Beginning balance   $ 125,448     $ 114,486   Additions (reductions)     (87,627 )     119,021   Less: write-off (1)     -       (104,735 ) Foreign currency translation adjustments     1,722       (3,324 ) Ending balance   $ 39,543     $ 125,448   (1) The Company wrote off the delinquent account balances against the allowance for credit losses after management has determined that the likelihood of collection is not probable.

Inventories (Tables)	6 Months Ended
	Mar. 31, 2024
Inventories [Abstract]
Schedule of Inventories	Inventories consisted of the following:     March 31, 2024     September 30, 2023   Raw materials   $ 2,385,295     $ 2,618,406   Work-in-progress     1,738,091       1,613,781   Finished goods     417,466       820,949   Inventories   $ 4,540,852     $ 5,053,136

Prepaid Expenses and Other Current Assets (Tables)	6 Months Ended
	Mar. 31, 2024
Prepaid Expenses and Other Current Assets [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following:     March 31, 2024     September 30, 2023   Other receivable (1)   $ 94,958     $ 28,852   Advance to suppliers (2)     1,827,237       803,745   Prepaid expenses (3)     280,652       60,000   Prepaid expenses and other current assets   $ 2,202,847     $ 892,597   (1) Other receivables primarily include advances to employees for business development, rental security deposit for the Company’s office lease and VAT tax refunds receivables and balances to be collected from third-party entities that do not relate to the Company’s normal sales activities.  (2) Advance to suppliers consists of advances to suppliers for purchasing of raw materials that have not been received. As of March 31, 2024, the aging of approximately 80% of our advance to suppliers are within six months. For balance of advance to suppliers aged more than six months, approximately 40% of the balance were subsequently utilized as of the date of the report, and the remaining balance is expected to be utilized by August 2024.   (3) Prepaid expenses primarily include prepaid marketing planning service fees and professional fees.

Leases (Tables)	6 Months Ended
	Mar. 31, 2024
Leases [Abstract]
Schedule of Operating Lease Related Assets and Liabilities	The table below presents the operating lease related assets and liabilities recorded on the balance sheets.     March 31, 2024     September 30, 2023   Operating lease right-of-use assets   $ 263,331     $       -                     Operating lease liabilities – current   $ 88,297     $ -   Operating lease liabilities – non-current     179,691       -   Total operating lease liabilities   $ 267,988     $ -
Schedule of Weighted Average Remaining Lease Terms	The weighted average remaining lease terms and discount rates for all of operating leases were as follows as of March 31, 2024 and September 30, 2023:     March 31, 2024     September 30, 2023   Remaining lease term and discount rate:             Weighted average remaining lease term (years)     2.25           -   Weighted average discount rate *     3.0 %     -   * The Company used incremental borrowing rate of 3.0% for its lease contracts.
Schedule of Maturities of Lease Liabilities	The following is a schedule, by years, of maturities of lease liabilities as of March 31, 2024: Remainder of 2024   $ 68,402   2025     136,806   2026     71,231   Total lease payments     276,439   Less: imputed interest     (8,451 ) Present value of lease liabilities   $ 267,988

Property, Plant and Equipment, Net (Tables)	6 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment, Net [Abstract]
Schedule of Property, Plant and Equipment, Net	Property, plant and equipment, net, consist of the following:     March 31, 2024     September 30, 2023   Buildings   $ 2,420,992     $ 2,396,519   Machinery and equipment     1,792,580       1,778,828   Automobiles     215,829       213,647   Office and electric equipment     588,789       569,261   Leasehold improvements     353,294       280,882   Subtotal     5,371,484       5,239,137   Less: accumulated depreciation     (3,907,377 )     (3,758,341 ) Property, plant and equipment, net   $ 1,464,107     $ 1,480,796

Land Use Right, Net (Tables)	6 Months Ended
	Mar. 31, 2024
Land Use Right, Net [Abstract]
Schedule of Land Use Right, Net	Land use right, net, consisted of the following:     March 31, 2024     September 30, 2023   Land use rights   $ 1,198,186     $ 220,178   Less: accumulated amortization     (73,782 )     (65,814 ) Land use right, net   $ 1,124,404     $ 154,364
Schedule of Estimated Future Amortization Expense for Land Use Rights	Estimated future amortization expense for land use rights is as follows: Years ending March 31,       2025   $ 24,351   2026     24,351   2027     24,351   2028     24,351   2029     24,351   Thereafter     1,002,649       $ 1,124,404

Short-Term Bank Loans (Tables)	6 Months Ended
	Mar. 31, 2024
Short-Term Bank Loans [Abstract]
Schedule of Short-Term Bank Loans	Short-term bank loans consisted of the following:     March 31, 2024     September 30, 2023   Industrial and Commercial Bank of China (1)   $ 4,155,000     $ 4,113,000   China Merchants Bank (2)     1,385,000       -   Agricultural Bank of China (3)     2,756,150       -   Jiangsu Bank (4)     1,385,000       -   Total short-term bank loans   $ 9,681,150     $ 4,113,000   (1) On September 28, 2023, Changzhou Zhongjin signed a loan agreement with Industrial and Commercial Bank of China to borrow $4,155,000 (RMB 30.0 million) as working capital for one year, with a maturity date of September 25, 2024. The loan had a fixed interest rate of 2.90% per annum. (2) On January 3, 2024, Changzhou Zhongjin entered into a loan agreement with China Merchants Bank to borrow $1,385,000 (RMB 10.0 million) as working capital. The loan has a fixed interest rate of 2.80% per annum and matures in one year. In addition, the Company’s major shareholder Mr. Erqi Wang, signed a maximum guarantee agreement with China Merchants Bank to provide personal credit guarantees for the loan. (3) On January 3, 2024, Changzhou Zhongjin entered into a loan agreement with Agricultural Bank of China to borrow $2,756,150 (RMB 19.9 million) as working capital. The loan has a fixed interest rate of 2.95% per annum and matures in one year. (4) On January 10, 2024, Changzhou Zhongjin entered into a loan agreement with Jiangsu Bank to borrow $1,385,000 (RMB 10.0 million) as working capital. The loan has a fixed interest rate of 3% per annum and matures in six months. In addition, the Company’s major shareholder Mr. Erqi Wang, signed a maximum guarantee agreement with Jiangsu Bank to provide personal credit guarantees for the loan. The loan was fully repaid on July 15, 2024.

Related Party Transactions (Tables)	6 Months Ended
	Mar. 31, 2024
Related Party Transaction [Line Items]
Schedule of Accounts Receivable - Related Parties	Accounts receivable, net consist of the following: Third Parties   March 31, 2024     September 30, 2023   Accounts receivable   $ 3,896,072     $ 3,408,714   Less: allowance for credit losses     (39,543 )     (125,448 ) Accounts receivable, net   $ 3,856,529     $ 3,283,266
Schedule of Due from Related Parties	Due from related parties consists of the following: Name   Related party relationship   March 31, 2024     September 30, 2023   Jiangsu Zhongjin Kanglu Information Technology Co., Ltd. (“Zhongjin Kanglu”) (1)   An entity controlled by the CEO   $ -     $ 4,189,813   Huaniaoyuan Catering Management (Changzhou) Co. Ltd.   An entity controlled by the CEO     65,037       50,711   Total due from related parties       $ 65,037     $ 4,240,524   (1) As of September 30, 2023, the balance due from a related party, Zhongjin Kanglu, was $4,189,813. During the year ended September 30, 2023, as a business collaboration, the Company made advances to Zhongjin Kanglu in the amount of $4,113,000 (RMB30.0 million) as for its temporary working capital needs during the normal course of business. The $4,113,000 advance made to Zhongjin Kanglu has been fully collected in October 2023. The Company expects to make no such advances to its related parties in the future.
Schedule of Due to Related Parties	Due to related parties consists of the following: Name   Related party relationship   March 31, 2024     September 30, 2023   Jiangsu Zhongjin Kanglu Information Technology Co., Ltd.   An entity controlled by the CEO   $ 116,302     $ -   Shanghai Situma Intelligent Technology Co., Ltd.   Minority shareholder of the Company     21,226       -   Huaniaoyuan Environmental Engineering (Changzhou) Co., Ltd.   An entity controlled by the CEO     637       630   Changzhou Zhongjian Kanglu Information Technology Co., Ltd   An entity controlled by the CEO     499       494   Total due to related parties       $ 138,664     $ 1,124
Schedule of Revenue from Related Parties	Revenue from related parties consists of the following:         For the Six Months Ended March 31,   Name   Related party relationship   2024     2023   Jiangsu Zhongjin Kanglu Information Technology Co., Ltd.   An entity controlled by the CEO   $ 227,339     $ 333,106   Zhongjiankanglu Industrial Development (Shanghai) Co., Ltd.   An entity controlled by the CEO     409,377       17,381   Zhongjin Jingau Rehabilitation Equipment (Beijing) Co. Ltd.   An entity controlled by the CEO     -       12,384   Zhongjin Hongkang Medical Technology (Shanghai) Co., Ltd.   An entity controlled by the CEO     539,662       -   Total revenue from related parties       $ 1,176,378     $ 362,871
Related Party [Member]
Related Party Transaction [Line Items]
Schedule of Accounts Receivable - Related Parties	Accounts receivable - related parties consists of the following: Name   Related party relationship   March 31, 2024     September 30, 2023   Shanghai Situma Intelligent Technology Co., Ltd.   Minority shareholder of the Company   $ 117,082     $ 393,068   Jiangsu Zhongjin Kanglu Information Technology Co., Ltd.   An entity controlled by the CEO     292,387       364,750   Jinmed International Co., Ltd.   An entity controlled by the CEO     -       141,131   Zhongjin Hongkang Medical Technology (Shanghai) Co., Ltd.   An entity controlled by the CEO     656,216       49,000   Zhongjiankanglu Industrial Development (Shanghai) Co., Ltd.   An entity controlled by the CEO     458,885       -   Subtotal         1,524,570       947,949   Less: allowance for credit losses         -       -   Total accounts receivable, net - related parties       $ 1,524,570     $ 947,949
Schedule of Deferred Revenue	Deferred revenue – related parties consist of the following: Name   Related party relationship   March 31, 2024     September 30, 2023   Jin Med Medical (Korea) Co., Ltd.   An entity controlled by the CEO   $ 128,860     $ 117,424   Zhongjiankanglu Industrial Development (Shanghai) Co., Ltd.   An entity controlled by the CEO     -       1,371   Jinmed International Co., Ltd.   An entity controlled by the CEO     2,332       -   Zhongjin Jingau Rehabilitation Equipment (Beijing) Co. Ltd.   An entity controlled by the CEO     329       325   Total deferred revenue – related parties       $ 131,521     $ 119,120

Taxes (Tables)	6 Months Ended
	Mar. 31, 2024
Taxes [Abstract]
Schedule of Components of the Income Tax Provision	The components of the income tax provision are as follows:     For the Six Months Ended March 31       2024     2023   Current tax provision             BVI   $ -     $ -   Hong Kong     -       -   PRC     285,302       135,492         285,302       135,492   Deferred tax provision                 BVI     -       -   Hong Kong     -       -   PRC     23,711       68,561         23,711       68,561   Income tax provision   $ 309,013     $ 204,053
Schedule of Deferred Tax Assets	Deferred tax assets, net are composed of the following:     March 31, 2024     September 30, 2023   Deferred tax assets:             Net operating loss carry-forwards   $ 113,753     $ 5,049   Inventory written down     135,064       144,106   Allowance for credit losses     6,124       19,008   Total     254,941       168,163   Valuation allowance     (124,500 )     (15,688 ) Total deferred tax assets, net   $ 130,441     $ 152,475
Schedule of Movement of the Valuation Allowance	Movement of the valuation allowance:     March 31, 2024     September 30, 2023   Beginning balance   $ 15,688     $ 14,248   Current year addition     109,201       1,844   Exchange difference     (389 )     (404 ) Ending balance   $ 124,500     $ 15,688
Schedule of Effective Tax Rate	The following table reconciles the China statutory rates to the Company’s effective tax rate for the six months ended March 31, 2024 and 2023:     For the Six Months Ended March 31,       2024     2023   China Income tax statutory rate     25.0 %     25.0 % Effect of PRC tax holiday     (14.6 )%     (9.9 )% Research and development tax credit     (6.8 )%     (4.8 )% Non-PRC entity not subject PRC income tax     5.7 %     - % Change in valuation allowance     6.5 %     0.1 % Others     (0.5 )%     - % Effective tax rate     15.3 %     10.4 %
Schedule of Taxes Payable	Taxes payable consist of the following:     March 31, 2024     September 30, 2023   Income tax payable   $ 547,461     $ 263,131   Value added tax payable     12,510       1,627   Other taxes payable     4,655       6,665   Total taxes payable   $ 564,626     $ 271,423

Organization and Business Description (Details) - USD ($)	Mar. 31, 2024	Oct. 07, 2023	Sep. 30, 2023	Aug. 21, 2023	Sep. 24, 2020	Feb. 25, 2020
Zhongjin International Limited [Member]
Organization and Business Description [Line Items]
Owns equity interest percentage						100.00%
Zhongjin HK [Member]
Organization and Business Description [Line Items]
Owns equity interest percentage					100.00%
Anhui Zhongjin [Member]
Organization and Business Description [Line Items]
Owns equity interest percentage		100.00%
Changzhou Zhongjin [Member]
Organization and Business Description [Line Items]
Equity interest percentage				80.00%
Zhongjin Kangma [Member]
Organization and Business Description [Line Items]
Equity interest percentage				20.00%
Erhua Med [Member]
Organization and Business Description [Line Items]
Consulting fee receivables (in Dollars)	$ 10,072,433		$ 7,713,617

Organization and Business Description (Details) - Schedule of Consolidated Financial Statements of the Company	6 Months Ended
	Mar. 31, 2024
Jin Med [Member]
Schedule of Consolidated Financial Statements of the Company [Line Items]
Date of Incorporation	Jan. 14, 2020
Place of Incorporation	Cayman Island
% of Ownership	Parent
Principal Activities	Investment holding
Zhongjin HK [Member]
Schedule of Consolidated Financial Statements of the Company [Line Items]
Date of Incorporation	Feb. 25, 2020
Place of Incorporation	Hong Kong
% of Ownership	100%
Principal Activities	Investment holding
Erhua Med [Member]
Schedule of Consolidated Financial Statements of the Company [Line Items]
Date of Incorporation	Sep. 24, 2020
Place of Incorporation	PRC
% of Ownership	100%
Principal Activities	WFOE, Investment holding
Changzhou Zhongjin [Member]
Schedule of Consolidated Financial Statements of the Company [Line Items]
Date of Incorporation	Jan. 26, 2006
Place of Incorporation	PRC
% of Ownership	VIE
Principal Activities	Design, development, manufacturing and sales of wheelchair and other mobility products
Taizhou Zhongjin [Member]
Schedule of Consolidated Financial Statements of the Company [Line Items]
Date of Incorporation	Jun. 17, 2013
Place of Incorporation	PRC
% of Ownership	100% controlled subsidiary of the VIE
Principal Activities	Design, development, manufacturing and sales of wheelchair and other mobility products
Zhongjin Jing’ao [Member]
Schedule of Consolidated Financial Statements of the Company [Line Items]
Date of Incorporation	Dec. 18, 2014
Place of Incorporation	PRC
% of Ownership	100% controlled subsidiary of the VIE
Principal Activities	Design, development, manufacturing and sales of wheelchair and other mobility products
Zhongjin Kangma [Member]
Schedule of Consolidated Financial Statements of the Company [Line Items]
Date of Incorporation	Aug. 21, 2023
Place of Incorporation	PRC
% of Ownership	80% controlled subsidiary of the VIE
Principal Activities	Sales of wheelchair and other mobility products
Anhui Zhongjin [Member]
Schedule of Consolidated Financial Statements of the Company [Line Items]
Date of Incorporation	Oct. 07, 2023
Place of Incorporation	PRC
% of Ownership	100%
Principal Activities	Newly incorporated – not in operation yet

Organization and Business Description (Details) - Schedule of Financial Statement Amounts and Balances of the VIE and VIE’s Subsidiaries - VIE [Member] - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Schedule of Financial Statement Amounts and Balances of the VIE and VIE’s Subsidiaries [Line Items]
Current assets	$ 32,548,259	$ 24,391,558
Non-current assets	2,011,402	1,787,635
Total assets	34,559,661	26,179,193
Current liabilities	14,687,268	8,763,714
Non-current liabilities	179,691
Total liabilities	$ 14,866,959	$ 8,763,714

Organization and Business Description (Details) - Schedule of Revenue - VIE [Member] - USD ($)	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule of Revenue [Line Items]
Net revenue	$ 10,556,891	$ 10,253,163
Net income	$ 2,201,868	$ 1,766,347

Organization and Business Description (Details) - Schedule of Cash Flow Statement - VIE [Member] - USD ($)	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule of Cash Flow Statement [Line Items]
Net cash provided by operating activities	$ 629,983	$ 2,743,493
Net cash used in investing activities	(3,560,418)	(7,073,829)
Net cash provided by financing activities	$ 5,692,303	$ 1,312,667

Summary of Significant Accounting Policies (Details) - USD ($)	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022
Summary of Significant Accounting Policies [Line Items]
Short-term investments	$ 17,113,103		$ 9,768,835
Interest income	808,363	$ 69,840
Allowance for doubtful accounts	39,543		$ 125,448	$ 114,486
Capitalization for lease	10,000
Warranty costs
Research and development expenses	$ 609,645	$ 631,034
VAT rates	13.00%	13.00%
VAT tax refunds	$ 361,431	$ 526,779
Employee benefit expenses	$ 244,722	$ 162,598
Wheelchairs [Member]
Summary of Significant Accounting Policies [Line Items]
Warranty term	10 years
Other Parts of Wheelchairs [Member]
Summary of Significant Accounting Policies [Line Items]
Warranty term	1 year
Wear Items [Member]
Summary of Significant Accounting Policies [Line Items]
Warranty term	6 months
Maximum [Member]
Summary of Significant Accounting Policies [Line Items]
Investments rate	3.40%
Minimum [Member]
Summary of Significant Accounting Policies [Line Items]
Investments rate	29.60%

Summary of Significant Accounting Policies (Details) - Schedule of Depreciation and Amortization of Property and Equipment	6 Months Ended
	Mar. 31, 2024
Leasehold improvement [Member]
Schedule of Property and Equipment Useful Lives [Line Items]
Leasehold improvement	Lesser of useful life and lease term
Minimum [Member] | Property and buildings [Member]
Schedule of Property and Equipment Useful Lives [Line Items]
Property, plant and equipment, Useful life	20 years
Minimum [Member] | Machinery and equipment [Member]
Schedule of Property and Equipment Useful Lives [Line Items]
Property, plant and equipment, Useful life	5 years
Minimum [Member] | Automobiles [Member]
Schedule of Property and Equipment Useful Lives [Line Items]
Property, plant and equipment, Useful life	3 years
Minimum [Member] | Office and electric equipment [Member]
Schedule of Property and Equipment Useful Lives [Line Items]
Property, plant and equipment, Useful life	3 years
Maximum [Member] | Property and buildings [Member]
Schedule of Property and Equipment Useful Lives [Line Items]
Property, plant and equipment, Useful life	25 years
Maximum [Member] | Machinery and equipment [Member]
Schedule of Property and Equipment Useful Lives [Line Items]
Property, plant and equipment, Useful life	10 years
Maximum [Member] | Automobiles [Member]
Schedule of Property and Equipment Useful Lives [Line Items]
Property, plant and equipment, Useful life	5 years
Maximum [Member] | Office and electric equipment [Member]
Schedule of Property and Equipment Useful Lives [Line Items]
Property, plant and equipment, Useful life	5 years

Summary of Significant Accounting Policies (Details) - Schedule of Land Use Rights	Mar. 31, 2024
Minimum [Member]
Schedule of Land Use Rights [Line Items]
Land use rights	46 years
Maximum [Member]
Schedule of Land Use Rights [Line Items]
Land use rights	50 years

Summary of Significant Accounting Policies (Details) - Schedule of Company’s Total Revenues by Geographic Market - USD ($)	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule of Company’s Total Revenues by Geographic Market [Line Items]
Total revenue	$ 10,556,891	$ 10,253,163
China Domestic Market [Member]
Schedule of Company’s Total Revenues by Geographic Market [Line Items]
Revenue	2,661,717	1,634,219
Overseas Market [Member]
Schedule of Company’s Total Revenues by Geographic Market [Line Items]
Revenue	$ 7,895,174	$ 8,618,944

Summary of Significant Accounting Policies (Details) - Schedule of Company’s Total Revenues by Product Categories - USD ($)	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule of Company’s Total Revenues by Product Categories [Line Items]
Total revenue	$ 10,556,891	$ 10,253,163
Wheelchair [Member]
Schedule of Company’s Total Revenues by Product Categories [Line Items]
Revenue	7,694,373	8,381,323
Wheelchair components and others [Member]
Schedule of Company’s Total Revenues by Product Categories [Line Items]
Revenue	$ 2,862,518	$ 1,871,840

Summary of Significant Accounting Policies (Details) - Schedule of Currency Exchange Rates	Mar. 31, 2024	Sep. 30, 2023	Mar. 31, 2023
Period-end Spot Rate [Member] | US [Member]
Schedule of Currency Exchange Rates [Line Items]
Currency Exchange Rates	1	1	1
Period-end Spot Rate [Member] | RMB [Member]
Schedule of Currency Exchange Rates [Line Items]
Currency Exchange Rates	7.2221	7.2952	6.8681
Average Rate [Member] | US [Member]
Schedule of Currency Exchange Rates [Line Items]
Currency Exchange Rates	1	1	1
Average Rate [Member] | RMB [Member]
Schedule of Currency Exchange Rates [Line Items]
Currency Exchange Rates	7.1828	7.0511	6.9784

Accounts Receivable, Net (Details) - USD ($) $ in Millions	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2025
Accounts Receivable Net [Line Items]
Accounts receivable, rate	82.30%
Accounts receivable, balance	$ 3.2
Forecast [Member]
Accounts Receivable Net [Line Items]
Accounts receivable, balance		$ 0.7

Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net - USD ($)	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2022
Schedule of Accounts Receivable, Net [Abstract]
Accounts receivable	$ 3,896,072	$ 3,408,714
Less: allowance for credit losses	(39,543)	(125,448)	$ (114,486)
Accounts receivable, net	$ 3,856,529	$ 3,283,266

Accounts Receivable, Net (Details) - Schedule of Allowance for Credit Losses - USD ($)		6 Months Ended	12 Months Ended
		Mar. 31, 2024	Sep. 30, 2023
Schedule of Allowance for Credit Losses [Abstract]
Beginning balance		$ 125,448	$ 114,486
Additions (reductions)		(87,627)	119,021
Less: write-off	[1]		(104,735)
Foreign currency translation adjustments		1,722	(3,324)
Ending balance		$ 39,543	$ 125,448
[1] The Company wrote off the delinquent account balances against the allowance for credit losses after management has determined that the likelihood of collection is not probable.

Inventories (Details) - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Inventories [Abstract]
Raw materials	$ 848,279	$ 901,963
Finished goods	22,411	29,885
Work-in-progress	$ 29,740	$ 28,861

Inventories (Details) - Schedule of Inventories - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Inventory [Abstract]
Raw materials	$ 2,385,295	$ 2,618,406
Work-in-progress	1,738,091	1,613,781
Finished goods	417,466	820,949
Inventories	$ 4,540,852	$ 5,053,136

Prepaid Expenses and Other Current Assets (Details)		6 Months Ended
	Aug. 31, 2024	Mar. 31, 2024
Prepaid Expenses and Other Current Assets [Line Items]
Percentage of advance supplier		80.00%
Forecast [Member]
Prepaid Expenses and Other Current Assets [Line Items]
Percentage of advance supplier	40.00%

Prepaid Expenses and Other Current Assets (Details) - Schedule of Prepaid Expenses and Other Current Assets - USD ($)		Mar. 31, 2024	Sep. 30, 2023
Schedule of Prepaid Expenses and Other Current Assets [Abstract]
Other receivable	[1]	$ 94,958	$ 28,852
Advance to suppliers	[2]	1,827,237	803,745
Prepaid expenses	[3]	280,652	60,000
Prepaid expenses and other current assets		$ 2,202,847	$ 892,597
[1] Other receivables primarily include advances to employees for business development, rental security deposit for the Company’s office lease and VAT tax refunds receivables and balances to be collected from third-party entities that do not relate to the Company’s normal sales activities. [2] Advance to suppliers consists of advances to suppliers for purchasing of raw materials that have not been received. As of March 31, 2024, the aging of approximately 80% of our advance to suppliers are within six months. For balance of advance to suppliers aged more than six months, approximately 40% of the balance were subsequently utilized as of the date of the report, and the remaining balance is expected to be utilized by August 2024. [3] Prepaid expenses primarily include prepaid marketing planning service fees and professional fees.

Leases (Details)	1 Months Ended		6 Months Ended
	Apr. 20, 2014 USD ($)	Apr. 20, 2014 CNY (¥)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2024 CNY (¥)
Leases [Line Items]
Lease term of contract	20 years	20 years
Approximately of annual rent	$ 39,000	¥ 250,000
Lease contracts borrowing rate percentage			3.00%
Operating lease expenses			$ 88,469	$ 24,198
Leasehold Improvements [Member]
Leases [Line Items]
Invested amount			$ 790,000		¥ 5,000,000

Leases (Details) - Schedule of Operating Lease Related Assets and Liabilities - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Schedule of Operating Lease Related Assets and Liabilities [Abstract]
Operating lease right-of-use assets	$ 263,331
Operating lease liabilities – current	88,297
Operating lease liabilities – non-current	179,691
Total operating lease liabilities	$ 267,988

Leases (Details) - Schedule of Weighted Average Remaining Lease Terms		Mar. 31, 2024	Sep. 30, 2023
Remaining lease term and discount rate:
Weighted average remaining lease term (years)		2 years 3 months
Weighted average discount rate	[1]	3.00%
[1] The Company used incremental borrowing rate of 3.0% for its lease contracts.

Leases (Details) - Schedule of Maturities of Lease Liabilities	Mar. 31, 2024 USD ($)
Schedule of Maturities of Lease Liabilities [Abstract]
Remainder of 2024	$ 68,402
2025	136,806
2026	71,231
Total lease payments	276,439
Less: imputed interest	(8,451)
Present value of lease liabilities	$ 267,988

Property, Plant and Equipment, Net (Details) - USD ($)	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2022
Property, Plant and Equipment, Net [Abstract]
Depreciation expense	$ 112,713	$ 111,964

Property, Plant and Equipment, Net (Details) - Schedule of Property, Plant and Equipment, Net - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Schedule of Property, Plant and Equipment, Net [Line Items]
Property, plant and equipment, gross	$ 5,371,484	$ 5,239,137
Less: accumulated depreciation	(3,907,377)	(3,758,341)
Property, plant and equipment, net	1,464,107	1,480,796
Buildings [Member]
Schedule of Property, Plant and Equipment, Net [Line Items]
Property, plant and equipment, gross	2,420,992	2,396,519
Machinery and equipment [Member]
Schedule of Property, Plant and Equipment, Net [Line Items]
Property, plant and equipment, gross	1,792,580	1,778,828
Automobiles [Member]
Schedule of Property, Plant and Equipment, Net [Line Items]
Property, plant and equipment, gross	215,829	213,647
Office and electric equipment [Member]
Schedule of Property, Plant and Equipment, Net [Line Items]
Property, plant and equipment, gross	588,789	569,261
Leasehold improvements [Member]
Schedule of Property, Plant and Equipment, Net [Line Items]
Property, plant and equipment, gross	$ 353,294	$ 280,882

Land Use Right, Net (Details) - USD ($)	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Land Use Right, Net [Abstract]
Amortization expense	$ 7,333	$ 2,501

Land Use Right, Net (Details) - Schedule of Land Use Right, Net - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Schedule of Land Use Right, Net [Abstract]
Land use rights	$ 1,198,186	$ 220,178
Less: accumulated amortization	(73,782)	(65,814)
Land use right, net	$ 1,124,404	$ 154,364

Land Use Right, Net (Details) - Schedule of Estimated Future Amortization Expense for Land Use Rights - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Schedule of Estimated Future Amortization Expense for Land Use Rights [Abstract]
2025	$ 24,351
2026	24,351
2027	24,351
2028	24,351
2029	24,351
Thereafter	1,002,649
Total	$ 1,124,404	$ 154,364

Short-Term Bank Loans (Details) ¥ in Millions				6 Months Ended
		Jan. 03, 2024 USD ($)	Sep. 28, 2023 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Jan. 10, 2024 USD ($)	Jan. 10, 2024 CNY (¥)	Jan. 03, 2024 CNY (¥)	Sep. 30, 2023 USD ($)	Sep. 28, 2023 CNY (¥)
Short Term Bank Loan [Line Items]
Bank borrow				$ 9,681,150					$ 4,113,000
Incurred interest expenses				93,256
Industrial and Commercial Bank of China [Member]
Short Term Bank Loan [Line Items]
Bank borrow	[1]			4,155,000					4,113,000
Industrial and Commercial Bank of China [Member] | Changzhou Zhongjin [Member]
Short Term Bank Loan [Line Items]
Bank borrow			$ 4,155,000							¥ 30.0
Working capital years			1 year
Fixed interest rate			2.90%							2.90%
China Merchants Bank [Member]
Short Term Bank Loan [Line Items]
Bank borrow	[2]			1,385,000
China Merchants Bank [Member] | Changzhou Zhongjin [Member]
Short Term Bank Loan [Line Items]
Bank borrow		$ 1,385,000						¥ 10.0
Working capital years		1 year
Fixed interest rate		2.80%						2.80%
Agricultural Bank of China [Member]
Short Term Bank Loan [Line Items]
Bank borrow	[3]			2,756,150
Agricultural Bank of China [Member] | Changzhou Zhongjin [Member]
Short Term Bank Loan [Line Items]
Bank borrow		$ 2,756,150						¥ 19.9
Working capital years		1 year
Fixed interest rate		2.95%						2.95%
Jiangsu Bank [Member]
Short Term Bank Loan [Line Items]
Bank borrow	[4]			$ 1,385,000
Jiangsu Bank [Member] | Changzhou Zhongjin [Member]
Short Term Bank Loan [Line Items]
Bank borrow						$ 1,385,000	¥ 10.0
Fixed interest rate						3.00%	3.00%
[1] On September 28, 2023, Changzhou Zhongjin signed a loan agreement with Industrial and Commercial Bank of China to borrow $4,155,000 (RMB 30.0 million) as working capital for one year, with a maturity date of September 25, 2024. The loan had a fixed interest rate of 2.90% per annum. [2] On January 3, 2024, Changzhou Zhongjin entered into a loan agreement with China Merchants Bank to borrow $1,385,000 (RMB 10.0 million) as working capital. The loan has a fixed interest rate of 2.80% per annum and matures in one year. In addition, the Company’s major shareholder Mr. Erqi Wang, signed a maximum guarantee agreement with China Merchants Bank to provide personal credit guarantees for the loan. [3] On January 3, 2024, Changzhou Zhongjin entered into a loan agreement with Agricultural Bank of China to borrow $2,756,150 (RMB 19.9 million) as working capital. The loan has a fixed interest rate of 2.95% per annum and matures in one year. [4] On January 10, 2024, Changzhou Zhongjin entered into a loan agreement with Jiangsu Bank to borrow $1,385,000 (RMB 10.0 million) as working capital. The loan has a fixed interest rate of 3% per annum and matures in six months. In addition, the Company’s major shareholder Mr. Erqi Wang, signed a maximum guarantee agreement with Jiangsu Bank to provide personal credit guarantees for the loan. The loan was fully repaid on July 15, 2024.

Short-Term Bank Loans (Details) - Schedule of Short-Term Bank Loans - USD ($)		Mar. 31, 2024	Sep. 30, 2023
Short-Term Debt [Line Items]
Short-term bank loans		$ 9,681,150	$ 4,113,000
Industrial and Commercial Bank of China [Member]
Short-Term Debt [Line Items]
Short-term bank loans	[1]	4,155,000	4,113,000
China Merchants Bank [Member]
Short-Term Debt [Line Items]
Short-term bank loans	[2]	1,385,000
Agricultural Bank of China [Member]
Short-Term Debt [Line Items]
Short-term bank loans	[3]	2,756,150
Jiangsu Bank [Member]
Short-Term Debt [Line Items]
Short-term bank loans	[4]	$ 1,385,000
[1] On September 28, 2023, Changzhou Zhongjin signed a loan agreement with Industrial and Commercial Bank of China to borrow $4,155,000 (RMB 30.0 million) as working capital for one year, with a maturity date of September 25, 2024. The loan had a fixed interest rate of 2.90% per annum. [2] On January 3, 2024, Changzhou Zhongjin entered into a loan agreement with China Merchants Bank to borrow $1,385,000 (RMB 10.0 million) as working capital. The loan has a fixed interest rate of 2.80% per annum and matures in one year. In addition, the Company’s major shareholder Mr. Erqi Wang, signed a maximum guarantee agreement with China Merchants Bank to provide personal credit guarantees for the loan. [3] On January 3, 2024, Changzhou Zhongjin entered into a loan agreement with Agricultural Bank of China to borrow $2,756,150 (RMB 19.9 million) as working capital. The loan has a fixed interest rate of 2.95% per annum and matures in one year. [4] On January 10, 2024, Changzhou Zhongjin entered into a loan agreement with Jiangsu Bank to borrow $1,385,000 (RMB 10.0 million) as working capital. The loan has a fixed interest rate of 3% per annum and matures in six months. In addition, the Company’s major shareholder Mr. Erqi Wang, signed a maximum guarantee agreement with Jiangsu Bank to provide personal credit guarantees for the loan. The loan was fully repaid on July 15, 2024.

Related Party Transactions (Details) ¥ in Millions	6 Months Ended	12 Months Ended
	Mar. 31, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2023 CNY (¥)	Oct. 31, 2023 USD ($)
Related Party [Member]
Related Party Transaction [Line Items]
Percentage of accounts receivable	56.90%
Due from related parties	$ 900,000
Related Party [Member] | Zhongjin Kanglu [Member]
Related Party Transaction [Line Items]
Due from related parties		$ 4,189,813
Zhongjin Kanglu [Member]
Related Party Transaction [Line Items]
Due from related parties				$ 4,113,000
Temporary working capital		$ 4,113,000	¥ 30.0

Related Party Transactions (Details) - Schedule of Accounts Receivable - Related Parties - Related Parties [Member] - USD ($)	6 Months Ended
	Mar. 31, 2024	Sep. 30, 2023
Related Party Transaction [Line Items]
Subtotal	$ 1,524,570	$ 947,949
Less: allowance for credit losses
Total accounts receivable, net - related parties	$ 1,524,570	947,949
Shanghai Situma Intelligent Technology Co., Ltd. [Member]
Related Party Transaction [Line Items]
Related party relationship	Minority shareholder of the Company
Subtotal	$ 117,082	393,068
Jiangsu Zhongjin Kanglu Information Technology Co., Ltd. [Member]
Related Party Transaction [Line Items]
Related party relationship	An entity controlled by the CEO
Subtotal	$ 292,387	364,750
Jinmed International Co., Ltd. [Member]
Related Party Transaction [Line Items]
Related party relationship	An entity controlled by the CEO
Subtotal		141,131
Zhongjin Hongkang Medical Technology (Shanghai) Co., Ltd. [Member]
Related Party Transaction [Line Items]
Related party relationship	An entity controlled by the CEO
Subtotal	$ 656,216	49,000
Zhongjiankanglu Industrial Development (Shanghai) Co., Ltd. [Member]
Related Party Transaction [Line Items]
Related party relationship	An entity controlled by the CEO
Subtotal	$ 458,885

Related Party Transactions (Details) - Schedule of Due from Related Parties - Related Party [Member] - USD ($)		6 Months Ended
		Mar. 31, 2024	Sep. 30, 2023
Related Party Transaction [Line Items]
Total due from related parties		$ 65,037	$ 4,240,524
Jiangsu Zhongjin Kanglu Information Technology Co., Ltd. (“Zhongjin Kanglu”) [Member]
Related Party Transaction [Line Items]
Related party relationship	[1]	An entity controlled by the CEO
Total due from related parties	[1]		4,189,813
Huaniaoyuan Catering Management (Changzhou) Co. Ltd. [Member]
Related Party Transaction [Line Items]
Related party relationship		An entity controlled by the CEO
Total due from related parties		$ 65,037	$ 50,711
[1] As of September 30, 2023, the balance due from a related party, Zhongjin Kanglu, was $4,189,813. During the year ended September 30, 2023, as a business collaboration, the Company made advances to Zhongjin Kanglu in the amount of $4,113,000 (RMB30.0 million) as for its temporary working capital needs during the normal course of business. The $4,113,000 advance made to Zhongjin Kanglu has been fully collected in October 2023. The Company expects to make no such advances to its related parties in the future.

Related Party Transactions (Details) - Schedule of Deferred Revenue - USD ($)	6 Months Ended
	Mar. 31, 2024	Sep. 30, 2023
Related Party Transaction [Line Items]
Total deferred revenue – related parties	$ 131,521	$ 119,120
Jin Med Medical (Korea) Co., Ltd. [Member]
Related Party Transaction [Line Items]
Related party relationship	An entity controlled by the CEO
Total deferred revenue – related parties	$ 128,860	117,424
Zhongjiankanglu Industrial Development (Shanghai) Co., Ltd. [Member]
Related Party Transaction [Line Items]
Related party relationship	An entity controlled by the CEO
Total deferred revenue – related parties		1,371
Jinmed International Co., Ltd. [Member]
Related Party Transaction [Line Items]
Related party relationship	An entity controlled by the CEO
Total deferred revenue – related parties	$ 2,332
Zhongjin Jingau Rehabilitation Equipment (Beijing) Co. Ltd. [Member]
Related Party Transaction [Line Items]
Related party relationship	An entity controlled by the CEO
Total deferred revenue – related parties	$ 329	$ 325

Related Party Transactions (Details) - Schedule of Due to Related Parties - Related Party [Member] - USD ($)	6 Months Ended
	Mar. 31, 2024	Sep. 30, 2023
Related Party Transaction [Line Items]
Total due to related parties	$ 138,664	$ 1,124
Jiangsu Zhongjin Kanglu Information Technology Co., Ltd. [Member]
Related Party Transaction [Line Items]
Related party relationship	An entity controlled by the CEO
Total due to related parties	$ 116,302
Shanghai Situma Intelligent Technology Co., Ltd. [Member]
Related Party Transaction [Line Items]
Related party relationship	Minority shareholder of the Company
Total due to related parties	$ 21,226
Huaniaoyuan Environmental Engineering (Changzhou) Co., Ltd. [Member]
Related Party Transaction [Line Items]
Related party relationship	An entity controlled by the CEO
Total due to related parties	$ 637	630
Changzhou Zhongjian Kanglu Information Technology Co., Ltd [Member]
Related Party Transaction [Line Items]
Related party relationship	An entity controlled by the CEO
Total due to related parties	$ 499	$ 494

Related Party Transactions (Details) - Schedule of Revenue from Related Parties - Related Party [Member] - USD ($)	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Related Party Transaction [Line Items]
Total revenue from related parties	$ 1,176,378	$ 362,871
Jiangsu Zhongjin Kanglu Information Technology Co., Ltd. [Member]
Related Party Transaction [Line Items]
Related party relationship	An entity controlled by the CEO
Total revenue from related parties	$ 227,339	333,106
Zhongjiankanglu Industrial Development (Shanghai) Co., Ltd. [Member]
Related Party Transaction [Line Items]
Related party relationship	An entity controlled by the CEO
Total revenue from related parties	$ 409,377	17,381
Zhongjin Jingau Rehabilitation Equipment (Beijing) Co. Ltd. [Member]
Related Party Transaction [Line Items]
Related party relationship	An entity controlled by the CEO
Total revenue from related parties		12,384
Zhongjin Hongkang Medical Technology (Shanghai) Co., Ltd. [Member]
Related Party Transaction [Line Items]
Related party relationship	An entity controlled by the CEO
Total revenue from related parties	$ 539,662

Taxes (Details) ¥ in Millions				1 Months Ended				6 Months Ended
	Mar. 26, 2023 CNY (¥)	Dec. 31, 2022 CNY (¥)	Mar. 14, 2022 CNY (¥)	Nov. 30, 2022	Nov. 30, 2021	Nov. 30, 2019	Nov. 30, 2018	Mar. 31, 2024 CNY (¥)	Mar. 31, 2024 HKD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2024 USD ($)
Taxes [Line Items]
Assessable profits amount (in Dollars) | $									$ 2,000,000
Income tax rate				15.00%	15.00%	15.00%	15.00%	15.00%	15.00%
Taxable income net (in Yuan Renminbi) | ¥	¥ 3		¥ 3					¥ 1
Enterprise income tax		2.50%						5.00%	5.00%
Income taxes (in Dollars) | $										$ 195,135	$ 294,310
Deferred tax assets percentage								100.00%	100.00%
Enterprise Income Tax [Member]
Taxes [Line Items]
Income tax rate		10.00%
Minimum [Member]
Taxes [Line Items]
Taxable income net (in Yuan Renminbi) | ¥		¥ 1
Maximum [Member]
Taxes [Line Items]
Taxable income net (in Yuan Renminbi) | ¥		¥ 3
Enterprise Income Tax [Member]
Taxes [Line Items]
Income tax rate								25.00%	25.00%
Hong Kong [Member]
Taxes [Line Items]
Profits tax at a rate								8.25%	8.25%
Assessable profits amount (in Dollars) | $									$ 2,000,000
Assessable profits percentage								16.50%	16.50%
Zhongjin Jing’ao [Member] | Enterprise Income Tax [Member]
Taxes [Line Items]
Income tax rate								5.00%	5.00%
Changzhou Zhongjin [Member]
Taxes [Line Items]
Income tax rate								15.00%	15.00%	15.00%
Taizhou Zhongjin [Member]
Taxes [Line Items]
Income tax rate								25.00%	25.00%	25.00%
Zhongjin Jing’ao [Member]
Taxes [Line Items]
Income tax rate								5.00%	5.00%	5.00%

Taxes (Details) - Schedule of Components of the Income Tax Provision - USD ($)	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Current tax provision
Current tax provision	$ 285,302	$ 135,492
Deferred tax provision
Deferred tax provision (benefit)	23,711	68,561
Income tax provision	309,013	204,053
BVI [Member]
Current tax provision
Current tax provision
Deferred tax provision
Deferred tax provision (benefit)
Hong Kong [Member]
Current tax provision
Current tax provision
Deferred tax provision
Deferred tax provision (benefit)
PRC [Member]
Current tax provision
Current tax provision	285,302	135,492
Deferred tax provision
Deferred tax provision (benefit)	$ 23,711	$ 68,561

Taxes (Details) - Schedule of Deferred Tax Assets - USD ($)	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2022
Deferred tax assets:
Net operating loss carry-forwards	$ 113,753	$ 5,049
Inventory written down	135,064	144,106
Allowance for credit losses	6,124	19,008
Total	254,941	168,163
Valuation allowance	(124,500)	(15,688)	$ (14,248)
Total deferred tax assets, net	$ 130,441	$ 152,475

Taxes (Details) - Schedule of Movement of the Valuation Allowance - USD ($)	6 Months Ended	12 Months Ended
	Mar. 31, 2024	Sep. 30, 2023
Schedule of Movement of the Valuation Allowance [Abstract]
Beginning balance	$ 15,688	$ 14,248
Current year addition	109,201	1,844
Exchange difference	(389)	(404)
Ending balance	$ 124,500	$ 15,688

Taxes (Details) - Schedule of Effective Tax Rate	6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Schedule of Effective Tax Rate [Abstract]
China Income tax statutory rate	25.00%	25.00%
Effect of PRC tax holiday	(14.60%)	(9.90%)
Research and development tax credit	(6.80%)	(4.80%)
Non-PRC entity not subject PRC income tax	5.70%
Change in valuation allowance	6.50%	0.10%
Others	(0.50%)
Effective tax rate	15.30%	10.40%

Taxes (Details) - Schedule of Taxes Payable - USD ($)	Mar. 31, 2024	Sep. 30, 2023
Schedule of Taxes Payable [Abstract]
Income tax payable	$ 547,461	$ 263,131
Value added tax payable	12,510	1,627
Other taxes payable	4,655	6,665
Total taxes payable	$ 564,626	$ 271,423

Concentrations (Details) - USD ($)	6 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Sep. 30, 2023
Concentration Risk [Line Items]
Cash deposit at financial institutions (in Dollars)	$ 225,356		$ 1,363,617
CHINA
Concentration Risk [Line Items]
Cash deposit at financial institutions (in Dollars)	8,637,315		5,561,070
Hong Kong [Member]
Concentration Risk [Line Items]
Cash deposit at financial institutions (in Dollars)	$ 1,955		$ 108
Supplier One [Member] | Supplier Concentration Risk [Member] | Accounts Payable [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	13.20%		10.50%
Customer One [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	53.70%	70.30%
Customer One [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	46.50%		53.10%
Customer [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	59.40%	78.00%
Customer [Member] | Subsidiaries [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	5.70%	7.70%
Customer Two [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	13.60%

Shareholders' Equity (Details)					6 Months Ended		12 Months Ended
		Feb. 08, 2024 $ / shares shares	Apr. 06, 2023 USD ($) shares	Mar. 30, 2023 USD ($) $ / shares shares	Mar. 31, 2024 USD ($) $ / shares shares	Mar. 31, 2023 USD ($) shares	Sep. 30, 2023 USD ($) $ / shares shares	Oct. 28, 2022 shares	Sep. 30, 2022 shares	Sep. 30, 2021 shares
Stockholders Equity [Line Items]
Stock split of ordinary shares		20
Common stock shares authorized	[1]				1,000,000,000		1,000,000,000
Common stock pre spilit shares		50,000,000
Common stock value per share (in Dollars per share) | $ / shares	[1]				$ 0.00005		$ 0.00005
Ordinary shares issued	[1]				156,547,100		155,947,100
Surrendered of ordinary shares								265,000,000
Total gross proceeds (in Dollars) | $			$ 378,840			$ 8,000,000
Net proceeds from issuance of initial public offering (in Dollars) | $				$ 6,800,000
Granted underwriters option purchase period				45 days
Statutory surplus percentage					10.00%
Reserve is equal percentage					50.00%
Restricted amounts (in Dollars) | $					$ 2,277,430		$ 2,010,890
Restricted net assets (in Dollars) | $					$ 2,363,989		$ 2,097,449
Minimum [Member]
Stockholders Equity [Line Items]
Common stock value per share (in Dollars per share) | $ / shares		$ 0.001
Maximum [Member]
Stockholders Equity [Line Items]
Common stock value per share (in Dollars per share) | $ / shares		$ 0.00005
Common Stock [Member]
Stockholders Equity [Line Items]
Common stock shares authorized		1,000,000,000
Common Stock [Member]
Stockholders Equity [Line Items]
Ordinary shares issued					400,000,000				135,000,000	135,000,000
Ordinary shares outstanding									135,000,000	135,000,000
Offering shares	[2]				30,000	1,000,000
IPO [Member]
Stockholders Equity [Line Items]
Offering shares				20,000,000
Public offering price (in Dollars per share) | $ / shares				$ 0.4
Total gross proceeds (in Dollars) | $				$ 8,000,000
IPO [Member] | Common Stock [Member]
Stockholders Equity [Line Items]
Offering shares				3,000,000
Over-Allotment Option [Member]
Stockholders Equity [Line Items]
Offering shares			947,100
[1] Retrospectively restated for effect of a 20-for-1 forward split on February 8, 2024. [2] Retrospectively restated for effect of a 20-for-1 forward split on February 8, 2024.

Segment Reporting (Details)	6 Months Ended
	Mar. 31, 2024
Segment Reporting [Line Items]
Reporting segment	1
Chief Executive Officer [Member]
Segment Reporting [Line Items]
Reporting segment	1

---